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Introduction to the Problem
Mild cognitive impairment (MCI) is a mild decline in a single domain or 
multiple cognitive domains. Although MCI usually causes cognitive changes that are 
noticeable by the individual and/or caregivers, the global cognition and activities of 
daily living (ADL) usually remain intact. However, the cognitive changes associated 
with MCI are generally not severe enough to interfere with the daily life and 
independent functions of the patient. While patients with MCI are more likely to 
develop Alzheimer’s disease or other dementias than patients without MCI, a diagnosis 
o f MCI does not always indicate that the patient will develop Alzheimer’s disease or 
dementia. MCI may resolve, and the patient’s cognitive exam may return to normal 
baseline or remain stable without progression. Symptoms of MCI are classified based 
on the thinking skills affected. MCI that affects memory is known as amnestic MCI. In 
the case o f amnestic MCI, a patient may start to forget important information that he or 
she could previously recall easily, such as appointments or recent conversations. MCI 
that affects thinking skills other than memory is known as non-amnestic MCI. Thinking 
skills possibly affected with this type o f MCI include the ability to make sound 
decisions, judgment of time, judgment of the sequence to complete complex tasks, or 
visual perception (Alzheimer’s Association, 2013). The most recently developed 
diagnostic criteria for MCI is the pre-dementia phase of Alzheimer’s disease.
Patients diagnosed with MCI usually have more difficulty and may take longer 
than their normal counterparts in performing cognitively demanding instrumental ADL. 
Activities that may be affected include shopping, driving, medication regimen, food
preparation, and handling finances. In older adults with MCI, even small subtle 
declines in cognitive abilities are associated with decreased independence and safety, 
increased caregiver burden, a decreased chance of reverting to normal cognitive status, 
and increased likelihood of developing dementia (Lin, Vance, Gleason, & Heidrich, 
2012). Although the causes of MCI are not completely understood, experts believe that 
early screening and diagnosis slow disease progression.
Background of the Problem
More than 16 million people in the United States live with some form of 
cognitive impairment. The greatest risk factor for cognitive impairment is age. As the 
baby boomer’s generation passes the age of 65 years, the number o f people living with 
cognitive impairments is expected to increase dramatically. With an estimated 5.1 
million Americans who are diagnosed with Alzheimer’s disease and are 65 years of age 
or older, Alzheimer’s disease is the most common type and the most well-known form 
of cognitive impairment. The projected increase o f this disease incidence is 13.2 
million by the year 2050 (CDC, 2011), resulting in a higher demand on the healthcare 
setting. The increasing economic burden and growing demand for care related to 
cognitive impairment will pose a serious challenge to the community, the state, and the 
nation. Apart from increased societal economic burdens, higher numbers of family 
members aiding in the care of the affected patients will experience greater demands—  
causing caregiver burnout. Currently, over 10 million family members provide care to a 
patient with a cognitive impairment.
Age is the primary risk factor for cognitive impairment. Other risk factors 
include family history, brain injury, education level, and other chronic
conditions. Other possible causes of MCI in older adults include medication side 
effects, metabolic and/or endocrine disorders, depression, dementia, and Alzheimer’s 
disease. While some of these causes, such as medication side effects and depression, 
can be reversed with treatment; others, such as Alzheimer’s disease, cannot be reversed. 
However, with early detection and diagnosis, symptoms can be treated, and families can 
be educated on the predictive cognition changes.
Patients who are developing cognitive impairment or who have dementia usually 
do not receive a formal diagnosis. In a review of literature, one study indicated that 
most primary care providers were unaware of cognitive impairments in more than 40% 
of their cognitive impaired patients. Another study revealed that > 50% of patients with 
dementia received no clinical cognitive screening by a primary care provider. The 
failure to evaluate for cognitive complaints is more likely to hinder the treatment of any 
underlying disease and comorbid conditions as well as to prevent safety issues for the 
patient and others. In most cases, cognitive impairment will worsen over time (National 
Institute for Learning [NIA], 2014). Providers who conduct early screening on patients’ 
age 65 years or older are better able to identify emerging cognitive deficits, pinpoint 
possible causes, and develop an appropriate plan o f care. Identifying patients who 
exhibit signs of cognitive impairment and taking appropriate steps to address their 
issues results in a positive impact on the patient, the community, and the state (NIA, 
2014).
Recommendations for routine cognitive assessment screenings in older adults 
vary and continue to evolve. The U.S. Preventive Services Task Force (USPSTF) 
developed guidelines that recommend cognitive screening in asymptomatic patients.
since the overall benefits have been reflected to outweigh the overall cost and risk 
(USPSTF, 2015). The USPTF identified screening tools that successfully identify 
people with early stages of dementia. Currently, the amount o f evidence-based research 
is inadequate to determine whether screening all older adults is beneficial (see 
Appendix B). However, minimal evidence was found to support any potential harm in 
screening for cognitive impairment.
The Centers for Medicare and Medicaid Services (CMMS) recommends 
including cognitive assessment screenings for early detection of MCI as part of the 
requirements of the annual wellness visit for older adults age 65 years or greater. Even 
though the CMMS recommends cognitive screenings annually, it does not specify what 
screening approach to use. The Alzheimer’s Association recommends brief assessment 
tools o f cognition that involve memory as well as formal interviews (see Appendix C). 
Patients who test positive for cognitive impairments are referred for a more 
comprehensive evaluation. The evaluation can be at a subsequent visit with a primary 
care provider or specialty clinician (Grober, Wakefield, Ehrlich, Mabie, & Lipton, 
2017).
Routine cognitive assessment will eventually become the standard of care as a 
screening strategy to improve and better manage effective treatment regimens. 
Treatment and other preventive measures, as they emerge, will be integrated into 
primary care clinics where much of the older adult population receives their healthcare. 
Screening tools and case findings will be essential in implementing treatment regimens, 
thereby allowing adults to benefit from early detection and diagnosis (Grober et al., 
2017). The overall evidence of routine cognitive screenings is insufficient. However,
several important reasons exist to screen and identify early mild cognitive impairments. 
Early detection has the potential to help patients make treatment decisions, including 
the treatment o f reversible causes o f dementia and the management of comorbid 
conditions. Early detection of mild cognitive impairments allows primary care 
providers to anticipate problems that the patient may have in understanding and 
adhering to recommended treatment regimens. Early detection also gives caregivers 
and family members the opportunity to begin planning for future problems that may 
result from the progression of cognitive impairment. Even though the overall evidence 
concerning routine screening is insufficient, providers should always remain aware of 
the early signs and symptoms o f cognitive impairment and should evaluate for 
treatment.
The National Institute of Aging (NIA) has educational information available on 
the screening and detection of mild cognitive impairments for patients and primary care 
providers. This educational information includes a database of detection tools to screen 
and help detect mild cognitive impairments. This collection of statistical data, 
guidelines, recommendations, and objectives accentuates the fact that MCI is a 
progressive cognitive disease with the potential to adversely affect both the health of the 
patient and the overall healthcare system. Primary care providers, including nurse 
practitioners and advanced practice nurses, have the potential to take an aggressive 
approach to MCI detection and treatment by adhering to USPSTF recommendations. 
Statement of the Problem
Dementia affects from 2.4 to 5.5 million Americans. Dementia’s prevalence 
increases with age by 5% in persons aged 71-79 years, 24% in those aged 80-89 years.
and 37% in those older than 90 years of age. Mild cognitive impairment is different 
from dementia in that mild cognitive impairment is not severe enough to interfere with 
instrumental ADLs. Various forms of cognitive impairment differ in their impact on the 
daily functions of older adults. To ensure and maintain the patient's ability to perform 
independent ADLs, routine testing for declining mental functions must be completed 
and is mandated by the U.S. Government. The lack of consistent cognitive screenings 
increases the patient’s chances of late diagnosis as well as possible detrimental effects 
and/or events.
Purpose of the Study
The purpose of this study was to determine primary care providers’ adherence to 
USPSTF (2015), and the Alzheimer’s Association’s (2013) recommendations and 
guidelines advocating annual cognitive impairment screening on patients ages 65 years 
and older. The Alzheimer’s Association issued an algorithm for detecting cognitive 
impairment in older adults; this cognitive assessment algorithm was accepted and 
mandated by U.S. Centers for Medicare and Medicaid Services during annual wellness 
visits o f patients 65 years and older. In addition to the Alzheimer’s Association, 
USPSTF acknowledges the increasing prevalence of cognitive impairment and the 
benefits of early detection. However, USPSTF argues a lack of research and 
information on the subject; to which, the current study attempted to aid the increasing 
data on cognitive screening in older adults (USPSTF, 2014). This study examined the 
amount of primary providers’ compliance in completing cognitive impairment 
screenings of older adults, probable barriers decreasing provider adherence of 
implementing annual cognitive testing of older adults, and the preferred methods and
tools utilized for cognitive impairment screening o f those adults ages 65 years and 
older.
Significance of the Research Project
With increasing advances in healthcare, people are living longer, but ironically 
their quality of life is diminishing. Over 5.1 million Americans over the age of 65 years 
are estimated to be living with some form of cognitive impairment—not including 
undiagnosed individuals. Along with other comorbidities commonly accompanying the 
geriatric population, cognitive impairment (i.e., Alzheimer’s disease, mild cognitive 
impairment, and other forms of dementia) heavily burdens patients, patients’ families, 
caregivers, the healthcare system, and the U.S. Government. In 2007, the U. S. 
Department of Health and Human Services, the CDC found approximately $647 million 
as the average cost for a government-funded (i.e., Medicaid) nursing facility to 
adequately care for an individual with Alzheimer’s disease (Wiese & Williams, 2015). 
Wanting to prevent future federal bankruptcy and improve the quality o f life for 
individuals diagnosed with age-related dementias, as well as their families and 
caregivers, the U.S. Government mandated cognitive screenings o f older adults during 
annual wellness visits (CDC, 2011).
In 2011, the CDC, the Centers for Medicare and Medicaid Services, the Agency 
for Healthcare Research and Quality, and the Administration on Aging branch of the 
United States Department o f Health and Human Services collaborated to combat the 
overwhelming burden o f age-related dementias (Wiese, Williams, & Tappen, 2014). 
With efforts to increase early diagnosis and treatment of age-related dementias, the U.S. 
government initiated the National Alzheimer’s Project Act, which required routine
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cognitive screening of adults over the age of 65 years (Wiese, Williams, & Tappen, 
2014). Over 5 years after the initiation of new guidelines warranting cognitive 
screening of older adults over 65 years, three questions justified investigation:
1. Do primary healthcare providers in Mississippi conduct mild cognitive 
impairment screenings on older adults, and, if so, how often?
2. What provider-generated barriers may decrease the likelihood of cognitive 
impairment screening in older adults during visits with primary care 
providers?
3. What screening methods do primary care providers use to detect mild 
cognitive impairments?
The current study attempted to answer these questions. Guided by Nola 
Pender’s theoretical framework and concepts as proposed in her Health Promotion 
Model, this study surveyed numerous primary care providers to discern the prevalence 
o f adequate screening for detection of cognitive impairment in older adults. The current 
study also raised awareness and promoted the necessity o f annual cognitive screening of 
patients ages 65 years and older.
The CDC, the Alzheimer's Association, the Centers for Medicare and Medicaid 
Services, and the Administration on Aging Branch of the United States Department of 
Health and Human Services collaborated to produce the Healthy People 2020 initiative, 
which specifically addresses the need for improvement in the detection and treatment of 
cognitive impairment in older adults (Wiese & Williams, 2015). With a lack of nursing 
research studies comparable to the current study, no recent evidence documented the
number of primary-care providers screening older adults to increase early detection of 
cognitive impairment in older adults.
Wiese and Williams (2015) composed a literature review to inform nurses of the 
current policies, tools, and benefits o f annual cognitive assessments for older adults. 
From licensed practical nurses to advanced practice nurses, many nurses are unaware of 
the national screening guidelines and the benefits regarding cognitive assessments of 
the geriatric population. Many nurses are also unaware that such screening is within 
their scope o f practice. The results of the current research study contributed to an 
increase in nursing knowledge of age-related dementia screening and nursing education 
in the importance of annual cognitive screening in older adults. These results promoted 
additional nursing research of early cognitive impairment detection in older adults and 
identified the most valid cognitive screening tools.
Conceptual Framework
Nola Pender's Health Promotion Model (HPM) served as the guideline for the 
theoretical framework for the research of the annual cognitive screenings in older 
adults. Presented in the 1980s, Pender integrated psychological, educational, and 
nursing concepts and theories to formulate her Health Promotion Model. The HPM is 
similar to Becker’s Health Belief Model in the promotion of disease prevention. 
However, the HPM differs fi-om Becker’s model in that it does not include negative 
factors, such as fear or threat, as a source of motivation for health behavior. Pender’s 
desired outcome from the HPM is that a person will have health-promoting behaviors, 
which will affect overall health, fimctional ability, and quality of life. The HPM theory 
notes patients have a unique set o f experiences and characteristics that directly affect
10
their behaviors related to health. Pender takes a holistic view of not only the physical 
health o f the patient, but also the surrounding factors that might influence the outcome 
of the patient’s well-being. As a nursing-based theory, Pender’s theoretical framework 
integrates key concepts of the nursing metaparadigm: person, health, environment, and 
nursing. Pender defined the concept of person as the focal point of the HPM 
(McCutcheon, Schaar, & Parker, 2016). Pender defined environment as the physical, 
social, and cultural surrounding, which can be manipulated to facilitate health- 
promoting behaviors. Health is described as a subjective, evolving experience 
throughout an individual’s lifespan. The HPM considers nursing responsible for linking 
the person and environment to promote behavior changes leading to optimal health 
(Pender, 2011). Pender incorporated these fundamental nursing concepts to formulate 
the proposition and assumptions of the HPM.
The HPM suggests behaviors affecting positive or negative health promotion 
and outcomes are controlled by various internal and external factors (Sakraida, 2014).
In Pender’s article explaining the HPM and its application to healthcare, she discussed 
the major theoretical conceptions of the HPM. The following key terms are defined for 
the purposes of understanding the HPM in relation to the present study:
1. Health-promoting behavior - an action directed towards promoting and 
maintaining positive health outcomes.
2. Prior-related behavior - the fi-equency of a past behavior that directly or 
indirectly affects health-promoting behaviors.
3. Personal factors - sociocultural, psychological, and biological characteristics 
(i.e., age, race, socioeconomic status, etc.) influencing healthy behaviors.
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4. Perceived benefits o f action - an anticipated benefit of accomplishing a 
behavior.
5. Perceived barriers to action - perceptions or actual blocks inhibiting 
performing health-promoting behaviors.
6. Perceived self-efficacy - personal confidence in successfully performing a 
behavior.
7. Activity-related affect - subjective feelings of negativity or positivity 
proceeding, during, or following a health-promoting behavior; and directly 
affects perceived self-efficacy in that an individual is less likely to be 
confident in a behavior with subjective feelings of negativity.
8. Interpersonal influences —the views, expectations, support, etc. received 
from family, healthcare providers, peers, etc. which influence an individual’s 
perception of a particular healthy behavior.
9. Situational influences — personal thoughts and perceptions of an impending 
behavior regarding aesthetics, additional options, and current environmental 
demands.
10. Commitment to a plan of action -  personal dedication to initiation of a 
health-promoting behavior.
11. Immediate competing demands and preferences -  various responsibilities or 
personal demands, which an individual may have greater or lesser amount of 
control over, that affects completing a health-promoting behavior (i.e. 
healthy diet, employment responsibilities). (Pender, 2011, p. 12).
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In one of her first research studies on the correlation of behavior to enhancing 
health promotion, Pender found that many individuals would utilize preventative and 
health-promoting services when made available in their community. In her study, 
Pender surveyed hundreds of men and women between the ages of 20 and 90 
concerning their thoughts on utilizing preventative and health-promoting services 
administered by a nurse practitioner. Although the research focus was on the behavioral 
influences affecting the utilization of nurse practitioners as opposed to physicians, the 
study found most of the sample population agreed to partake in health-promoting 
services when offered by any healthcare provider (Pender & Pender, 1980). This 
finding would later become the HPM’s theoretical claim stating, “Families, peers, and 
healthcare providers are important sources o f interpersonal influence that can increase 
or decrease commitment to and engagement in health-promoting behaviors” (Pender,
2011, p. 5). The current research study addressed the significance o f healthcare 
provider commitment to and engagement in positive healthcare outcomes, especially 
regarding cognitive screening in older adults.
Many nursing researchers have based and tested their studies with Pender’s 
HPM. McCutcheon et al. (2016) integrated the HPM into their study of college-aged 
males’ behaviors in preventing human papillomavirus (HPV). McCutcheon et al.
(2016) suggested most health preventive models were deficient and focused on fear as 
an incentive, whereas Pender’s HPM emphasized positive methods to initiate and 
maintain health-promoting behaviors.
The HPM’s theoretical claims and basis in advancing human potential closely 
align with the present study of early detection of cognitive impairment in older adults.
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The HPM theoretical statements suggest individuals are more likely to increase desired 
behaviors when perceived beneficial or deemed efficient— allowing the individual to be 
perceived as competent (Pender, 2011). For primary healthcare providers, the perceived 
benefit to action would be earlier diagnosis and treatment of age-related dementias, to 
which the provider would enhance his or her competency in secondary preventative and 
health-promoting services. For primary providers not performing cognitive screenings, 
the perceived barriers to action may include various forms of activity-related effects, 
such as inexperience with using cognitive screening tools, length of examination, lack 
of time to perform cognitive screening in addition to other exams, or inadequate 
reimbursement for cognitive screenings. These activity-related effects, as stated in the 
HPM, are directly affected by the providers’ perceived self-efficacy. By surveying the 
frequency of cognitive screening of older adults in the primary care setting and 
surveying the primary care provider’s perspective on the lack of cognitive impairment 
screening, this study attempted to identify the perceived barriers and perceived self- 
efficacy to promote a positive behavioral change. As recommended in Pender’s HPM, 
primary healthcare providers were allowed to observe the data identifying the lack of 
and importance of cognitive screening in older adults, to which implementation of 
routine cognitive screenings would begin to increase.
This current study utilized the HPM as a guide to identifying the perceived 
barriers to action and perceived self-efficacy of primary providers’ non-adherence to the 
national guidelines requiring annual cognitive screening of older adults. Through 
surveying primary care providers, this study incorporated the theoretical assumptions
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and propositions of the HPM to promote compliance with the national standard of 
routine cognitive screening in the geriatric population.
Research Questions
In order to guide data collection regarding primary care providers’ adherence to 
screening recommendations and guidelines, the following research questions were 
formulated:
1. Do primary care providers in Mississippi conduct mild cognitive impairment 
screenings on older adults; if  so, how often?
2. What provider-generated barriers may decrease the likelihood of cognitive 
impairment screening in older adults during visits with primary care 
providers?
3. What screening methods do primary care providers use to detect cognitive 
impairments?
Definition of Terms 
Primary care providers
Theoretical: Primary care providers are healthcare professionals who serve as 
the first contact a patient makes with the healthcare delivery system and act as the 
principal point of continuing care for established patients by coordinating specialty care 
and other services a patient may need (American Academy of Family Physicians 
[AAFP], 2014).
Operational: For the purpose of this study, primary care providers are 
physicians, nurse practitioners, physician assistants, or other medical practitioners who
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render primary care to older adults over the age of 65 years and respond to the web- 
based survey.
Mild cognitive impairment
Theoretical: Mild cognitive impairment is an intermediate stage between the 
expected cognitive decline of normal aging and the more serious decline of dementia 
("Mayo Clinic," 2016).
Operational: For the purpose o f this study, mild cognitive impairment is defined 
as a mild decline in a single domain or multiple cognitive domains, and it indicates a 
significant risk of progression to dementia or Alzheimer’s disease in patients older than 
65 years.
Older adult
Theoretical: Any patient that is > 65 years of age who receives medical 
treatment (“Patient,” 2016).
Operational: For the purpose of this study, the older adult is defined as a self- 
identified person over the age of 65 years who receives care from a primary care 
provider choosing to participate in this study by responding to the web-based survey.
Screening method
Theoretical: Screening is defined as a preliminary procedure, such as a test or 
examination, to detect the most characteristic sign or signs o f a disorder that may 
require further investigation (“Screening,” n.d). A method is defined as means or 
manner of procedure, especially a regular and systematic way of accomplishing 
something ("Method," n.d.).
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Operational: For the purpose of this study, screening methods included any 
documented evidence of mild impairments including, but not limited to, written 
questionnaires, oral questions, health history, screenings, or electronic medical records 
(EMR).
Provider-Generated Barriers
Theoretical: Provider is defined as any individual, institution, or agency that 
provides health services to healthcare consumers (“Mayo Clinic,” 2016). Generated is 
defined as brought into existence, produced, or originated (“Generated,” 2018). 
Barriers is defined as a factor that tends to restrict the free movement, mingling, or 
interbreeding of individuals or populations (“Barriers,” 2018).
Operational: For the purpose of this study, provider-generated barriers are any 
factors originating with the provider that restrict the likelihood that the provider will 
screen for mild cognitive impairments in older adults.
Assumptions
For the purpose of this study, the following assumptions were made:
1. Due to the anonymity of the survey, the researchers assumed participants 
were honest about their current practices and thoughts regarding cognitive 
impairment screening of older adults.
2. In utilizing healthcare providers (i.e., physicians, nurse practitioners, and 
physician assistants) within the primary care setting, the researchers 
assumed all participants had adequate and equivalent professional and 
educational competencies regarding healthcare within the geriatric 
population
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3. Participants who agreed to participate in the current study were not coerced 
or awarded incentives to encourage participating in this research study.
4. The researchers assumed the sample population of primary care providers 




The purpose of this study was to determine primary care providers’ adherence to 
the recommendations established by the United States Preventive Services Task Force 
(USPSTF) (2014) and the guidelines published by the Alzheimer’s Association (2013). 
The USPSTF is an independent group of national experts in evidence-based practice 
and prevention measures that work to improve health by making evidence-based 
recommendations about clinical preventive services, such as screenings for the early 
detection of mild cognitive impairment. According to the USPSTF, “This 
recommendation applies to universal screening with formal screening instruments in 
community-dwelling adults in the general primary care population who are older than 
age 65 years and have no signs or symptoms of cognitive impairment” (USPSTF, 2014, 
p. 1). The Centers for Medicare and Medicaid Services (CMS) amended its 
recommendations for annual wellness visit (AWV) effective January 1, 2011. The 
amendment included guidelines for what is included in the AWV. According to the 
CMS website, “the following services to an eligible beneficiary by a health professional 
. . . detection of any cognitive impairment that the individual may have” (CMS, 2011, p. 
2). With cognitive screening covered in the AWV, the Alzheimer’s Association 
published the Cognitive Assessment Toolkit (see Appendix E) as a guideline to help 
providers assess mild cognitive impairment quickly and efficiently {Cognitive 
Assessment Toolkit^ n.d.). This chapter introduces the theoretical framework, presents a 
review of literature in reference to the present study, and further includes 
summarizations of work by Nola Pender and other research based on the HPM.
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Theoretical Framework
According to Nola Pender, her Health Promotion Model is driven by the desire 
to increase well-being to foster human potential (Pender, 1996). Using the HPM as a 
guideline for the present study was advantageous, as it aligned the researchers to focus 
on the overall well-being and potentiality of patients with mild cognitive impairment.
At the start of the study, there was no cure of MCI, but there was opportunity to prevent 
further losses through medication, lifestyle, and behavioral modification. In 
recognizing MCI earlier, rather than later, providers were better able to prepare the 
patient and family for the advancement o f the disease and for the modifications to the 
patient’s environment and treatment. In so doing, the provider helped create the best 
possible outcome for all affected. For example, early in diagnosis, the provider might 
have connected the family to resources to help enhance the patient’s nutrition through 
education of meal planning and preparation, daily caloric goals, and ease of availability 
of food and services. If the patient and family would have had a nutritional plan in 
place as the disease progresses, the patient would experience overall better health and 
wellness due to his or her optimal nutritional status. By using the HPM as a guideline 
to the study, the researchers were able to use a holistic view of the patient and health- 
promoting strategies to formulate appropriate assumptions and create effective methods 
of study to promote early recognition of MCI and anticipate difficulties that could 
hinder understanding and adherence to a treatment program.
Kelley, Sherrod, and Smyth (2009) conducted a research study in fall 2009.
This study utilized a retrospective chart review of 250 charts. The population included 
males and females within the clinic who had a history of smoking and coronary artery
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disease (CAD) (Kelley et al., 2009). O f the 250 charts reviewed, only 150 patient 
charts met the parameters of the study. Data were obtained utilizing a “smoking 
cessation chart review form” (Kelley et al., 2009, p. 87). The following research 
questions were addressed in the study:
1. Is smoking cessation therapy being implemented with known coronary artery 
disease patients who smoke with clinical diagnosis o f acute coronary 
syndrome?
2. What timeframe (including prior diagnosis up to one year after diagnosis) is 
smoking cessation addressed with known coronary artery disease patients 
who smoke with a clinical diagnosis of acute coronary syndrome? (Kelley et 
al., 2009, p. 85)
The coneeptual framework of the study was based on Pender’s theory of the 
HPM. The results o f the study revealed that 68.7% of the patient sample did receive 
smoking cessation teaching prior to or up to one year o f the diagnosis o f coronary artery 
disease (Kelley et al., 2009, p. 89). According to Kelley et al.,
Pender’s HPM addresses many of these factors from the patient perspective by 
accounting for various characteristics that determine why one person may quit 
smoking while another will not, even with identical smoking cessation 
intervention. However, the most relevant HPM construct for this study was 
interpersonal influences. (Kelley et ah, 2009, p. 90)
The major limitation of the study was the small scale with which it was carried 
out. Another limitation seen was only 150 of the charts accessed met criteria for the
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study. Finally, the last limitation listed was that the data collection tool had no validity 
or reliability for its usefulness established (Kelley et ah, 2009).
Mehrabbeik, Mahmoodabad, Khosravi, and Fallahzadeh (2017) conducted a 
study entitled Breahfast Consumption Determinants Among Female High School 
Students o f  Yazd Province Based on Pender’s Health Promotion Model. Their work 
consisted of a cross-sectional study examining 200 high school female students utilizing 
a researcher-made questionnaire based on Nola Pender’s Health Promotion Model. 
Cluster sampling method was utilized in selecting the students. According to the study, 
the “children and adolescence” growth and development stage requires more nutrients 
to sustain normal growth patterns. However, the stage is also the most crucial period 
for correction of dietary pattern. With this correction, breakfast is described to have the 
most positive effects on nutrition and cognitive function. Thus, the purpose of the study 
was to promote the importance of breakfast and its effects on physical and cognitive 
development. Mehrabbeik et ah found 23% of students ate breakfast every day, and 3% 
never ate breakfast. Few students (11.3%) stated eating a variety o f cakes or cookies as 
breakfast. One limitation of this study included using a specific demographic rather 
than a variety of ages and gender. Contrary to this, a strength found in this study was 
the utilization of Pender’s HPM as the theoretical guideline. Mehrabbeik et ah provided 
in-depth insight to the following five components of the HPM: (a) positive activity- 
related effect, (b) interpersonal influences, (c) prior related behavior, (d) perceived 
barriers of action, and (e) self-efficacy. Because Mehrabbeik et ah designed and 
implemented the study based on Pender’s HPM, they concluded, “that Pender’s Health 
Promotion Model is a good predictive model for breakfast consumption among student.
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Given that its components predicted 33% of breakfast consumption, in planning 
educational interventions, special attention to these components would be very helpful” 
(Mehrabbeik et ah, 2017, p. 5065).
Pender’s Health Promotion Model was used in two very important facets o f the 
current research. First, Pender’s model was used as a focus for the questions in the 
survey. The current research was considered whether or not primary care providers 
were routinely screening for mild cognitive delays in patients over the age of 65 years. 
The survey questions intended to include several questions aimed at why providers may 
not be screening adequately or at all. These questions used Pender’s model as a base to 
examine what barriers exist to adequate screening. Secondly, Pender’s model was used 
to help shape follow-up teaching that was indicated with providers. Pender believed 
that personal, self-initiated changes are essential to true and lasting change. The key to 
making a difference, as it was found that the screening was not being done on an 
adequate level, was based on the learner seeing a positive benefit in the suggested 
changes. In the current research, the change increased the knowledge for a need of 
routine and early screening with a future benefit o f better healthcare outcomes for 
patients and their families.
Review of Related Research
Malmstrom et al. (2015) implemented the following two studies: (a) to examine 
the use of The Rapid Cognitive Screen (RCS) to test for mild cognitive impairment and 
dementia by primary care physicians and (b) to examine the ability of the RCS to detect 
MCI and dementia in an outpatient clinic setting/primary care setting. According to 
Malmstrom et al., one in nine persons aged 65 years or older and 32% of persons over
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85 years of age are estimated to have Alzheimer’s disease, and the CDC’s expectation is 
that this number will triple by 2050. Primary care physicians frequently do not properly 
identify persons with cognitive dysfunction, and no gold standard screening tool 
currently exists to detect cognitive dysfunction. Because dementia and cognitive 
impairment interfere with patients’ ADLs, the lack of consistent cognitive screening 
decreases the chance of early diagnosis and possibly increases the likelihood of 
detrimental effects and/or events. The Diagnostic and Statistical Manual of Mental 
Disorders (4* edition; DSM-IV) criteria were used to make the diagnosis of mild 
cognitive impairment or dementia in this study, and there was no theoretical framework 
for the study identified.
Malmstrom et al. (2015) identified the following three objectives for Study 1: 
Examine the RCS sensitivity and specificity for MCI and dementia, evaluate the RCS 
predictive validity for nursing home placement and mortality, and compare the RCS to 
the Clock Drawing Test (CDT) plus recall. Study 1 utilized the RCS, which included 
three items from the Veterans Affairs’ Saint Louis University Mental Status (SLUMS) 
exam. Malmstrom et al. were testing the ability of the RCS to differentiate between 
variables of normal cognition, MCI, and dementia as noted in the DSM-IV. The patient 
was to recall five words, perform a clock-drawing test, remember a story, and recall the 
fact that Chicago was located in the state o f Illinois (insight). The RCS was scored on a 
scale from 0-10 with zero being the worst and 10 being the best. The patient could 
score a total of 5 points for memory, 4 points for clock drawing, and 1 point for the 
story recall. In 2003, the Malmstrom et al. began recruiting from the Saint Louis 
Veterans Affairs Medical Center hospitals. The sample population included 702 male
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participants ranging from 65-92 years of age. Dementia was present in 12% (ji = 82) o f 
the participants, and MCI was present in 26% {n = 180). Scores from the study were 
evaluated against the DSM-IV criteria for diagnosis of mild neurocognitive disorder or 
dementia. Malmstrom et al. also performed a follow-up evaluation 7.5 years later to 
evaluate the association of RCS scores with nursing home placement and mortality. O f 
the 702 participants studied, Malmstrom et al. were able to follow up with 533 
participants with no changes in demographic data. Due to changes in primary care 
providers, incorrect contact information, or inactive electronic medical records, some 
participants were unable to be located.
The only objective for Study 2 was to examine the ability of the RCS to detect 
dementia and MCI in an outpatient setting. The sample population included 168 
participants ranging from 60-90 years o f age. In 2013, the researchers began recruiting 
participants from the Saint Louis University Geriatric Medicine and Geriatric 
Psychiatry outpatient clinics. The study participants included 104 females and 64 males, 
out of which 71 were of African American decent and 92 o f Caucasian decent. In this 
study, 36% (M = 61) of participants were diagnosed with MCI and 44% {n = 74) of 
participants with dementia.
Malmstrom et al. (2015) analyzed data using IBM SPSS Statistics, version 22 
(Somers, NY) and SAS, version 9.2 (SAS Institute, Inc., Cary, NC) for Receiver 
Operating Characteristic (ROC) contrasts. Statistics were reported as means, standard 
deviations (SD), or percentages. Scores from RCS (0-10) and CDT plus recall (0-5) 
were used for ROC curves for MCI and dementia. Sensitivity and specificity were 
calculated using a standard approach. Results from ROC contrasts were computed to
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“compare the total areal under the curve (UAC) of the screening tests (RCS vs. CDT 
plus recall) for MCI and for dementia on the DSM-IV” (Malmstrom et al., 2015, p.
742). Malmstrom et al. also reported odd ratios (ORs) and 95% confidence intervals 
(CIs) adjusted for the age of the participant reported for the logistic regression analysis.
According to the results o f Study 1, the RCS was superior to the CDT plus recall 
in predicting both dementia and MCI. Study 2 also found that RCS was successful in 
predicting dementia and/or MCI with the use o f the SLUMS exam in the outpatient 
settings. Both tests were found to have good sensitivity for the detection of dementia on 
the DSM-IV, with optimal scoring for dementia to be < 5 for RCS and < 2 for CDT plus 
recall. When testing for MCI, the RCS exhibited a higher specificity with an optimal 
score of < 7, while the CDT plus recall only had optimal scores of < 3. Although there 
was little difference in the two screening methods in reference to dementia, the RCS is a 
better detector for MCI which led Mahnstrom et al. to find it as an overall better 
screening method for predicting both dementia and MCI. In < 3 minutes, the RCS can 
be administered in a primary care setting with preliminary results showing it superior to 
CDT plus recall in detecting MCI. Further study of the CDT plus recall as a tool alone 
for detecting MCI would assist in solidifying these preliminary results. Because 
participants whose scores detected dementia or MCI were less likely to expire or be in a 
long-term care facility 7.5 years after screening, it would be advantageous to conduct 
long-term research to study the effects of predicting dementia and MCI through not 
only the RCS but through the CDT plus recall as well.
One strength found in this study is the author's’ use of RCS as a screening tool. 
Regardless o f patient load and busy schedules, RCS can be administered and scored
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quickly in the primary care setting; and it could be widely available to providers as it is 
not a copyrighted material. With a variety o f demographic data, this study offered a 
fairly thorough assessment of the use of the RCS as an appropriate screening method for 
MCI and dementia. However, a larger sampling from more than one region or setting 
would give a more complete estimate o f sensitivity and specificity of the screening 
tools. Another issue that could be improved upon is for a complete follow-up for 
patients as there was nearly a 25% loss of patient follow-up in Study 1.
Muller, Perische, Heymann, Elbing, and Laske (2017) executed a study 
comparing the diagnostic accuracy of the digital CDT against the conventional CDT for 
discrimination of patients in the early course of Alzheimer’s disease from cognitively 
healthy individuals. According to Muller et al., 50% of cognitively impaired cases go 
undiagnosed, with the number of cognitively impaired individuals increasing 
dramatically as the elderly population increases. Moreover, there is a considerable delay 
in the diagnosis of dementia, which reduces the efficacy of available treatments.
Current diagnostic standards of dementia are time-consuming (including psychometric 
testing), invasive (including spinal fluid testing), and expensive (including neuro­
diagnostic imaging). There is a need to develop fast, easy noninvasive and inexpensive 
diagnostic tools to accurately detect people with cognitive impairment and dementia. 
Early diagnosis through fast and accurate screening is the key to starting medications 
and treatments needed and allowing for careful planning of financial and support 
systems.
Muller et al. (2017) sought to study several areas identified in the study 
including the following: (a) clinical and demographic characteristics o f the participants.
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performance on the CDT in patients with amnestic mild cognitive impairment (aMCI), 
early dementia o f Alzheimer’s type (eDAT), and healthy individuals/healthy control 
(HC); (b) screening value of the CDT in patients with aMCI, eDAT, and healthy 
individuals; performance on the CDT in patients with aMCI showing normal 
conventional Clock Drawing Test (cCDT) scores and healthy controls; and (c) 
screening value of the CDT in patients with aMCI showing normal cCDT score and 
healthy controls.
Out o f 70 participants included in this study, 34 were females and 36 were males 
with the mean age 66.9 + 10.3 years. All participants included were right-handed and 
had normal or corrected-to-normal visual acuity and sufficient hearing ability. No 
participants were included with a physical handicap that affected his or her ability to 
perform the tasks indicated. Muller et al. (2017) also conducted a depression exam 
utilizing the Geriatric Depression Scale (GDS) to exclude symptoms of depression that 
could interfere with test results. Patients with aMCI or EDAT were recruited from the 
Memory Clinic o f the Department of Psychiatry and Psychotherapy at the University 
Hospital o f Tubingen. All participants underwent physical, neurological, and 
neuropsychological and psychiatric examinations. Neuropsychological assessment 
included the use o f the Mini Mental Status Exam (MMSE) and the Trial Making Test 
(TMT-a). The results from these tests were compared to the diagnostic criteria for 
eDAT defined by the National Institute of Neurological and Communicative Disorders 
and Stroke Alzheimer’s Disease and Related Disorders Association. To qualify for 
eDAT criteria, participants had to score 4 points on the Global Deterioration Scale. 
Furthermore, the diagnosis of aMCI was defined according to the Mayo criteria.
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including presence of a memory complaint, objectively impaired memory function, 
intact ADLs, and the absence of dementia.
The CDT was performed using a Windows Surface Pro 4 digitizer and a 
handheld stylus pen. The tablet assessed different patient movements including time-in- 
air and time-on surface calculated in milliseconds according to their binary coding. 
Total-time corresponded to the time-in-air plus time-on-surface. All participants 
completed the cCDT on the tablet with a handheld stylus pen following the instruction 
to draw a circle (clock face) with the numbers in the appropriate positions and to place 
the hands on the clock representing “ 10 past 11 o’clock.” Scoring ranged from 1 point 
(perfect) to 6 points (not representative of a clock at all). A score > 3 was considered 
impaired.
Muller et al. (2017) analyzed data using statistical software package (SPSS— 
version 23). For all tests, the level o f statistical significance was set to p <  0.05. Data 
were also analyzed using the Pearson chi-square test to detect group differences in 
gender distribution. Kruskal-Wallis test was used to detect group differences in cCDt 
and GDS scores. One-way analysis o f variance (ANOVA) was used to assess group 
differences in age, education and global cognition (MMSE), Trial Making Test Part A 
(TMT-a) and Part B, time-in-air, time-on-surface, and total-time. According to the 
Muller et al., receiver operating characteristics (ROC) curves were established to 
illustrate the specificity o f dCDT variables (i.e., time-in-air, time-on-surface, and total 
time) as well as cCDT scores in relation to sensitivity in classifying Healthy Control 
(HC) individuals and patients with aMCI.
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Muller et al. (2017) examined the influence of aMCI and early dementia 
development on alterations in movement execution. Muller et al. studied these 
movements in comparison to the traditional CDT scoring. The traditional scoring 
system reveals poor sensitivity but excellent specificity in discriminating aMCI patients 
from healthy individuals. Even in aMCI patients with normal cCDT scores, usage of in­
air trajectories yielded excellent sensitivity and a very good specificity in discriminating 
from healthy individuals. The proportion of aMCI patients with normal cCDT scores 
was 80% of all aMCI patients. It is inferred that these findings indicate that even if  the 
clock drawing falls into the range of “normal” performance, it is not necessarily 
implicative that the subject is cognitively normal. It is also found that digitalized 
assessment o f one’s non-visible time-in-air movements can be used as supplementary 
information in identifying participants in the pre-dementia stage of Alzheimer’s disease.
Hessler et al. (2013) sought to determine the effectiveness of the Six Item 
Cognitive Impairment Test (6CIT) when used to screen patients for cognitive 
impairment or dementia in the primary care setting. Hessler et al. predicted that the 
number of people affected by dementia will double every 20 years. This statistic alone 
is enough to warrant providers to diligently screen elderly patients and patients with risk 
factors for cognitive impairment or dementia. Hessler et al. foimd that practitioners 
were more likely to screen patients if they had access to tests that were easy to 
administer and tests that provided effective and consistent results. The Six Item 
Cognitive Impairment Test (6CIT) has an administration time of 2 to 4 minutes, which 
fits well with the busy schedule of a general practitioner. The 6CIT is also thought to 
be as reliable and consistent as the mini-mental state examination. The purpose of this
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study was to determine if  the 6CIT is a suitable screening tool for the primary care 
setting as it has been used in previous studies but not specifically in the primary care 
setting.
The previous studies conducted with the 6CIT were in controlled settings, such 
as dementia and geriatric centers; therefore, Hessler et al. (2013) wanted to test the 
validity and reliability in a non-controlled environment. This particular study was part 
of the large population-based intervention program referred to as INVADE 
(Intervention Project on Cerebrovascular Disease and Dementia in the District of 
Edersberg) that investigated the effects of primary medical care interventions on the 
incidence of dementia. The INVADE trial studied prevention at the primary care level 
in Barvaria, Germany. In order to participate in the study, the following criteria were 
outlined: (a) the patient must belong to a specific health insurance company referred to 
as AOK, (b) live in Edersburg, and (c) be 55 years or older. There were no outlined 
exclusion criteria. The screening process took place from 2001 to 2003. From an 
original selection of 11,317 people, 3,908 patients signed informed consent and agreed 
to participate in the study. To determine a baseline, the patients were given a 6CIT at 
the initial examination. Patients were then examined at three follow-up exams: Exam I 
at 2 years. Exam II at 4 years, and Exam III at 6 years. The test has a maximum score of 
28 with a cutoff of 10 to 11 for a diagnosis o f dementia and a score of 7 to 8 for milder 
cases.
Of the 3,908 participants examined, 1,600 were male, 2,308 were female, and 
the mean age was 67.7 years. Hessler et al. (2013) used 72 different general 
practitioners to conduct the screenings. The mean 6CIT score was 2.7 (SD = 3.9).
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Patients remained in the study an average of 72.1 months. Over the course of the study, 
528 (or 14%) o f the patients interviewed at baseline were diagnosed with dementia. 
Considering all factors (i.e., user error, age, gender, etc.), patients with a 6CIT score 
above the 7-8 cutoffs had a threefold to fourfold increased risk for dementia. The 6CIT 
proved to be a stable test over a long period of time and was able to identify most 
patients without dementia. However, it failed to identify a large population of patients 
with dementia. Based on the findings stated above, Hessler et al. (2013) determined 
that the 6CIT was not suitable for use as routine screening instrument in the primary 
care setting as it simply has the potential to overlook too many cases of dementia.
Some of the strengths o f the 6CIT study were the focus on the test’s 
functionality, specifically in the primary care setting. Hessler et al. (2013) 
acknowledged prior 6CIT studies and their effectiveness in diagnosing dementia; but, to 
their knowledge, this was the first 6CIT study designated to the primary care setting 
only. This study was also able to test real-world suitability and validity over three 
distinct time periods. The major weakness of the study was the inability o f the 6CIT to 
conduct a thorough dementia assessment on nearly 4,000 total patients. The group 
members instead were forced to use dementia diagnosis from insurance claims to 
compare the reliability o f the 6CIT findings.
Fowler et al. (2015) conducted a 24-month cluster-randomized trial with two 
parallel groups. The purpose of this study was to determine if  access to cognitive 
reports altered physician screening practices and treatment methods. As the aging 
population increases, the number of patients with cognitive impairment will also 
increase. Today, more patients are seeking medical treatment in the primary care
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setting instead of going to a specialist; therefore, it is suggested that cognitive screening 
should take place in the primary care setting even though cognitive screening can be 
time-consuming and challenging. In January 2011, Medicare and Medicaid services 
began covering the cost o f an annual wellness visit; and, when performed thoroughly, 
these assessments can be very beneficial in early diagnosis of cognitive impairment. 
Fowler et al. (2015) sought to determine if identifying patients with mild cognitive 
impairment could result in a change in the physicians’ approach to treatment or if  an 
early diagnosis could impact the progression of cognitive decline.
Fowler et al. (2015) identified two hypotheses. The first hypothesis stated that 
primary care physicians in the cognitive report group (CR) who received cognitive 
reports based on neuropsychological testing would perform dementia screening test, 
refer patients to specialists for diagnostic assessment, and prescribe anticholinesterase 
inhibitors more frequently than providers in the treatment as usual group (TAU)
(Fowler et al., 2015). The second hypothesis was that the patients o f physicians in the 
CR group would have a slower rate of progression o f cognitive deficits over 2 years 
than cognitively impaired patients in the TAU group (Fowler et al., 2015). This 
hypothesis was based on the belief that cases of reversible cognitive impairment would 
see improvement due to spontaneous resolution or treatment of the underlying cause. In 
more serious cases, if  the cause of impairment was believed to be Alzheimer’s disease, 
the prognosis would be improved by prescribing cognitive enhancing medication.
According to Fowler et al. (2015), the randomization of the study was 
accomplished by focusing on primary care practices rather than individual primary care 
physicians (PCP) and patients. Randomization at the PCP level was thought to
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influence the results of the study due to several factors. Those factors included 
physicians calling upon a colleague to cover each other’s patients thereby possibly 
sullying results between groups or patients sharing providers possibly causing flawed 
results. The chosen practices were broken into two groups: control report (CR) and 
treatment as usual (TAU). Twelve primary care practices from southwestern 
Pennsylvania were chosen according to specific geographic locations, such as urban, 
suburban, and rural. Two of the 12 were defined as urban, and 2 as rural. Eight of the 
12 were suburban and were further classified based on the number o f physicians 
participating in the study. Each site was randomly assigned to the CR and TAU groups 
with 6 sites in each group. Practices were recruited from October 2005 to January 
2006, and patients were recruited from January 2006 to January 2008. Physicians were 
given freedom to select the patients themselves. Patients with a diagnosis of dementia 
on their medical record or with a mini-mental state exam (MMSE) score o f 18 or below 
were excluded. Patients with complaints of memory loss who did not have a diagnosis 
of dementia, however, were not excluded. A total of 731 patients were referred for the 
study, 183 declined participation, and a total of 581 patients completed the baseline 
assessment. Fifteen of the patients were deemed ineligible related to not meeting the 
mentioned criteria. The final sample included 533 patients; o f these, 423 returned for 
the final 2-year assessment. The TAU group represented 169 of these patients, and the 
CR group accounted for 254 patients. A total of 110 patients were lost to follow-up due 
to factors, such as primary care changes, lack of interest, or expiration (Fowler et al., 
2015).
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Data were collected by means of a structured chart abstraction tool and included 
demographics, neuropsychological tests, self-related questionnaires, and electronic 
medical records. Information was collected over four periods: 12 months before 
baseline, baseline to 12 months after baseline, 13-24 months, and 25-30 months. 
Participants were ultimately given the diagnosis of normal, mild cognitive impairment, 
or dementia, which was determined by guidelines set by the University of Pittsburgh 
Alzheimer’s Disease Research Center.
The mean age of participants at entry to the study was 73.6 years. Of the 
participants, 58.9% were male and 63.8% were married. There were no significant 
baseline differences between the two study groups. The results of the study by Fowler 
et al. (2015) revealed no major difference in the way physicians treated the patients on 
either side at the end of the 24 months. Physicians who received cognitive reports, 
however, were more likely to order further testing and prescribe medication than the 
physicians in the treatment as usual group; but there was no significant improvement in 
those patients with MCI or dementia in either control group. One theory is that most 
physicians prefer a wait-and-see approach over aggressive therapy, especially if  the 
patient does not have complaints concerning their cognitive impairment symptoms. In 
the future, researchers would like the physicians involved in this type study to be more 
specific with their documentation and more focused with their cognitive screening 
assessment.
Fowler et al. (2015) claimed that at the time of their study there was no other 
study that had been previously conducted in this manner. Many studies had been 
published on screening for cognitive impairment, but no previous study had tested
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specifically the different behaviors of primary care physicians in relation to the presence 
or absence of previous cognitive reports. Another one of the strengths to this study was 
the comprehensive cognitive function assessment that was utilized. Previous studies 
have only implemented a brief neurological exam. Although the study had several 
strengths, there were also some weaknesses. The major problem with Fowler et al.’s 
study was the demographic breakdown—with a majority o f patients identifying their 
race as white. Because physicians were able to choose the patient population, concern 
arose that physicians may have targeted patients who were already known to have 
cognitive impairment.
Fowler et al. (2015) constructed a very relevant and well-planned study. The 
research group went to great lengths to keep the study neutral and eliminate as many 
biases as possible. The population and sample were clearly identified as well as the 
data collection methods and instruments used during the course o f this randomized trial. 
Fowler et al. could have improved this study by requiring physicians to perform specific 
cognitive screenings on every patient in both control groups. This change would have 
provided more consistent and thorough results. The charting was also very minimal in 
some cases since several physicians only mentioned “memory problems” in their 
respective documentation.
Wiese, Williams, and Tappen (2014) completed a systematic literature review of 
peer-reviewed publications identifying modifiable barriers to cognitive screening in 
rural areas in the U.S. In the U.S., cognitive impairment with regard to mild cognitive 
impairment, Alzheimer’s disease, and dementia is rapidly increasing in correlation with 
the rise in the older adult population. Wiese et al. (2014) suggested every 67 seconds
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one person develops Alzheimer’s disease in America, and 75% of those individuals 
diagnosed with Alzheimer’s disease live in long-term healthcare facilities by the age of 
80 years. An estimated 5.2 million Americans have yet to be diagnosed with 
Alzheimer’s disease, and over 50% of those undiagnosed live in rural regions of the 
United States. Wiese et al. (2014) proved the significance of their study in alluding to 
the U. S. government's acknowledgment of the need for increasing the detection of 
MCI, as proposed in the Healthy People 2020 initiative. In addition to Healthy People 
2020 goals, Wiese et al. cited reputable organizations, such as the Alzheimer’s 
Association, the Alzheimer’s Foundation of America, and the 111* Congress Special 
Committee on Aging, along with six peer-reviewed publications (2014). This review by 
Wiese et al. (2014) focused on the barriers resulting in the lack of cognitive screening in 
rural regions o f the U.S. and offered resolutions to these barriers with the utilization of 
Carrillo and Carrillo’s Healthcare Access Barriers (HCAB) model. Carrillo and 
Carrillo’s framework suggested three modifiable barriers: financial, structural, and 
cognitive. Wiese et al. stated their research question as the following: What are the 
barriers to cognitive screening in rural U.S. populations? Seeking to answer this 
research question, Wiese et al. (2014) reviewed several recent studies that addressed 
and correlated with modifiable barriers of the HCAB model (2014).
The methodology of this study was clearly defined. Wiese et al. (2014) utilized 
current peer-reviewed publications to complete a literature review addressing the 
barriers o f the HCAB model (i.e. financial, structural, and cognitive). Due to the 
qualitative structure of the study, there was no setting, sample, or independent and 
dependent variables. Wiese et al., however, identified the population under study as
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rural residents in the U.S. and the variables o f interest as the three barriers identified in 
the HCAB model.
Wiese et al.’s (2014) interpretations were depicted in a chart. The chart 
included each peer-review publication, the original purpose and design o f each 
publication, and the barriers that each publication identified. In addition, the chart 
categorized each barrier listed into principal barriers o f the HCAB model. Wiese et al. 
(2014) found that all six peer-reviewed publications recognized cognitive/emotional 
barriers, specifically the lack of knowledge. Wiese et al. specified that many of the 
publications addressed the barrier of lack of provider knowledge. Several of the 
publications described instances in which healthcare providers believe cognitive 
impairment is a part o f the normal aging process and thought an early diagnosis of 
Alzheimer’s disease was futile (Wiese et al., 2014). Wiese et al.’s implications for 
improving provider knowledge of the need and the importance of cognitive impairment 
screening included the following:
1. Correct inappropriate responses o f primary healthcare providers due to 
misconceptions and lack of expertise in screening for cognitive impairment.
2. Educate healthcare providers on the benefits of cognitive impairment 
screenings.
3. Educate primary healthcare providers regarding the mandatory screening of 
Medicare recipients during annual wellness exams (Wiese et ah, 2014).
Markwick, Zamboni, and de Jager (2012) conducted a comparative study on the 
ability of the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State 
Examination (MMSE) in the early detection of mild cognitive impairment. The
38
performance of the MoCA subtest was compared at the same cutoff score as the 
MMSE. The cutoff score for the MoCA was < 26, and the cutoff score o f the MMSE 
was > 27. The MoCA detected cognitive impairments not detected by the MMSE in the 
majority o f the participants screened. The MoCA appeared to be a sensitive screening 
test for the detection of early cognitive impairments (Markwick et ah, 2012). Cognitive 
impairments are considered a transitional state between normal aging and Alzheimer’s 
disease and are typically indicated by the presence of cognitive impairment in those 
greater than the expected age in the absence o f dementia. The ability to be able to 
detect cognitive impairments by using screening methods will help with the diagnosis of 
early dementia and management of the disease.
The early identification of cognitive impairments may be a precursor to 
Alzheimer’s disease or other dementias and will possibly lead to improved patient care 
of those diagnosed with dementia or other cognitive disorders. Treatment is most 
beneficial when the symptoms are mild and people are able to cope. It is recommended 
that screening should be used on those who have an increased risk of developing 
cognitive impairments.
A review o f the screening methods in primary care revealed that the most 
commonly used cognitive screening instrument for dementia is the MMSE. The MMSE 
assesses cognition in five subtest areas. The subtest areas include orientation, 
registration, recall, attention/concentration/calculation, and language. Despite its 
popularity, the MMSE has several limitations. These limitations could possibly limit 
the effectiveness o f this screening in different populations. Race, education, and 
language ability affect the performance on the MMSE. The MMSE’s ability to
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differentiate between those with mild cognitive impairment and healthy subjects is 
limited. The meta-analysis showed that across several studies, the results showed 
sensitivity to detect MCI in 62.7%, a specificity of 63.3%, and a positive predictive 
value of only 37%. The cutoff scores for the MMSE are as follows: < 26 is abnormal 
interpretation, <21 has increased odds of dementia, and >25  has decreased odds of 
dementia (Markwick et al., 2012). The MMSE was designed to screen for dementia in a 
time when there was little research on mild cognitive impairments. Now there are 
screens available that would be more sensitive in the detection of mild cognitive deficits 
and should be more widely used.
Another screening tool is the Montreal Cognitive Assessment (MoCA). This 
tool assesses multiple aspects of cognition, short-term memory, functioning, attention, 
concentration, and orientation to place and time. The MoCA was designed specifically 
for screening patients who present with mild cognitive difficulties and sensitive to 
deficits in cognition. With a possible score of 30 points, 73% of those studied obtained 
scores below the cutoff o f 26 points. Even though their scores on the MMSE fell within 
the normal range, MoCA had a sensitivity of 90% for detecting mild cognitive 
impairment in the subgroups. It also revealed that the MoCA had a very high 
consistency and retest reliability (Markwick et al., 2012).
Sensitivity results of this population used a cutoff score o f 26. The MoCA had a 
sensitivity o f 83% to detect MCI. The MMSE included the memory task which is 
limited and does not include a cued recall component. Additionally, there is not any 
test of executive function or working memory. Several attributes contributed to the 
MoCA for their findings of improved detection of MCI when compared to the MMSE.
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The main purpose of this study was to evaluate research in a group of older adults to 
utilize the benefits of the MoCA, as opposed to the MMSE for the use of detection of 
MCI in clinic settings (Markwick et al., 2012).
Participants were selected from a longitudinal memory and aging study (Oxford 
Project to Investigate Memory and Aging=OPTIMA) and were older adults with no 
medical history of a stroke or vascular events. They had attended regular OPTIMA 
appointments for over a year. These participants were assessed with a counter-balanced 
method of using MMSE and MoCA, followed by a full battery of neuropsychological 
tests covering cognitive domains. The OPTIMA assessment included medical history, 
examination, brain imaging, and dementia screening blood test. Diagnosis was based 
on the results and from the full assessment (Markwick et al., 2012).
The statistical analysis was carried out by using PASW statistics 18. The 
univariate analysis o f variance (ANOVA) was used to test for age, gender, and 
education on MMSE and MoCA scores. The sensitivity o f the MoCA was to detect 
cognitive impairments with a cutoff score < 26 and then investigated and compared to 
the MMSE score with a cutoff > 27. The cutoff score can distinguish between those 
with MCI and cognitively normal subjects. If the scores were < 24 or 30, then it is 
generally considered to be indicative of dementia (Markwick et al., 2012).
There were 107 consecutive participants, male and female, with a mean age of 
76 years. There were no significant associations of gender, age, or education with the 
MMSE and MoCA. MMSE scores ranged from 24-30, and the MoCA scores ranged 
from 13-30. The correlation between these two-screening tests was significant. This 
study group had MoCA scores < 26, which indicated cognitive impairment. The
41
MMSE used the cutoff > 27, and 33,7% still fell below the MoCA cutoff. The general 
agreement o f the diagnosis included 79 controls, 20 MCI, 6 probable Alzheimer’s 
disease, and two other dementia-related diagnoses. The MoCA scores that were below 
26 included 18.6% with dementia, 37.2 with MCI, and 44.2% controls. This showed 
80% sensitivity to MCI and 100% sensitivity to dementia. In this wide population, the 
MoCA detected more participants with cognitive impairments than the MMSE.
In the elderly population, the MoCA detected more participants with cognitive 
impairments than the MMSE. Results suggested that screening for cognitive 
functioning, such as orientation to place and time, remains important. However, 
screening with a broader range of cognitive tasks, including those not represented in the 
MMSE, would be important in identifying mild cognitive difficulties that might go 
undetected. The findings did have implication for the choice o f screening instruments 
used in clinic settings, especially for those with early cognitive impairments, where the 
MMSE was not sensitive enough to detect the deficits. The MoCA is more suitable 
than the MMSE in screening for mild cognitive impairments. In conclusion, the study 
demonstrated that in an elderly population, the MoCA detected more subjects with 
cognitive impairment than the MMSE. Also, the cognitive impairment was evident 
across a variety of cognitive tasks.
Fowler et al. (2012) performed a cross-sectional study to determine primary care 
patients’ perceptions of dementia screening and evaluate the possibility of an 
association between their perceptions and their willingness to undergo screening. The 
study utilized the PRISM-PC, a questionnaire created by the researchers, to assess the 
study participants’ perceptions of dementia (Fowler et al., 2012). The Mini-Mental
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State Examination (MMSE) was used for dementia screening in the patients who agreed 
to be screened for dementia after the PRISM-PC.
According to Fowler et al. (2012), dementia is a debilitating and degenerative 
neurological condition that, at the time of the study, affected about 4.5 million people in 
the U.S. Fowler et al. theorized that an understanding of patients’ perceptions o f the 
benefits and harms of dementia screening may help to show any possible barriers and 
facilitators to implementing sufficient dementia screening programs in primary care. 
Fowler et al. stated that this study and others like it are necessary because, according to 
the USPSTF, the evidence to systematically screen for dementia in primary care is 
insufficient due to a lack of studies evaluating the efficiency, benefits, and harms of 
dementia screening in primary care (Fowler et al., 2012). There were no hypotheses in 
the study.
The study was conducted from January 2008 to June 2009 at a community-based 
primary care clinic. A face-to-face interview was utilized. Participants included men 
and women ages 65 years and above. A total o f 554 people participated in the study 
which included 388 females, 166 males, 313 African Americans, and 363 people ages 
70 years or older. All interviews were conducted in the clinic, and privacy was ensured 
before the interview. The questionnaire and subsequent screening— if the patient 
agreed—were all conducted at the same time.
For this study, the PRISM-PC was used to determine the patient’s perceptions of 
dementia screening during a face-to-face interview. The PRISM-PC was developed by 
the researchers to examine the perceived harms and benefits o f dementia. In this 
questionnaire, Alzheimer’s Disease, served as a proxy for “dementia” because early
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research revealed that people more readily understood this term (Fowler et al., 2012). 
The PRISM-PC has a total of 50 questions. Basic demographic data was established in 
the first 12 questions, including age, sex, race, education, annual income, and living 
situation. These initial questions also delved into the patient’s experience with 
Alzheimer’s disease. Additionally, there are 38 questions that measured the patient’s 
knowledge of and attitudes toward the acceptability, benefits, and harms o f dementia 
screening. The questionnaire was scored on a 1-5 point Likert scale. A selection of 1 
designated strongly agree, and a selection of 5 designated strongly disagree. After the 
questionnaire, the participants who agreed to dementia screening were screened using 
the MMSE. Fowler et al. (2012) stated that participants whose results were positive on 
the MMSE were referred to the local memory clinic for a diagnostic assessment.
According to the Fowler et al. (2012), the majority of participants (89.7%) 
agreed to be screened for dementia upon completion of the questionnaire. Study 
participants’ beliefs about screening and the benefits and harms associated with it were 
associated with their likelihood of accepting dementia screening. Participants who were 
more strongly in agreement with the questions on the PRISM-PC geared toward the 
benefits of knowing about dementia earlier were much more likely to agree to 
screening. The odds of refusing the screening were significantly higher in patients aged 
70-74 years {OR = 5.65, p  < 00) and mildly higher in patients aged 75-79 years {OR = 
3.63, p  = .01) than in the reference group of patients aged 65-69 years. Further analysis 
of the data showed that the only significant sociodemographic difference between the 
participants who accepted screening and those who refused was age. Race, sex, 
education, annual income, and living situation did not have a measurable effect on the
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participant’s likelihood to accept screening. In summary, the younger patients, ages 65- 
69 years, were most likely to accept screening; and the middle age range in the study, 
ages 70-75 years, were least likely to accept screening.
Fowler et al. (2012) identified several weaknesses in their study. First, there 
was an inherent selection bias as a result of the recruitment process. Since the study 
only recruited from the patients in the community-based clinic, there were many groups 
not reached by the study. Another limitation was the sample size. Fowler et al. 
acknowledged that inferences about perceptions and behavior are more difficult with a 
small sample. Small sample sizes can skew statistics and lead to a limited 
generalizability of the study to the larger population. Also, since it seems the 
participants only used one clinic for the study, this could limit the ability to generalize 
the study to the larger population, especially to other socioeconomic groups. Finally, 
the researchers also addressed the fact that there was not any follow-up data collected 
about the reasons any of patients had for refusing dementia screening. The researchers 
recommended future studies include further testing of instruments, such as the PRISM- 
PC, to attempt to determine whether patients who are already experiencing some 
cognitive impairment perceive screening differently from those without any cognitive 
impairment (Fowler et al., 2012).
Berres, Krumm, Mistridis, Monsch, and Taylor (2015) performed a longitudinal 
study with the intention of modeling the longitudinal course of different 
neurophysiological functions preceding the diagnosis of mild cognitive impairment due 
to Alzheimer’s disease. Berres et al. specifically wanted to determine the average time 
before a mild cognitive impairment diagnosis that each neurophysiological and clinical
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variable diverged from the course of a neurologically healthy individual. The ability to 
identify the type and sequence of cognitive decline before a mild cognitive impairment 
diagnosis is crucial to understanding the pathogenesis of Alzheimer’s disease (Berres et 
al., 2015). It is also very important in initiating much needed therapeutic interventions. 
The study focused on patients during the period where cognitive impairments were not 
yet manifested in daily life. If Alzheimer’s disease could be predicted in this period, it 
would greatly improve the ability to implement disease-modifying interventions. While 
patients’ (who will eventually be diagnosed with Alzheimer’s disease) cognitive 
performance in preclinical mild cognitive impairment stage is still normal, according to 
diagnostic criteria, their neurophysiological function will inevitably begin to decline 
when compared to individuals who remain cognitively healthy (Berres et al., 2015). 
According to Berres et al. (2015), there have been very few studies to examine the 
cognitive functioning of individuals preceding a diagnosis o f mild cognitive 
impairment.
Berres et al. (2015) did not appear to have any hypothesis on the study.
However, the researchers did list information from preceding studies that was 
applicable to this study. Previous studies seemed to be in agreement that verbal and 
visual episodic memory appeared to be the first and most affected cognitive functions in 
preclinical mild cognitive impairment. According to those studies, verbal and visual 
episodic memory could decline as early as 7 to 10 years prior to a diagnosis of mild 
cognitive impairment. According to Berres et al. (2015), all o f these studies reinforced 
the importance of the subsequent dementia diagnosis when researching the pattern of 
cognitive decline in preclinical mild cognitive impairment.
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Baseline testing was conducted on patients from 1997 to 2001. This testing 
included a clinical physical exam, medical history questionnaire, neurophysiological 
evaluation, and assessment of depression to ensure that all participants were completely 
physically and mentally healthy. The study followed 87 participants from 1997 to 
2013. The participants were reevaluated every 2 years after the initial baseline 
testing. These réévaluations consisted of a comprehensive neurophysiological 
examination. An informant, a person close to the participant who could give valuable 
insight into any changes since the previous assessment, was also consulted every 2 
years. This informant step helped uncover slight changes in the participant that only 
someone present in day-to-day life would notice (Berres et al., 2015).
This study utilized the longitudinal BASEL project (Basal Study on the Elderly). 
After the initial examination visit, at each visit the participants were evaluated using an 
identical version of the Consortium to Establish a Registry for Alzheimer’s Disease- 
Neuropsychological Assessment Battery (CERAD-NAB). The CERAD-NAB is a 
comprehensive neuropsychological assessment. The informants were given the 
IQCODE to fill out about the participants at every evaluation. This 16-item 
questionnaire asks the informant to compare the participant’s present cognitive function 
to their function 2 years prior. The IQCODE is scored on a scale o f 1 to 5 with 1 being 
much improved and 5 being much worse. The study analyzed changes in both the 
participants’ and the informants’ scores o f the 27 participants who were later diagnosed 
with mild cognitive impairment compared to the 60 participants who remained 
cognitively intact even after the study’s completion (Berres et al., 2015).
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The statistical analysis o f the study was done with cubic splines, an alternative 
cubic function for analysis. Cubic splines were used because simple linear, quadratic, 
and cubic functions were not sufficient due to the portions o f function being nearly 
linear or even consistent at some intervals since many of the participants had little or no 
change throughout the study (Berres et al., 2015). All areas assessed in patients who 
remained neurologically intact (NC-NC) increased or stayed the same throughout the 
study. According to Berres et al., the following results were given for NC-MCI 
participants. Verbal delayed recall initially decreased slightly— around 8 years prior to 
MCI diagnosis—but drastically decreased around 2 years before diagnosis. Verbal 
savings followed an almost identical pattern. Verbal encoding, visual episodic delayed 
recall, and visual savings performance declined approximately 4 years before an MCI 
diagnosis. Verbal discriminability and executive fimctions declined approximately 2 
years prior to diagnosis. In NC-MCI participants, a decline in semantic fluency was 
statically noted approximately 4 years before the MCI diagnosis. A very gradual 
decline was noted in constructional praxis fimctioning around 6 years prior to the MCI 
diagnosis. A decline was noted in psychomotor speed around 2 years prior to MCI 
diagnosis. In language assessment with the Boston naming test and with the IQCODE 
questionnaire, a very mild variation was seen in both 2 years before the mild cognitive 
impairment diagnosis. Finally, a statistically significant difference was not noted 
between NC-NC and NC-MCI participants in phonemic fluency prior to the MCI 
diagnosis (Berres et al., 2015).
Berres et al. (2015) concluded that this study definitely indicated that using a 
complete neurophysiological evaluation can bring neurological decline to light before
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mild cognitive diagnosis criteria is met. However, they also point out some areas o f 
needed improvement to the study. First, Berres, et al. indicated that the study should be 
recreated with a larger sample. A small sample size always carries the risk of an 
inability to generalize the results to the larger population. Another limitation listed was 
the sample used was one of convenience, so the results might be less likely to be 
generalizable to the population as a whole. Berres et al. suggested that future research 
be conducted to determine whether changes in scores on neuropsychological testing 
provide more sensitive markers of future MCI diagnosis than cross-sectional scores as 
well as the optimal combination of neuropsychological test scores, CSF, PET, and MRI 
measures to predict progression to Alzheimer’s disease.
In conclusion, the purpose of this study was to determine primary care 
providers’ adherence to the recommendations established by the USPSTF and the 
guidelines published by the Alzheimer’s Association. With nearly 5 million Americans 
currently diagnosed with Alzheimer’s disease and dramatic increases expected over the 
next 30 years, the need for a more rapid and efficient screening tool is becoming more 
imperative. This chapter detailed review of literature specific to research on screenings 
for the early detection of mild cognitive impairment. After review of the above 
literature, it is concluded that annual cognitive screenings would be beneficial in 
enhancing overall patient health and quality-of-life outcomes, lessening caregiver strain, 




The purpose of this study was to determine if and how often primary care 
providers adhere to the guidelines recommended by the USPSTF and the Alzheimer’s 
Association pertaining to screening for mild cognitive impairments. Mild cognitive 
impairment is a mild decline in single or multiple cognitive domains and indicates a 
significant risk of progression to dementia or Alzheimer’s disease. The Alzheimer’s 
Association guidelines dictate that all patients should be screened on an annual basis—  
regardless of whether they are exhibiting signs of cognitive impairment (Alzheimer’s 
Association, 2013). The USPSTF recommends screening all adults in the primary care 
setting aged 65 years or older who have no signs or symptoms of mild cognitive 
impairment. (USPSTF, 2014). Aiming to identify self-reported compliance with the 
guidelines, the current researchers conducted a web-based study using a questionnaire 
created specifically to gather and analyze information fi*om the providers. The current 
study helped to determine whether responding providers are screening for MCI and, if 
so, what screening methods are being utilized. This chapter will discuss the design and 
implementation of the study, the population and sample studied, the method of data 
collection, and analysis of the findings.
Design of the Study
A quantitative descriptive study design was utilized for this research. Beck and 
Polit (2017) stated that the purpose of descriptive research is “to observe, describe, and 
document aspects of a situation as if naturally occurs and sometimes to serve as a 
starting point for a hypothesis generation or theory development” (p. 206). Descriptive
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research is popular in healthcare settings due to its focus on observation and description 
and not on manipulation or experimentation. Since the purpose of the study was to 
deduce whether or not providers are screening without interfering with their process or 
test a hypothesis, the current study design was the most appropriate. This study utilized 
a web-based survey on SurveyMonkey, Inc. to gather and analyze data. The data 
gathered included the following: demographic data, likelihood to screen, current 
screening practices, factors that increase likelihood to screen, barriers to screening, and 
screening criteria. The current researchers assessed the providers’ compliance with 
guidelines for screening through a web-based survey, since this method increased the 
pool of providers available to the study. The web-based survey was not limited 
geographically as a compliance audit or chart review.
Protection of Human Subjects
Permission to conduct the study was obtained from the Institutional Review 
Board of Mississippi University for Women (see Appendix A). Human subjects were 
used when providers were asked to complete a survey questionnaire indicating current 
cognitive screening practices utilized in the clinical primary care setting. The 
guidelines used for proper screening were those set by the USPSTF in screening for 
cognitive impairments in patients age 65 years or older in the primary care setting (see 
Appendix B). During data collection, intense caution was taken to protect participants’ 
anonymity. To ensure this anonymity remained intact, a non-traceable survey was 
utilized via SurveyMonkey, Inc. The information obtained was used only for this 
research project. This information remained closely guarded, stored only in a secure 
location, and deleted after data collection was completed. The SurveyMonkey, Inc.
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account was deleted upon completion of the research project. As stated by 
SurveyMonkey Inc.’s website policy, at the time that the account was deleted the 
collected data were automatically removed from the website’s server.
Instrumentation
The online survey utilized SurveyMonkey, Inc. to host the survey during the 
study and maintain the data collection throughout the duration o f the research. The 
survey utilized a series of researcher-developed questions (see Appendix F) specifically 
tailored to this research. The researchers used this survey to collect data from primary 
care providers in Mississippi and other surrounding U.S. states and territories regarding 
their self-reported compliance with the recommendations for screening for MCI. Data 
collected on the survey included demographic data, current screening practices, 
likelihood to screen, factors that increase likelihood to screen, barriers to screening, 
screening tools used, and whether the provider’s current place of employment has 
specific screening guidelines.
This survey was comprised of multiple-choice questions, with two questions 
having the option for multiple answers. Questions 1-4 elicited responses concerning 
demographic data including state o f residence, area of practice, title of provider, and age 
o f provider. Questions 5 and 6 pertained to the first research question and elicited 
responses concerning current screening practices and likelihood to screen. Questions 7 
and 8 pertained to the second research question and attempted to discover factors that 
increase likelihood to screen and barriers to screening. Questions 7 and 8 had the 
option for the participant to select multiple answers if  more than one option was 
relevant to them. Questions 9 and 10 pertained to the third research question and
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elicited responses concerning screening tools used and whether the participant’s current 
place of employment has specific screening guidelines in place. The options listed in 
the factors that increased likelihood to screen, barriers to screening, and screening tools 
used were chosen based on current literature and prior research on MCI screening. This 
survey did not undergo any psychomotor testing but had face validity determined by a 
panel of expert researchers.
Setting of the Study
The setting for this study was primary care providers in Mississippi and other 
surrounding U.S. states and territories. The research was conducted via a web-based 
survey available to any primary care providers reached by the survey. The survey was 
distributed through SurveyMonkey, Inc. protocols and through posting by the 
researchers to social media outlets such as Facebook, Inc. and provider-specific groups. 
To reduce the likelihood of unqualified subjects completing the survey, the provider 
groups chosen on social media outlets were closed-groups open only to licensed 
providers. The members o f the groups were introduced to the study, invited to complete 
the survey at their discretion, and asked to share the survey with their qualified 
colleagues if  possible.
Population and Sample
The population for this study included primary care providers from Mississippi 
and other surrounding U.S. states and territories. The survey generated a convenience 
sample of providers who agreed to participate by answering the web-based survey. This 
sample was reached via postings on social media outlets and word of mouth. The 
researchers studied approximately 100 surveys from providers at primary care clinics in
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the state of Mississippi and other surrounding U.S. states and territories. The survey 
was available on SurveyMonkey, Inc. from March 26, 2018, to May 25, 2018.
Methods of Data Collection
After reviewing available options, the research team settled upon creating a 
questionnaire through SurveyMonkey, Inc. Several local primary care providers were 
presented with an opportunity to participate in the study. The research team also made 
the survey available on social media outlets to local providers. Providers who agreed to 
participate were given a thorough explanation of the study, and any and all questions 
were answered regarding the nature and reason for the research project and data 
collection. Providers who agreed to participate were instructed to complete a brief 
questionnaire through the SurveyMonkey, Inc. website. The information collected from 
the survey remained anonymous, and no identifying data related to the provider or the 
provider’s practice was available in any fashion.
Methods of Data Analysis
Data were compiled upon completion of the surveys. The website utilized for 
the survey, SurveyMonkey, Inc., compiled the analysis. Upon completion o f the 
analysis, data were transferred to another source of data collection, such as Microsoft 
Excel. Findings were broken down using percentages, descriptive statistics, and central 
tendency.
Other
At the end of the survey, an option was provided to leave contact information, 
including an email address for participants who would like to be updated with the 
findings of the study. Once all data were collected and measured, providers who
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participated in the study and elected to leave their contact information were sent a thank 
you letter and the findings yielded from the research. A copy of the outline of the 





With an increasing number of Americans over the age of 65 years diagnosed 
with various forms of cognitive impairment, patients and patients’ families take on 
substantial financial and emotional burdens o f managing a diagnosis of cognitive 
impairment. Over 10 years ago, the CDC estimated an average of approximately $600 
million was needed to manage a patient with Alzheimer’s disease living within an 
assisted-living and/or nursing facility. With cost o f treatment steadily rising and quality 
of life diminishing for adults with cognitive impairment, the U.S. Government 
mandated cognitive screenings of patients the age of 65 years during annual wellness 
visits in order to increase early diagnosis and treatment of age-related dementias (CDC, 
2011).
Over 100 primary healthcare providers were anonymously surveyed via a web- 
based program to compute the following information: the amount o f primary providers’ 
compliance in completing cognitive impairment screenings of older adults, any 
probable barriers decreasing provider adherence o f implementing annual cognitive 
testing of older adults, and the preferred methods and tools utilized for cognitive 
impairment screening of those ages 65 years and older. The following chapter will 
discuss the results of this study and display primary care providers’ adherence to the 
USPSTF and the Alzheimer’s Association’s recommendations and guidelines 
advocating for annual cognitive impairment screening on patients aged 65 years or 
greater.
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Profile of Study Participants
The target sample population for this study included primary care providers 
practicing in the southeast region o f the United States. To reduce unqualified subjects 
who were healthcare providers not practicing in primary care, this study’s anonymous, 
web-based survey was advertised on voluntary, closed-groups on social media outlets 
for licensed primary care providers. After participants in this study voluntarily 
completed a brief anonymous survey, members o f the closed-groups were asked to 
share the survey with their qualified colleagues at their discretion.
Over 100 participants completed the survey. Qualified subjects consisted of 
primary care providers, including physician assistants, certified nurse practitioners, and 
physicians practicing in family medicine and/or internal medicine in primarily the 
southeast region. While maintaining anonymity, the initial three questions of the survey 
provided disqualifying demographics in requesting participants’ state o f primary 
practice, professional title, and primary area of practice. With these screening questions 
in place, the majority of the study participants were identified as certified nurse 
practitioners in family practice working in Mississippi.
Statistical Results
Primary care providers’ adherence to the USPSTF guidelines were examined by 
an anonymous survey of 101 providers fi"om all over the country, but primarily in 
Mississippi and the surrounding states. The results are addressed below.
The providers who took the survey reported their professional title. In regard to 
the type of provider in the sample (A =101), 13 were medical doctors (MD), 84 were
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nurse practitioners (NP), and 4 were physician assistants (PA). The results for the 











What is your professional title?
MD NP PA
Figure 1. Professional title of survey responders.
Figure 2 demonstrates the area of practice of each provider who responded to 
the survey. When the answers on the following questions were compiled and the data 
analyzed, only answers from family practice, internal medicine, and geriatrics/long-term 
care were used in the data analysis. This distinction was made because the providers 
are practicing in the emergency room or urgent care for mainly acute issues and are not 
held to the same screening standards. The answers associated with the urgent care and 
emergency room providers will not be included in any of the following data. The 
results revealed 66 family practice, 15 internal medicine, 12 geriatrics/long-term care, 7 
urgent care, and 1 emergency room response. Figure 2 displays a compilation of the 
responses to the question regarding primary area of practice.
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What is your primary area of practice?
IFamily Practice
G crS« .T rlcis/L onE  
Term i arf
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Emergency
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Figure 2. Area of practice.
The third question elicited the age of the provider responding to the survey. 
There were four categories given for age. Group 1 was ages 21-35 years. Group 2 was 
ages 36-50 years. Group 3 was ages 51-65 years, and Group 4 was ages 65 years and 
older. The age distribution of the providers who responded to the survey is shown in 
Figure 3.
What is your age?
S I - 6 5
20%
Figure 3. Age of participants.
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The remaining questions in the survey examined the screening practices of the 
providers who responded. When asked which response best described screening 
practices for mild cognitive impairment in patients age 65 years and older, 55 providers 
responded that, I  screen patients i f  they or their family mention a concern over memory 
problems or a decline in ability to perform ADLs. A total of 29 providers responded 
that, I  screen every patient aged 65 years and older every year at their wellness visit, 
and 10 providers responded that I  do not screen patients fo r mild cognitive impairment. 
See Figure 4 for these findings.
Which response best describes your screening practices for mild 
cognitive impairment in patients age 65 and older?
I do not screen % 
patients for Mild \ 
Cognitive 
impairment.
I screen every 
patient aged 65 and 
older every year at 
their wellness...
I screen patients 
if they or their 
family mention a 
concern over mem.
Figure 4. Screening practices.
The providers were also asked, “If a patient over 65 years of age comes into 
your clinic without any obvious signs of cognitive impairment, how likely are you to 
screen this patient for mild cognitive impairment?” Their responses were divided into 
four categories: (1) I  will not screen, (2) I  am not likely to screen, (3) I  am somewhat 
likely to screen, and (4) I  will very likely screen. The responses were as follows: 15
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providers chose Iw ill not screen, 43 providers chose I  am not likely to screen, 25 
providers chose I  am somewhat likely to screen, and 11 providers chose Iw ill very likely 
screen. Ihese results are demons Ira Led in Figure 5.
If a patient over 65 years of age comes into your clinic without any obvious 
signs of cognitive impairment, how likely are you to screen this patient for 
mild cognitive impairment?
f wtU notm
la m  not 
likely to ...
I am som ew hat 
Ukely to ...
I will very 
likely screen
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Figure 5. Likelihood to screen.
Providers were asked which factor/factors make them more likely to screen 
patients over 65 years of age for mild cognitive impairment. They were instructed to 
choose all relevant answers with an option to choose Other and describe a specific 
answer not listed above. The option. Patient has not been screened in at least 12 
months, was chosen 23 times; the option, Patient’s family mentions deterioration or 
change in patient’s behavior, was chosen 72 times; the option. Patient appears 
somewhat lost in the conversation, was chosen 69 times; the option. Patient admits to 
forgetfulness or memory loss issues, was chosen 69 times; the option. Guidelines that 
dictate how often a patient should be screened, was chosen 33 times; and Other was
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chosen two times with the responses as Personality changes and All o f  the above. 
These results are displayed in Figure 6.
Which factor/factors make you more likely to screen patients over 65 years 
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Figure 6. Factors increasing likelihood of screening.
Providers were asked which factor/factors make you less likely to screen 
patients over 65 years of age for mild cognitive impairment. They were instructed to 
choose all relevant answers and given the option to choose Other and describe a specific 
answer. The choice Concerns over unnecessary testing was chosen 24 times; the choice 
Lack o f  clear guidelines on when and how to screen was chosen 31 times, the choice 
Lack o f  clear guidelines as to which screening tool to use was chosen 31 times, and the 
choice Lack o f  adequate time with each patient was chosen 65 times. The choice Other 
was chosen 10 times with some responses being: I  started from  the beginning testing 
this age group. No concerns, able to tell detailed medical (history) and recent events 
well. Concerns that patients may be offended or upset by screening. Patient refusal, 
(Patient) worries over consequences o f  a dementia score. And No real treatment or
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cure and Insurance reimbursement is so poor and we have so many we have to see to 
make any money. These results are displayed in Figure 7.
Which factor/factors make you less likely to screen patients over 65 
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Figure 7. Factors decreasing likelihood of screening.
In order to determine the preferred screening tool for MCI, the providers were 
asked the following question: When/if you screen for mild cognitive impairment, and 
what screening tool do you use most often? The responses were as follows: Mini Mental 
State Examination was chosen 57 times. Short Portable Mental Status Questionnaire 
was chosen 2 times, Mini-Cog was chosen 16 times, clock test was chosen 6 times, and 
3-word recall test was chosen 9 times. The remaining 3 providers chose Another 
screening tool and inserted the following 3 answers: MoCA, Animal fluency, and We 
actually use a combination o f  these-in yearly wellness exams, use 3-word recall and 
clock test. I f  there is an acute issue, use mini mental exam. The Health Risk Assessment 
tool was not chosen by any provider, and 4 providers chose I  do not use any screening 
tools. These results are displayed in Figure 8.
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When/if you screen for mild cognitive impairment, what screening 
tool do you use most often?
Another screening 
tool
{do not use any 
screening toob^ 
3 Word Recall Test
Clock Test
Mini-Cog





Figure 8. Screening tool preference.
The providers were asked if their current clinic or current place of employment 
had set guidelines in place for screening for mild cognitive impairment. O f the 94 
responses used to analyze the data, 27 responded yes and 67 responded no. Those 
results are displayed in Figure 9.
Does your current clinic/place of employment has set guidelines 
in place for screening for mild cognitive impairment?
No
Yes
Figure 9. Guidelines at current place of employment.
64
The final question was added as an option at the end of the survey. The question 
consisted of the option for participants to leave their email address if  they wished to 
receive the results o f the survey. This question was optional, and participants could 
choose to end the survey without entering a response. If provided, email addresses were 
not associated with any previous answers, which protected the anonymity of the survey. 
Of the 101 providers surveyed, 18 chose to leave their email address and were sent the 
results at the conclusion o f data analysis.
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CHAPTER V 
Summary, Conclusions, and Recommendations
Mild cognitive impairment (MCI) is a mild decline in a single domain or 
multiple cognitive domains. A diagnosis of MCI drastically increases a person’s risk of 
eventually developing Alzheimer’s disease. More than 16 million people in the U.S. 
live with some form of cognitive impairment. Age is the biggest risk factor for 
developing cognitive impairment, and advances in technology and medicine are 
allowing people to live longer than ever. The projected increase of this disease 
incidence is 13.2 million by the year 2050 (CDC, 2011), thereby increasing the 
healthcare strain and economic burden. In 2007, the CDC reported approximately $647 
million as the average cost for a government-funded (i.e. Medicaid) nursing facility to 
adequately care for an individual with Alzheimer’s disease (Wiese & Williams, 2015).
Alzheimer’s disease is not reversible; therefore, early detection, diagnosis, and 
treatment o f MCI are imperative. Unfortunately, patients who are developing cognitive 
impairment or who have dementia usually do not receive a formal diagnosis. Studies 
indicated that most primary care providers were unaware of cognitive impairments in 
> 40% of their cognitively impaired patients. Another study revealed that > 50% of 
patients with dementia received no clinical cognitive screening by a primary care 
provider. With efforts to increase early diagnosis and treatment of age-related 
dementias, the U.S. Government initiated the National Alzheimer’s Project Act, which 
required routine cognitive screening of adults over the age of 65 years (Wiese et al., 
2014). According to the USPSTF, screening was recommended on a yearly basis and 
applies to community-dwelling adults in the general primary care population who are
66
older than the of 65 years and have no signs or symptoms of cognitive impairment. The 
CMS amended their recommendations for the Annual Wellness Visit (AWV) effective 
January 1, 2011, to include guidelines for screening for cognitive impairment during the 
AWV (CDC, 2011). Over 5 years after the initiation of new guidelines warranting 
cognitive screening of older adults over 65 years o f age, three questions justified 
investigation:
1. Do primary care providers conduct mild cognitive impairment screenings 
in older adults?
2. What provider-generated barriers may decrease the likelihood of cognitive 
screening in older adults during visits with primary care providers?
3. What screening methods do primary care providers use to detect mild 
cognitive impairment?
The purpose of this research study was to answer these questions. A 
quantitative descriptive study design was utilized for this research. The research team 
utilized a researcher-created, web-based survey on Survey Monkey Inc. to gather 
information from primary care providers in Mississippi and other southern U.S. states 
and territories. The information gathered included providers’ screening practices, 
likelihood to screen, factors that increased or decreased likelihood of screening, and 
clinic screening guidelines. The results gathered will be used to increase provider 
knowledge and improve patient outcomes.
This chapter contains the details of a research study that was created with the 
hope of helping primary care providers understand the importance of routinely and 
consistently screening for and diagnosing cognitive impairment as early as possible.
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The summary and discussion of the findings, the limitations of the study, conclusions of 
the study, and the implication of the findings are analyzed within the chapter. 
Recommendations for future research and compliance with suggested screening 
guidelines in primary care practice based on the conclusions of this study are also listed. 
Summary of Findings
Over 100 primary healthcare providers, including physicians, physician 
assistants, and nurse practitioners, were anonymously surveyed via a web-based 
program to compute the following: (a) primary providers’ compliance in completing 
cognitive impairment screenings of older adults, (b) probable barriers decreasing 
provider adherence of implementing annual cognitive testing of older adults, and (c) 
the preferred methods and tools utilized for cognitive impairment screening of those 
ages 65 years and older. O f the 101 surveys completed, 83.17% were submitted by 
nurse practitioners, 12.87% were physicians, and 3.96% were physician assistants. O f 
the survey takers, 65.35% practiced in primary care settings and 14.85% were in an 
internal medicine setting. The remaining 19.8% of survey takers practiced in urgent 
care, geriatrics, long-term acute care, or emergency room settings. Survey results 
indicated that only 28.71% of providers routinely screened patients aged 65 years and 
older every year at their wellness visit, and 58.42% only screened if the patient or a 
family member voiced concern over memory problems or a decline in the ability to 
perform ADLs.
Surprisingly, even with the current guidelines in place to screen every patient 65 
years or older for MCI at their AWV, 44.55% of providers answered that they were not 
likely to screen for MCI if  the patient presented with no obvious signs of MCI, and only
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12.87% answered that they were very likely to screen the patient. Eighty percent o f 
providers answered that the patient’s family member mentioning deterioration or 
changes in the patient’s behavior was the biggest factor in choosing to screen a patient 
for MCI, and 72.22% answered that the biggest factor deterring them from routinely 
and consistently screening patients was lack of adequate time with the patient. The 
Mini Mental State Examination was the most popular screening tool used by 57.43% of 
providers.
Discussion of Findings
In one of her first research studies on the correlation o f behavior to enhancing 
health promotion, Nola Pender found that many individuals would utilize prevention 
and health-promoting services when made available to their community. Although the 
research focus was on the behavioral influences affecting the utilization of nurse 
practitioners as opposed to physicians, the study revealed most o f the sample population 
agreed to partake in health-promoting services when offered by any healthcare provider 
(Pender & Pender, 1980). This finding would later become the HPM’s theoretical claim 
stating, “Families, peers, and healthcare providers are important sources of 
interpersonal influence that can increase or decrease commitment to and engagement in 
health-promoting behaviors” (Pender, 2011, p. 5). The current study addressed the 
significance of healthcare provider commitment to and engagement in positive 
healthcare outcomes, especially regarding cognitive screening in older adults.
The findings o f the current researchers were similar to those of Fowler et al. 
(2015) in that the current study also revealed primary care providers are lacking in their 
assessment of MCI. Fowler et al. (2015) aimed to determine if  identifying patients wdth
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mild cognitive impairment could result in a change in providers’ approach to treatment 
or if an early diagnosis could impact the progression of cognitive decline. Therefore, 
the findings of each study were congruent, and each study demonstrated a need for 
primary care providers to screen for MCI regardless of available time or standardized 
tool.
Muller et al. (2017) concluded there is a need to develop fast, easy, non- 
invasive, and inexpensive diagnostic tools to accurately detect people with cognitive 
impairment and dementia. The current researchers found that 72.22% of the providers 
surveyed stated that time was the determining factor in not screening for cognitive 
impairment. Although there are significant data found related to the importance of early 
screening and diagnosis of mild cognitive impairment, providers continue to find less 
and less time for screenings related to the number of patients to be seen to meet 
reimbursement goals. For that reason, Muller et al. (2017) and the current study echo 
similar findings in the need for a standardized, rapid, and inexpensive diagnostic tool to 
be used in the primary care setting.
Malmstrom et al. (2015) found that primary care providers frequently do not 
properly identify persons with cognitive dysfunction because no gold standard 
screening tool currently exists to detect cognitive dysfunction. Because dementia and 
cognitive impairment interfere with patients’ ADLs, the lack of consistent cognitive 
screening decreases the change o f early diagnosis and possibly increases the likelihood 
of detrimental effects and/or events. Similarly, the current researchers found that 
34.44% of providers stated they did not screen because there is a lack of standardized 
tools. The current study and the reviewed literature agreed in that, if  given a
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standardized tool, primary care providers will be able to enhance the patient’s 
continuity in the healthcare setting, as well as provide patients and their families with 
the confidence and support needed to accept early screening.
Although not addressed in the study’s questionnaire and research, Fowler et al. 
(2 0 1 2 ) recognized another aspect in barriers to completing routine cognitive 
assessment. Fowler et al. (2012) performed a cross-sectional study to determine 
primary care patients’ perceptions of dementia screening and to evaluate the possibility 
o f an association between their perceptions and their willingness to undergo screening. 
In the current study, when asked about factors making it less likely for providers to 
screen patients 65 years of age and older, one participant specified that (Patient) 
worries over consequences o f  a dementia score. And No real treatment or cure. While 
patient perception was not originally considered in the design o f the present study, 
Fowler et al. (2012) discussed significant reasoning for further investigation into this 
component.
Regardless of identified barriers, the current study and literature reviewed 
demonstrated significant need for early cognitive screening in adults age 65 years and 
older. According to Pender’s work with the Health Promotion Model, the nursing 
discipline is responsible for linking the person and environment to promote behavioral 
changes leading to optimal health (Pender, 2011). Therefore, it is important to consider 
the outcome of the patient’s well-being. Whether lack of education, lack of time, non­
standardized screening tools, or negative patient perceptions, it is imperative for the 
primary care provider to treat the patient physically and psychosocially in order to 
produce the best possible outcome.
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Limitations
Although well-constructed to obtain primary care providers’ adherence to the 
current guidelines regarding cognitive screening in older adults, the current study 
presented with several limitations, which may have decreased the generalizability of its 
findings. The federal government issued guidelines requiring annual cognitive screening 
of older adults, however no gold standard screening tool existed for detecting cognitive 
impairment; therefore, this study’s results of the primary care providers’ utilization and 
competency of a single screening tool could not be accurately measured. In lacking a 
single cognitive screening tool, the researchers were unable to uniformly measure and 
critique study participants. In addition to the absence of an exemplar cognitive 
screening tool, there was no benchmark screening instruments with a high specificity 
and/or sensitivity for diagnosing MCI. Most cognitive screening tools detected 
generalized cognitive impairment and not specifically MCI, which required further 
assessment and possible referral to a specialist for a more accurate diagnosis.
The validity of the research was affected by the small sample size and 
geographical location. The research project was only implemented as a survey and was 
posted on several social platforms for primary care providers. The sample size was 
made up of only 101 primary care providers’ responses. Additionally, posting on social 
media platforms allows for providers from many states to have access to the survey.
The majority o f respondents were from Mississippi; however, several other states were 
represented. Thus, the small sample size and geographical location limited the amount 
and number of samples that could be reviewed, narrowing our field of research and 
generalizability.
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Another key limitation within the study was that not all o f the providers 
surveyed were primary care providers. O f the respondents, 7.62% did not work in a 
primary care setting. Of the 7.62%, 0.99% worked in an emergency room setting and 
6.93% worked in an urgent care setting. Working in settings outside the primary care 
setting could potentially affect the intended results, as emergency/urgent care settings 
are not required to test for cognitive impairment on a routine basis. Another limitation 
was the possibility o f inadequate reporting by the healthcare providers. Without a 
uniform cognitive screening tool and a substantial number of primary providers 
excluded in the convenience sample, this research study proposed several limitations, 
which may have affected the generalizability o f the study's findings. Furthermore, 
collecting data in a period of 30 days may have limited the amount o f surveys that could 
have been obtained.
Conclusions of the Findings
The goal of the current study was to determine primary care providers’ 
adherence to the guidelines established by the USPSTF for mild cognitive impairment 
screenings. According to the results, the researchers determined adherence to the 
guidelines established by the USPSTF were inadequate. The results revealed that only 
12.87% of primary care providers surveyed screen according to the recommendations o f 
the USPSTF. Consequently, 28.71% of the primary care providers surveyed stated they 
do not screen at all for MCI. Based on these results, the researchers concluded that 
compliance to recommended screenings established by USPSTF among primary care 
providers is insufficient and there was a great need for further education on this topic.
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Implications
The purpose of this study was to determine primary care providers’ adherence to 
USPSTF and the Alzheimer’s Association’s recommendation and guidelines advocating 
annual cognitive impairment screening on patients ages 65 years or greater. Primary 
care providers, including nurse practitioners and advanced practice nurses, have the 
potential to take an aggressive approach to MCI detection and treatment by adhering to 
USPSTF recommendations. This current study utilized Nola Pender’s Health 
Promotion Model (HPM) as a guide to identifying the perceived barriers to action and 
perceived self-efficacy o f primary providers’ nonadherence to the national guidelines 
requiring annual cognitive screening of older adults. Through surveying primary care 
providers, this study incorporated the theoretical assumptions and propositions of the 
HPM to promote compliance with the national standard of routine cognitive screening 
in the geriatric population.
Based on the findings o f this study, there is a great need for further education of 
the USPSTF guidelines and the Alzheimer’s Association recommendations for routine 
screenings for MCI in the primary care setting. As nurse practitioners are often the first 
access to health care in rural areas, this education of early screenings is of great 
importance. In 2007, the Centers for Disease Control and Prevention (CDC) found 
approximately $647 million as the average cost for a government-funded (i.e. Medicare) 
nursing facility to adequately care for an individual with Alzheimer’s disease (Wiese & 
Williams, 2015). With adequate routine screenings and early diagnosis, providers can 
decrease the risk o f complications related to MCI and decrease the costs o f caring for 
individuals with cognitive impairments later in diagnosis. Advance practice nurses, as
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well as other providers, not only have the ability to change outcomes for patients; but 
they have the responsibility also to educate their patients, families, and colleagues about 
the significance of early screening fur MCI.
The CMS recommends indulging cognitive assessment screening for early 
detection of MCI as a part of the requirements o f the annual wellness visit for adults 
ages 65 years and older (see Appendix D). Even though CMS recommends cognitive 
screenings annually, they do not specify what screening approach to use. The federal 
government issued guidelines requiring annual cognitive screening of older adults; 
however, no gold standard screening tool existed for detecting cognitive impairment. In 
addition to the absence of an exemplar cognitive screening tool, there were no 
benchmark screening instruments with a high specificity and/or sensitivity for 
diagnosing MCI. Most cognitive screening tools detected generalized cognitive 
impairment and not specifically MCI, which required further assessment and possible 
referral to a specialist for a more accurate diagnosis. Due to the stated findings, further 
implications for standardized cognitive impairment screening and scoring across 
different disciplines in the medical field would provide better continuity in care for 
patients and decrease prevalence of delayed diagnosis of MCI.
Recommendations
Based on the significant findings of this study, recommendations for future 
study should be discussed. It is important to consider whether or not providers are 
influenced in screening for MCI. Payer source should be identified in those patients 
screened to identify a trend. It would be interesting to identify whether or not providers 
are considering the reimbursement versus the long-term benefit prior to screening
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patients for MCI. Another argument could lie in the outcomes of those identified as 
having an MCI. Once identified, research could include plan of care after diagnosis. 
Researchers could evaluate the aggressiveness of treatment once the provider makes the 
diagnosis. Lastly, one aspect to consider when performing future research is the 
provider’s awareness of the recommended guidelines. Research aimed at identifying 
whether or not providers are aware of current recommendations for screening for MCI 
could foster fruitful research data for long-term planning. As previously discussed 
regarding implications, a standardized assessment tool is vital to continuity of care 
between providers and prevention/treatment of MCI. With proper education and an 
appropriate assessment tool, patients would experience less decline in cognitive 
abilities, increased independence and safety, a decrease in caregiver burden, a decrease 
in the progression of dementia, and an increased chance of maintaining baseline 
cognitive status.
As discussed, implications for future research were a vital outcome o f this study. 
While the study findings are significant, without further data, the motivation to increase 
awareness is minimal. The outcomes of this study indicate that further research for 
MCI screening in the primary care setting by nurse practitioners and physicians is 
warranted. The study raised the following aforementioned topics for future research. 
Further investigation into providers’ awareness of current guidelines, deterring payor 
sources, the impact o f time to screen, and the availability o f screening tools would yield 
more gainful data for future implications.
76
REFERENCES
Alligood, M. R., & Marriner-Tomey, A. (2010). Nursing theorists and their work.
Maryland Heights, MO: Mosby Elsevier.
Alzheimer’s Association. (2013, March). Alzheimer's Association recommendations fo r  
operationalizing the detection o f  cognitive impairment during the Medicare 
annual wellness visit in a primary care setting. Retrieved from 




Annual wellness visit (A WV), including personalized prevention plan services (PPPS) .
(2011). Retrieved from https://www.cms.gov/Gutreach-and-Education/Medicare 
-Leaming-Network-MLN/MLNMattersArticles/Downloads/MM7079 
Barriers. (2018). Merriam-Webster.com. Retrieved from https://www.merriam- 
webster.com/dictionary/barriers 
Beck, C. T., & Polit, D. F. (2017). Nursing research generating and assessing evidence 
fo r  nursing practice (10th ed). Philadelphia, PA: Wolters Kluwer Health.
Berres, M., Krumm, S., Mistridis, P., Monsch, A., & Taylor, K. (2015). The 12 years 
preceding mild cognitive impairment due to Alzheimer's Disease: The temporal 
emergence of cognitive decline. Journal o f  Alzheimer's Disease, 48, 1095-1107. 
Retrieved from http://dx.doi.org/10.3233/JAD-150137
77
Centers for Disease Control and Prevention. (2011). Cognitive impairment: A call fo r  
action, now! U.S. Department o f Health and Human Services, Centers for 
Disease Control and Prevention.
Cognitive assessment toolkit: A guide to detect cognitive impairment quickly and 
efficiently during the Medicare annual wellness visit, (n.d.). Retrieved from 
https://www.alz.org/documents_custom/141209-CognitiveAssessmentToo-kit- 
final
Final recommendation statement: Cognitive impairment in older adults screening. 
(2014). Retrieved from https://www.uspreventiveservicestask 
force.org/Page/Document/RecommendationStatementFinal/cognitive- 
impairment-in-older-adults-screening#citation24 
Fowler, N. R., Boustani, M. A., Frame, A., Perkins, A. J., Monahan, P., Gao, S., . . .
Hendrie, H. C. (2012). Impact of patients' perceptions on dementia screening in 
primary care. Journal o f  the American Geriatric Society, 60{6). Retrieved from 
http://dx.doi.0 rg/lO.l 111/j. 1532-5415.2012.03991.x 
Fowler, N. R., Morrow, L., Chiappetta, L., Snitz, B., Huber, K., Rodriguez, E., &
Saxton, J. (2015, September 1). Cognitive testing in older primary care patients: 
A cluster-randomized trial. Alzheimer's and Dementia: Diagnosis, Assessment 
and Disease Monitoring, 1, 349-357. Retrieved from http://dx.doi.0 rg/lO .lOl6  
/j.dadm.2015.06.009 
Generated. (2018). Merriam-Webster.com. Retrieved from https://www.merriam- 
webster. com/dictionary/generate
78
Grober E., Wakefield, D., Ehrlich, A., Mabie, P., & Lipton, R. (2017). Identifying 
memory impairment and early dementia in primary care. Alzheimer’s and 
dementia: Diagnosis, assessment, and disease monitoring. 
doi:10.1016/j.dadm.2017.01.006 
Hessler, J., Bronner, M., Etgen, T., Ander, K., Forstl, H., Poppert, H., & Bickel, H. 
(2013, October 6 ). Suitability of the 6 CIT as a screening test for dementia in 
primary care patients. Aging and Mental Health, 18{A), 515-520.
Kelley, J. A., Sherrod, R. A., & Smyth, P. (2009, Fall). Coronary artery disease and 
smoking cessation intervention by primary care providers in a rural clinic.
Online Journal o f  Rural Nursing and Health Care, 9(2), 82-94.
Lawson, T. (2014). Systems model. In M. Algood (Ed.). Nursing theorists and their 
work (8 th ed). St Louis, MO: Elsevier.
Lin, F., Vance, D. E., Gleason, C. E., & Hendrich, S. M. (2012). Taking care of older 
adults with mild cognitive impairment: An update for Nurses Journal o f  
Gerontological Nursing. Journal o f  Gerontological Nursing, 38(12), 22-37. 
doi. 10.3928/00989134-20121106-02 
Mahnstrom, T. K., Voss, V. B., Cruz-Oliver, D. M., Cummings-Vaughn, L. A.,
Tumosa, N., Grossberg, G. T., & Morley, J. E. (2015, November 7). The rapid 
cognitive screen (RCS): A point-of-care screening for dementia and mild 
cognitive impairment. Journal o f  Nutrition, Health and Aging, 19, 741-744. 
Retrieved from http://dx.doi.org/10.1007/sl2603-015-0564-2 
Markwick, A., Zamboni, G., & A. de Jager, C. (2012). Profiles o f cognitive subtest
impairment in the Montreal Cognitive Assessment (MoCA) in a research cohort
79
with normal Mini-Mental State Examination (MMSE) scores. Journal o f  
Clinical and Experimental Neuropsychology, 34(1), 750-757.
McCutcheon, T., Schaar, G., & Parker, K. L. (2016). Pender's health promotion model 
and HPV health-promoting behaviors among college-aged males: Concept 
integration. Journal o f  Theory Construction and Testing, 12-19.
Mehrabbeik, A., Mahmoodabad, S. S., Khosravi, H. M., & Fallahzadeh, H. (2017, 
August). Breakfast consumption determinants among female high school 
students o f Yazd Province based on Pender's health promotion model.
Electronic Physician, 9(8), 5061-5067. Retrieved from http://dx.d0 i.0 rg/http://dx 
.doi.org/10.19082/5061 
Muller, S., Preische, O., Heymann, P., Elbing, U., & Laske, C. (2017, April 11).
Increased diagnostic accuracy of digital vs. conventional clock drawing test for 
discrimination of patients in the early course of Alzheimer's disease from 
cognitively healthy individuals. Frontiers in Aging Neuroscience, 9(1), 1-10. 
Retrieved from http://dx.doi.org/10.3389/fiiagi.2017.00101 
Pender, N. J. (1996). Health promotion in nursing practice. New York, NY: Appleton- 
Century-Crofts.
Pender, N. J. (2011). Health promotion model manual. Retrieved from University of 
Michigan Deep Blue, http:hdl.handle.net/2027.42/85350 
Pender, N. J., & Pender, A. R. (1980). Illness prevention and health promotion services: 
Predicting potential consumers. American Journal o f  Public Health, 798-803. 
Sakraida, T. J. (2014). Health promotion model. In M. R. Alligood (Ed.), Nursing
theorists and their work (8th ed., pp. 396-416). St. Louis, MO: Elsevier Mosby.
80
Screening fo r  cognitive impairment in older adults. (2015, March). Retrieved from 
http://uspreventiveservicestaskforce.org 
Wiese, L. K., & Williams, C. L. (2015). Annual cognitive assessment for older adults: 
Update for nurses. Journal o f  Community Health Nursing, 187-198.
 ̂ Wiese, L. K., Williams, C. L., & Tappen, R. M. (2014). Analysis o f barriers to 
cognitive screening in rural populations in the United States. Advances in 









Â of Eimttèncefùr Wmm and Men
1100 CfeDege Stpe<̂  MIJW-16Ô3 






College o£ axui Heaiüi Science
1100 Ccflege Shre^ MUW- 910 
Columbus, MmsWppi 39701
EtearDr. McCarter:
I am pleased to Worm you that the meWers Of the Iristitutioiml Review Board (DRB) 
have reviewed the following proposed research and have approval it as submitted
Name of S ta ^  Early Eklecdon of Mild Cognitive Impairment m
Older Adults Ihrou^ the Use of Anntml Screening 
in W  Priinaiy Care Setting 
Research Facall^Advison Carey McCac^, HuD.
Ihvestigatacs: Jonhcn Lundy, Donald Tisdale, diaries Kn^p,
Jî sica Mann, and Kayla McModse
I w i#i you W*ch suex^ss in your research.
Thomas C  Richardson, Ph.D.
TCR/te
pc Tmnmie McCoy, htshhttimial RW #v Btmrd (ZhaLiiman
8 2
APPENDIX B 
USPSTF Cognitive Screening Recommendations
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Final Recommendation Statement
Cognitive Impairment in Older Adults: Screening
Reœ m m endations m ade by the USPSTF are independent o f the U. S, governm ent They should  not be construed as an o fficial position o f the Agency fo r Heattficare  Research and  
Quality o r t t ie  U.S. Departm ent o f Health artd Human Services.
R ecom m endation  Sum m ary
Summary of Recommandation
P o p u la tio n R ecom m endation
G rad e  
(Whafs This?)
Older Adults The USPSTF concludes that the current evidence is insufficient to a s s e s s  the  balance of benefits and harm s of screening for cognitive impairment.
S ee  the Clinical Considerations section tor suggestions for practice regarding the I statem ent.
Table of C on ten ts
Recom mendation Summary Update of Previous USPSTF Recom mendation
Preface R ecom m endations of O thers
Rationale M embers of the U.S. Preventive Services Task Force
Clinical Considerations References
Other Considerations Copyright and Source information
Discussion
Preface
The U.S. Preventive Services Task Force (USPSTF) m akes recommendations about the e ffectiveness o fs p e d h c  preventive care  serv ices fo r patients w ittiout re la ted signs o r  
symptoms.
i t  trases its  recommertdations on the  evidence o f both the benefits and  harm s o f  tite  service a nd  an assessm enf o f the balance. The USPSTF does not cons ide r the costs o f  
providing a service in  this assessm ent
The USPSTF recognizes that d in ica i dedsions involve m ore considerations than evidence alone. C lin idans should understand the e v ide rxe  b u t individualize d eds ion  makirtg to 
the specific patient o r situation. Simiiarty, ttre USPSTF notes that po licy  and  coverage dedsions involve considerations in addition to the evidence o f d in ic a i berjetits and  harms.
Rationale
Importance
Dementia affects approximately 2.4 to 5 .5  million Americans. Its prevalence increases with age, to 5% in persons aged  71 to 79 y ears, 24%  In those aged  80 to 89 years, and 
37% In those older ttian 90 years. Mild cognitive impairment (MCI) is different from dem entia in that the cognitive impairment is not severe  enough to interfere with instrumental 
activities of daily life. It is difficult to estim ate the prevalence of MCI, and estim ates range widely, from 3% to 42%  in adults ag ed  65 y ears  and older.
Detection
The USPSTF found adequate  evidence that som e screening tools have sufficiently high sensitivity a nd  specificity to be dinicaliy useful in identifying dem entia.
Benefits o f Detection and Early Intervention
The USPSTF found inadequate direct evidence on the benefits of screening for cognitive Im pairm ent Evidence show s that several drug therapies and nonpharm acologic 
Interventions have a  small effect on cognitive function m easu res  In the short term  for patients with mild to m oderate dem entia, but the magnitude of the  clinically relevant benefit 
Is uncertain. The USPSTF found adequate  evidence that interventions targeted to caregivers have a  small effect on m easures of caregiver burden and depression , but the 
magnitude of the clinically relevant benefit is uncertain. The USPSTF found no published evidence on the effect of screening on decision making or planning by patients, 
clinicians, or caregivers.
Harms of Detection and Early Intervention or Treatment
The USPSTF found Inadequate evidence on the harm s of screening for cognitive impairment and of nonpharm acologic interventions. It found adequate  evidence that 
acetylcholinesterase inhibitors (AChEis) are  associated  with adverse  effects, som e of which a re  serious, including central nervous system  disturbances and  arrhythmia. 
Gastroirrtestinai sym ptom s are  also common.
USPSTF Assessment
The USPSTF concludes that the evidence on screening for cognitive impairment is lacking and  that th e  balance of benefits and  harm s cannot be determined.
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Clinical Considerations
Patient Population Under Consideration
This recommendation applies to universal screening with formal screening instruments in community-dwelling adults in the general primary care population who are older than 
age 65 years and have no signs or symptoms of cognitive impairment. Early detection and diagnosis of dementia through the assessm ent of patient-, family-, or physician- 
recognized signs and symptoms, some of which may be subtle, are not considered screening and are not the focus of this recommendation.
Suggestions for Practice Regarding the I Statement
Potential Preventable Burden
The prevalence of dementia in the United States is 5% in persons aged 71 to 79 years, increasing to 24% in those aged 80 to 89 years and 37% In those older than 90 years^> ^ 
The prevalence of older adults with MCI is difficult to estimate because of differences in the definition of MCI and methods used in studies; estimates range widely, from 3% to 
42% in adults age 65 years and older. Approximately 40% to 50% of older adults report subjective memory symptoms. The rate of progression of MCI to dementia is uncertain 
2
Although the evidence on routine screening is insufficient, there may be important reasons to identify early cognitive impairment. In addition to its potential to help patients make 
diagnostic and treatment decisions, including treatment of reversible causes of dementia and management of comorbid conditions, early recognition of cognitive impairment 
allows clinicians to anticipate problems patients may have in understanding and adhering to recommended therapy. This Information may also be useful to patients and their 
caregivers and family members in anticipating and planning for future problems that may develop as  a result of progression of cognitive impairment. Although the overall 
evidence on routine screening is insufficient, clinicians should remain alert to early signs or symptoms of cognitive impairment (for example, problems with memory or language) 
and evaluate as appropriate. The National Institute on Aging has information on the detection and management of cognitive impairment for patients and clinicians, including a 
database of tools to detect cognitive impaintient (available at www.nia.nih.govThis link goes offsite. Click to read the external link disclaimer).
Potential Harms
Information about the harnis of screening, including labeling and the effect of false-positive results, is limited. Acetylcholinesterase inhibitors are associated with adverse effects, 
some of which are serious, including central nervous system disturbances and bradycardia. Gastrointestinal symptoms are also common. Information about the harms of 
nonpharmacologic interventions is limited, but these harms are assum ed to be small. Exercise interventions are not associated with serious adverse effects.
Costs
The cost of screening varies depending on the screening instrument. Some instmments take little time and are free to the public. The most widely studied instnjment, the Mini- 
Mental State Examination (MMSE), takes approximately 10 minutes to administer and is not free. Total health, long-term, and hospice care costs for dementia in the United 
States were an estimated $183 billion in 2011. Medicare and Medicaid pay approximately 40% to 70% of these costs, representing $130 billion. These costs do not include the 
estimated $202 billion in uncompensated care that infonnai caregivers provide annually^.
Current Practice
At present, diagnosis of dementia primarily occurs as  a  result of a clinician's suspicion of patient symptoms or caregiver concerns and not as a  result of routine fornial screening. 
As much as  29% to 76% of patients with dementia or probable dementia in the primary care setting are u n d iag n o sed ^ , in 2011, Medicare added detection of cognitive 
impainnent to the new annual wellness visit benefit, and the Alzheimer's Association has published guidance on how to implement this benefit.
Assessment of Risk
Increasing age is the strongest known risk factor for cognitive impairment. The e4 allele of the apolipoprotein E gene is a  reported risk factor for Alzheimer disease. Other 
reported risk factors for cognitive impairment include cardiovascular risk factors (such as  diabetes, tobacco use, hypercholesterolemia, hypertension, and the metabolic 
syndrome), head trauma, learning disabilities (such a s  Down syndrome), depression, alcohol abuse, physical frailty, low education level, low social support, and having never 
been married.
Several dietary and lifestyle factors have been associated with decreased risk for dementia; these factors have weaker supporting evidence than those previously mentioned. 
Adequate folic acid intake, low saturated fat intake, longer-chain w-3 fatty acids, high fruit and vegetable intake, MedKemanean diet, moderate alcohol intake, educational 
attainment, cognitive engagement, and participation in physical activity are all associated with decreased risk for dementia.
Screening Tests
Screening tests for cognitive impairment in the clinical setting generally include asking patients to perform a  series of tasks that a ssess  at least 1 cognitive domain (memory, 
attention, language, and visuospatial or executive functioning). Blood tests  and radiology examinations are not currently used a s  screening tests  but are often used after a  
positive screening result to confirm the diagnosis of dementia and determine its subtype. Although optimum sensitivity and specificity of the MMSE probably vary depending on 
the patient's age and education level, a large body of literature suggests that a general cut point of 23/24 or 24/25 (score considered ‘positiveTnegative’)  is appropriate for most 
primary care populations.
Other instruments with more limited evidence include the Clock Drawing Test, Mini-Cog Test, Memory Impainnent Screen, Abbreviated Mental Test, Short Portable Mental 
Status Questionnaire, Free and Cued Selective Reminding Test, 7-Minute Screen. Telephone Interview for Cognitive Status, and Informant Questionnaire on Cognitive Decline 
in the Elderly. Each of these tes ts  has reasonable perfonnance in some studies, but estimates of sensitivity and specificity vary, and the optimum diagnostic threshold or cut 
point for many of these instalments is unclear. For infomation on all instruments reviewed by the USPSTF, including the Montreal Cognitive Screening Assessment, the St.
Louis University Mental Status examination, and other instruments with 2 or fewer studies, se e  the full evidence report (available at wwww. uspre ventiveserviceslaskforce org)^.
Treatment and Interventions
Treatment of cognitive impairment focuses on several signs and symptoms, including quality-of-life, cognition, mood, and behavioral impairments.
Several pharmacologic and nonpharmacologic interventions aim to prevent, slow, or reverse cognitive impainnent in older adults or improve caregiver burden and depression. 
Pharmacologic treatments approved by the U.S. Food and Doig Administration include AChEls and memantine. Nonpharmacologic interventions include cognitive training, 
lifestyle behavioral interventions, exercise, educational interventions, and multidisciplinary care interventions. Several interventions focus on the caregiver and aim to improve 
caregiver morbidity and delay institutionalization of persons with dementia.
Other Approaches to Prevention
The USPSTF has published recommendations related to several of the risk factors for cognitive impairment, including counseling on tobacco cessation, alcohol use, healthful 
diet, physical activity, and falls prevention and screening for high cholesterol, hypertension, and depression (available at wwww.uspreventlveservicestaskforce.org).
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Other C onsiderations
Reseai c/i Needs and Caps
More research on screening for and treatm ent of MCI is needed. Evidence on the effect of screening and early detection of mild to m oderate dementia on decision making, 
planning, or other important patient outcom es is a critical gap in the evidence. Given the lack of evidence that treatm ent affects long-term cognitive outcomes for mild to 
m oderate dementia, its effect on decision making and planning could be the most compelling reason for screening. However, no studies provided information on this effect. More 
research on the harms of screening is needed. R esearch on new interventions that address the changing needs of patients and families and interventions that clearly have an 




Dementia is an acquired condition characterized by a  decline in at least 2 cognitive dom ains (loss of memory, attention, language, and visuospatial or executive functioning) that 
is severe enough to affect sociai or occupational functioning^. Patients with dementia may also exhibit behavioral and psychological symptoms. The major dementia syndrom es 
in older adults include Alzheimer disease, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, Parkinson d isease with dementia, and dem entia of mixed 
cause (8). Mild cognitive impairment Is different from dementia in that the cognitive impairment is not severe enough to interfere with instnimental activities of daily life.
Dementia affects approximately 2.4 to 5.5 million Americans, but its prevalence is difficult to determine because of differences in definitions and populations used in studies (8 - 
10). Age is the most important risk factor. Data from large population-based surveys indicate that the prevalence of dementia in the United States is 5% in persons aged 71 to 79 
years, 24% in those aged  80 to 89 years, and 37% in those older than 90 years*^. Prevalence varies by race; prevalence in adults aged 71 years and older in 1 large study was 
21.3% for blacks and 11.2% for whites’' ' ' . The prevalence of Alzheimer d isease in Hispanics is approximately 1.5 times that seen  in the white population"" '^ . Dementia also 
affects more women than men. In persons aged 71 years and older, approximately 16% of women have dementia compared with 11% of men; these  differences are primarily 
explained by w omen's longer life expectancy rather than any sex-based risk factors Alzheimer d isease accounts for 60% to 80% of all dementia, frontotemporal dementia 
accounts for 12% to 25%, 10% to 20% is considered vascular dementia, 5% to 10% is considered dementia with Lewy bodies, and 10% to 30% is considered dementia with 
mixed cause®' It is difficult to estimate the prevalence of MCI, and estim ates range widely, from 3% to 42% in adults aged 65 years and older, depending on the population 
and diagnostic criteria used'®' '^ .
Scope of Review
In 2003, the USPSTF concluded that the evidence w as insufficient to recommend for or against routine screening for dementia in older adults. To update its recommendation, 
the USPSTF commissioned a  systematic review of the evidence on screening for cognitive impairment, including dementia and MCI. The evidence review gathered evidence on 
the benefits, harms, and test performance of screening instruments to detect cognitive impairment in older adults and the benefits and harms of commonly used  treatm ent and 
m anagem ent options for older adults with MCI or early dementia and their caregivers. Important potential benefits included decision making, cognitive function, physical function, 
quality of life, safety, and caregiver burden. The USPSTF reviewed a  significant amount of evidence, including available studies on caregiver burden and future planning (the full 
evidence report is available at wwww.uspreventiveservicestaskforce.org)'. The review focused on screening adults in the  general primary care population and m anagem ent of 
screen-detected patients with cognitive Impairment, excluding delirium. The review on treatm ent and m anagem ent focused on studies of adults with mild to m oderate dementia 
because these are the  patients most likely to be identified by screening.
Accuracy o f Screening Tests
The review identified 55 studies on instalm ents that screen for cognitive impainnent. Forty-six of the studies provided evidence on the sensitivity and specificity of screening for 
dementia, and 27 provided evidence on MCI. Included studies had to use a diagnostic reference standard (such a s  the Diagnostic and Statistical Manual o f M ental DisonJers,
Third or Foig th  Edition) o r criteria from the National institute of Neurological Disorders and Stroke and the Alzheimer's D isease and Related Disorders Association (now known 
a s  the Alzheimer's Association). T hese studies were conducted in primary care-relevant populations, and most instruments were brief (slO  minutes) and administered in a 
clinical setting. Studies on self-administered instruments were also reviewed.
Screening instruments evaluated in more than 2  studies include the MMSE, Clock Drawing Test, verbal fluency tests, Informant Questionnaire on Cognitive Decline in the 
Elderly, Memory Impairment Screen, Mini-Cog Test, Abbreviated Mental Test, and Short Portable Mental S tatus Questionnaire. The MMSE w as the most evaluated instalment, 
with 25 published studies. The MMSE is a 30-point instrument with 11 items. It has  been studied in various populations; the m ean age of participants ranged from 69 to 95 
years, the m ean prevalence of dementia ranged from 1.2% to 38.0%, and education level also varied widely but w as not always reported. For the most commonly reported cut 
points (23/24 or 24/25 [scorn considered 'positiveTnegativeT), the pooled sensitrvity from 14 studies (involving 10,185 participants) w as 88.3% (95% Cl, 81.3% to 92.9%) and 
specificity w as 86.2% (95% Cl, 81.8% to 89 .7% )''^ . The other Instruments were studied in far fewer studies (4 to 7 studies each), had limited reproducibility in primary c a re -  
relevant populations, and had unknown optimum cut points. Sensitivity and specificity ranged widely in these studies.
Effectiveness of Early Detection and Treatment
No trials evaluated the direct effect of screening for cognitive impairment by comparing screened and unscreened older adults and reporting important patient outcomes, 
including decision-making outcomes. The review identified more than 130 studies on several interventions for managing or treating mild to m oderate dementia, including 
pharmacologic and nonpharmacological interventions. Pharmacologic interventions induded U.S. Food and Drug Administratiorr-approved medications for the  treatm ent of 
Alzheimer d isease with the purpose of preventing or delaying cognitive impainnent (AChEls and memantine), medications for cardiovascular risk reduction for vascular 
dementia, nonsteroidal anti-inflammatory dntgs, gonadal steroids, and dietary supplements. The review also considered evidence on nonphannacologic interventions, including 
interventions aimed primarily at the caregiver or patient-caregiver dyad and at the patient (such a s  cognitive training, rehabilitation, or stimulation, with or without motor skills 
training interventions; exercise inten/entions; multidisciplinary care imerventions involving assessm en t and care coordination; and education-only interventions).
Fifty-four trials provided evidence on AChEls for the treatm ent of mild to m oderate Alzheimer d isease (donepezil, galantamine, rivastigmine, and tacrine), including 4 trials of 
persons with MCI. Ten additional trials reported on memantine in persons with moderate dementia. Many studies reported differences in sco res on the Alzheimer's D isease 
/Assessment Scale-Cognitive Subscale (ADAS-cog). The /AD/AS-cog is a  validated instrument that a s se s s e s  memory, attention, orientation, language, and praxis. S cores range 
from 0 to 70, with higher scores signifying greater cognitive impairment; a  change of 4 points or more is commonly accepted to be clinically significant for patients with mild to 
moderate dementia. Acetylcholinesterase inhibitors and memantine improved global cognitive function by approximately 1- to 3-point differences on the ADAS-cog. A m eta­
analysis of 7 rivastigmine trials reported a 3-polnt difference on the ADAS-cog (-3 .06  [95% Cl, -4 .48  to -1.65]; f  = 92.6%). Only 4 trials were conducted in persons with MCI 
and reported global cognitive function'®"^'. These trials of donepezil and galantamine generally showed a small but unclear clinical effect on global cognitive function. Only one 
half of the trials reported global physical function; findings were inconsistent and sparsely reported. Few studies reported outcom es beyond 6 months. Longer-term studies were 
generally consistent with studies of shorter duration and demonstrated statistically significant small improvements of unknown clinical importance.
The review considered 26 studies that evaluated other m edications or supplem ents, including low-dose aspirin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (or 
"statins'^, nonsteroidal anti-inflammatory drugs, gonadal steroids, and dietary supplem ents, and did not find any evidence that these  medications or supplem ents provided a 
benefit in global cognitive or physical function in persons with mild to moderate dementia o r M CI'.
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Tfie review identified 59 studies ttiat evaluated the effect of nonpharmacological interventions aimed a t the caregiver or both the  patient and caregiver. Most of th ese  trials 
evaluated interventions that included an  educational com ponent designed to increase caregiver skills. Although the approaches to education in the interventions varied, there 
w as a  generally consisten t finding of a  small benefit on caregiver burden and depression outcom es in persons caring for patients with m oderate dementia. The clinical meaning 
of the changes in caregiver burden and depression is unknown but on average is probably small at best. Ten studies on exercise interventions w ere reviewed; the clinical effect 
of th ese  results on important outcom es is uncertain b ecau se  of the limited num ber of trials and  variability in studied populations, exercise interventions, and reported outcom es.
Fifteen cognitive intervention trials provided som ew hat inconsistent evidence that cognitive stimulation with or without cognitive training seem s to improve global cognitive 
function m easures in the short term  for persons with MCI or dementia. However, the magnitude and certainty of the  dinicai benefit is difficult to determ ine b ecau se  of the limited 
num ber of trials, dinicai and statistical heterogeneity combined, and im predsion of results.
Potential Harms of Screening and Treatment
No studies reported on d ired  or indirect harm s from false-positive or false-negative results, psychological harm s, unnecessary  diagnostic testing, or labeling. O ne study 
provided som e information on the potential harm s of screening for cognitive impairment in primary care, in this study of 3573 older adults, approximately one half of patients who 
had a  positive screening result for cognitive impairment (207 out of 434 patients) ded ined  a  formal diagnostic work-up for dementia. Only 233 out of 3573 partidpants initially 
ded ined  to be screened^^'
Adverse effects from AChEls are common. Withdrawal or discontinuation ra tes  in studies of AChEis w ere 14% for donepezil and rivastigmine and 17% for galantamine. Serious 
adverse  effects from th ese  medications seem  to occur with similar frequency across the different AChEls. Bradycardia and adverse  effects related to bradycardia (such a s  falls 
and syncope) may result from taking AChEls. Tacrine, which had very high discontinuation ra tes  in trials, has an  uncommon but serious adverse effect of liver toxidty. Tacrine is 
no longer used  in the United S tates for this reason. In trials, m em antine did not differ from placebo in the  percentage of withdrawals from medication due to adverse  or serious 
adverse  effeds. Evidence on the harm s of nonpharm acologic interventions in patients with dem entia or their caregivers is limited.
Estimate of Magnitude of Net Benefit
The USPSTF found no evidence on the d ired  benefits and harm s of screening for cognitive impairment and therefore considered the indired evidence on screening accuracy, 
early treatm ent, and harm s. Evidence is adequate  that som e screening tools can  accurately identify dementia. Treatm ent of mild to m oderate dem entia with several drug 
therapies and nonpharm acologic interventions results in small im provements in m easures of cognitive fundion and  caregiver outcom es, but the dinicai significance of th ese  
improvements is uncertain. The USPSTF found no published evidence on the e ffed  of screening on d edsion  making or planning by patients, d in idans, or caregivers. Evidence 
on the harm s of screening and nonpharm acologic interventions is inadequate. The USPSTF found adequate  evidence that AChEls a re  a sso d a te d  with adverse  effeds, som e of 
which are serious. Overall, the USPSTF w as unable to estim ate the balance of benefits and harm s of screening for cognitive impairment.
How Does Evidence Fit With Biological Understanding?
Dementia is the manifestation of various pathophysiologic changes in the brain; therefore, the  developm ent of early interventions that result in an  important dinicai e ffed  on all 
types of dem entia is difficult. The e x a d  causal m echanism  for m any types of dem entia is unknown. Most dem entia in the United S ta te s  is a  result of Alzheimer d isease, which is 
the target of m ost U.S. Food and Drug Administration-approved drugs for dementia. Given that cunen t therapies for dementia do not seem  to a ffed  the long-term progression of 
mild to m oderate cognitive impairment, the hope is for effedive interventions that can help patients and caregivers prepare for dealing with dem entia symptoms.
Response to Public Comment
A draft version of this recom mendation statem ent w as posted for public com m ent on the USPSTF Web site from 5 Novem ber to 2 D ecem ber 2013. Several com m ents agreed  
with the insuffidency of the  evidence. A few com m ents d isagreed with the recom mendation, and som e com m ents expressed  confusion about the meaning of an I s ta tem en t and 
how it may affed  early deted ion . The recom mendation contains suggestions for practice regarding the I sta tem ent and notes that, although evidence on routine screening is 
insuffident, there may be important reasons to identify eariy cognitive impairment in spedfic  d rcum stances. O ther com m ents requested darification on the meaning of screening 
and for whom the recom mendation is intended; in response, information w as added to the recommendation. A few com m ents provided evidence on additional risk fad o rs  for 
cognitive impairment and  suggested  additional research  gaps; th ese  w ere added to the Clinical Considerations sed ion . The importance of vascular c a u se s  of dem entia w as 
mentioned in a few comm ents, and information on USPSTF recom m endations related to vascular risk fad o rs  w as added.
U pdate of P rev ious USPSTF R ecom m endation
This reœ m m endation u p dates the 2003 USPSTF recom mendation on screening for dementia. This updated recom m endation differs from the 2003 recom mendation in that it 
considers the evidence on screening for and treatm ent of MCI in addition to dem entia and how screening a ffed s  d ed sio n  making and planning. The current evidence review 
found much m ore information on the test perform ance of screening instrum ents than in 2003, and the USPSTF conduded  that there is now adequate  infomnation on the test 
performance of som e screening tools. Similar to the findings of the 2003 evidence review and recom mendation, the USPSTF found that pharmacologic treatm ents result in small 
benefits of unknown dinicai significance and conduded  again that the  overall evidence is insuffident to m ake a  recom mendation on screening.
R ecom m endations of O thers
In 2011, Medicare began covering the de tedion  of cognitive impairment a s  a  part of the new annual w ellness visit benefit. In 2013, the  Alzheimeris A ssodation published 
guidance on the d e ted ion  of cognitive impairment during the annual w ellness visit and recom m ended an algorithm involving a health risk a ssessm en t, patient observation, and 
unstrudured  questioning. The Alzheimeris A ssodation recom m ends the u se  of a  brief s trudured  a ssessm en t (such a s  the G eneral P raditioner A ssessm ent of Cognition, Mini- 
Cog Test, Memory Impairment Screen, Alzheimer D isease 8-item informant Interview, or the short version of the Informant Q uestionnaire on Cognitive D edine in the Elderly) if 
signs or symptoms of cognitive impairment a re  present or if an  informant is not available to confimn the ab sen ce  of signs or symptoms^^.
M em bers of th e  U.S. P reventive S erv ices Task Force
M embers of the U.S. Preventive Services Task Force at the time this recom m endation w as finaiizedt are Virginia A. Moyer, MD, MPH, Chair (Anterican Board of Pediatrics, 
Chapel Hill, North Carolina); Michael L. LeFevre, MD, MSPH, Co-Vice Chair (University of Missouri School of Med id ne, Columbia, Missouri); Albert L. Siu, MD, MSPH, Co-Vice 
Chair (Mount Sinai School of M edidne, New York, and Ja m e s  J. P e ters  V eterans Affairs Medical Center, Bronx, New York); Linda Ciofu Baumann, PhD, RN (University of 
W isconsin, Madison, Wisconsin); S usan  J. Curry, PhD (University of Iowa College of Public Health, Iowa City, Iowa); Mark Ebell, MD, MS (University of Georgia, Athens, 
Georgia); F randsco  A.R. Garcia, MD, MPH (Pima County Departm ent of Health, Tucson, Arizona); Je ss ica  Herzstein, MD, MPH (Air Produds, Allentown, Pennsylvania); 
Douglas K. Owens, MD, MS (Veterans Affairs Palo Alto Health C are System , Palo Alto, and Stanford University, Stanford, California); William R. Phillips, MD, MPH (University of 
W ashington, Seattle, W ashington); and Michael P. Pignone, MD, MPH (University of North Carolina, Chapel Hill, North Carolina). Former USPSTF m em bers R osanne Leipzig, 
MD, PhD, Kirsten Bibbins-Domingo, MD, PhD, and Adelita G onzales Cantu, PhD, RN, also contributed to the  developm ent of this recommendation.
t  For a  list of cument Task Force mem bers, go to w w w.usprevenfiveservicestaskforce.org/m em bers.htm .
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Alzheimer's Association recommendations for operationalizing the detection 
of cognitive impairment during the Medicare Annual Wellness Visit in a 
primary care setting.
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Guideline Status
This is the current release of the guideline.
Recommendations
Major Recommendations
Recommended Algorithm for Detection of Cognitive Impairment 
During the Annual Wellness Visit (AWV) 
Incorporating A ssessm ent of Cognition During the AWV
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The Alzheimer's Association Medicare Annual Wellness Visit Algorithm 
for A ssessm ent of Cognition for consistency (see  Figure 1 in the 
original guideline document) illustrates a stepwise process. The 
process is intended to detect patients with a high likelihood of having 
dementia. The AWV algorithm includes both structured a ssessm en ts  
discussed previously (in the original guideline document) and other 
less structured patient- and informant-based evaluations. By 
assessing and documenting cognitive status on an annual basis 
during the AWV, clinicians can more easily determine gradual 
cognitive decline over time in an Individual patient—a key criterion for 
diagnosing dementia due to Alzheimer's d isease and other  
progressive conditions affecting cognition.
For patients with a previous diagnosis of mild cognitive impairment 
(MCI) or dementia, this should be documented and included in their 
AWV list of health risk factors. Annual unstructured and structured 
cognitive assessm en ts  could be used to monitor significant changes in 
cognition and potentially lead to a new diagnosis of dementia for 
those with MCI or new care recommendations for those with 
dementia.
Detection of Cognitive Impairment During the AWV—Initial Health 
Risk A ssessm ent (HRA) Review, Conversations, and Observations 
The first step in detection of cognitive impairment during the AWV 
(see  Figure 1, Step A in the original guideline document), involves a 
conversation between a clinician and the patient and, if present, any 
family m ember or other person who can provide collateral 
information. This introduces the purpose and content of the AWV, 
which includes: a review of the HRA; observations by clinicians 
(medical and associated staff); acknowledgment of any self-reported  
or informant-reported concerns; and conversational queries about 
cognition directed toward the patient and others present. If any 
concerns are noted, or if an informant is not present to provide 
confirmatory information, further evaluation of cognition with a 
structured tool should be performed.
Patient completion of an HRA is a required elem ent of the AWV and 
can be accomplished with the help of a family m ember or other 
knowledgeable informants, including a professional caregiver.
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Published Centers for Medicare and Medicaid Services (CMS) guidance 
offers healthcare professionals flexibility as to the specific format, 
questions, and delivery m ethods that can be used for an AWV HRA. 
The following questions may be suitable for the AWV HRA and have 
been tested and evaluated in the general population through the  
Behavioral Risk Factor Surveillance System  or presented as HRA 
exam ple questions:
1. During the past 12 months, have you experienced confusion or 
memory loss that is happening more often or is getting worse?
2. During the past 7 days, did you need help from others to perform 
everyday activities such as eating, getting dressed, grooming, 
bathing, walking, or using the toilet?
3. During the past 7 days, did you need help from others to take care of 
things such as laundry and housekeeping, banking, shopping, using 
the telephone, food preparation, transportation, or taking your own 
medications?
A noted deficit in activities of daily living (ADLs) (e .g .,  eating and 
dressing) or instrumental activities of daily living (lADLs) (e .g .,  
shopping and cooking) that cannot be attributed to physical 
limitations should prompt concern, as there is a strong correlation 
between decline in function and decline in cognitive status across the  
full spectrum of dementia. In addition to clinically observed concerns, 
any patient- or informant-reported concerns should trigger further 
evaluation. Positive responses to conversational queries, such as  
"Have you noticed any change in your memory or ability to complete  
routine tasks, such as paying bills or preparing a meal?" should be 
followed up with a structured assessm en t of cognition.
Upon realizing the time constraints of a typical primary care visit, if 
no cognitive concerns surface during the initial evaluation and this 
information is corroborated by an informant, the clinician may elect  
not to perform a structured cognitive assessm en t and assum e that 
the patient is not currently dem ented. This approach is supported by 
studies in populations with low rates of dementia that su ggest  the 
absence of memory difficulties reported by informants and patients 
reduces the likelihood that dementia is present.
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Structured Cognitive A ssessm ent Tools for Use with Patients and 
Informants During the AWV
The second step in detection of cognitive impairment during the AWV 
( see  Figure 1, Step B in the original guideline document) requires 
cognitive a sse ssm en t using a structured tool. Based on synthesis of 
data from the six review articles previously discussed (in the original 
guideline document), patient tools suitable for the initial structured 
assessm en t are the General Practitioner A ssessm ent of Cognition 
(GPCOG), Mini-Cog, and Memory Impairment Screen (MIS). 
Recognizing that there is no single optimal tool to detect cognitive 
impairment for all patient populations and settings, clinicians may 
select other brief tools to use in their clinical practice, such as those  
listed in Table 3 in the original guideline document. The 15 brief tools  
listed were evaluated in multiple review articles (passed through at 
least two review search criteria for tools possibly suited for primary 
care) or are used in the Veterans Administration (VA). Tools listed in 
Table 3 in the original guideline document are subject to the  
inclusion/exclusion criteria of each review and do not represent the 
entire listing of the > 100  brief cognitive a ssessm en t tools that may 
be suitable for primary care practices.
If an informant is present, defined as som eon e who can attest to a 
patient's change in memory, language, or function over time, it is 
suitable to use the Eight-item Informant Interview to Differentiate 
Aging and Dementia (AD8), the informant com ponent of the GPCOG, 
or the Short Informant Questionnaire on Cognitive Decline in the  
Elderly (IQCODE), during the AWV.
Primary Care Workflow Considerations
According to the algorithm, any patient who does not have an 
informant present should be a ssessed  with a structured tool. For such 
patients (and for practices that implement structured assessm en ts  
during all AWVs), completion of this structured a ssessm en t can be 
administered by trained medical staff as the first step for cognitive 
impairment detection. This could improve office efficiency. To 
increase acceptance of a structured assessm en t, the reason provided 
to the patient can be normalized with a statem ent such as, "This is 
something I do for all of my older patients as part of their annual
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visit." When the initial a ssessm en t prompts further evaluation, 
explanation of results should be deferred until a more comprehensive  
evaluation has been completed. "There are many reasons for not 
getting every answer correct. More evaluation will help us determine 
that," is an exam ple statem ent that may encourage patients to 
pursue further testing.
Full Dementia Evaluation
Patients with a ssessm en ts  that indicate cognitive impairment during 
the AWV should be further evaluated to determine appropriate 
diagnosis (e .g .,  MCI, Alzheimer's d isease) or to identify other causes. 
As reflected in the algorithm (see  Figure 1, Step C in the original 
guideline document), initiation of a full dementia evaluation is outside 
the scope of the AWV, but can occur in a separate visit either on the 
sam e day, during a newly scheduled visit, or through referral to a 
specialist. Specialists who have expertise in diagnosing dementia  
include geriatricians, geriatric psychiatrists, neurologists, and 
neuropsychologists. The two-visit approach has been cited as a time- 
effective process to evaluate suspected dementia in primary care and 
is consistent with the two-step approach widely used in epidemiologic 
research on dementia. Regardless of the timing and setting, clinicians 
are encouraged to counsel patients to include an informant in the  
diagnostic process.
Components of a full dementia evaluation can vary depending on the 
presentation and include tests  to rule in or out the various causes of 
cognitive impairment and establish its severity. Diagnostic 
evaluations include a com plete medical history; assessm en t of 
multiple cognitive domains, including episodic memory, executive  
function, attention, language, and visuospatial skills; neurologic exam  
(gait, motor function, reflexes); ADL and lADL functioning; 
assessm en t for depression; and review for medications that may 
adversely affect cognition. Standard laboratory tests  include thyroid- 
stimulating hormone (TSH), complete blood count (CBC), serum B1 2 , 
folate, complete metabolic panel, and, if the patient is at risk, testing  
for sexually transmitted d iseases (human immunodeficiency virus, 
syphilis). Structural brain imaging, including magnetic resonance  
imaging (MRI) or computed tomography (CT), is a supplemental aid
92
in the differential diagnosis of dem entia, especially if neurologic 
physical exam findings are noted. An MRI or CT can be especially  
informative in the following cases: dementia that is of recent onset  
and is rapidly progressing; younger onset dementia (< 6 5  years of 
age); history of head trauma; or neurologic sym ptom s suggesting  
focal disease.
Clinical Algorithm(s)
An algorithm titled "Alzheimer's Association Medicare Annual Wellness 



























To provide primary care physicians with guidance on cognitive 
assessm en t during the Annual Wellness Visit (AWV) and when referral 
or further testing is needed
Target Population
Medicare beneficiaries during their Medicare Annual Wellness Visit 
(AWV)
Interventions and Practices Considered
1. Conversation between clinician and patient/informant
2. Patient completion and clinician review of a Health Risk A ssessm ent  
(HRA)
3. Use of a structured assessm en t tool, including:
• General Practitioner A ssessm ent of Cognition (GPCOG)
• Mini-Cog
• Memory Impairment Screen (MIS)
• Eight-item Informant Interview to Differentiate Aging and 
Dementia (AD8)
• Short Informant Questionnaire on Cognitive Decline in the  
Elderly (IQCODE)






Methods Used to Collect/Select the Evidence
Searches of Electronic Databases
Description of Methods Used to Collect/Select 
the Evidence
A MEDLINE (PubMed) search conducted in October 2011 , using the 
key words "screening or detection of dementia or cognitive 
impairment," yielded over 500 publications. To narrow the search to 
tools more applicable to the Annual Wellness Visit (AWV), the
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workgroup sought to determine whether the literature offered a 
consensus regarding brief cognitive a sse ssm en t during time-limited  
primary care visits.
The workgroup focused on system atic evidence review (SER) studies  
published since 2000 , resulting in four studies by Lorentz et al., 
Brodaty et al., Holsinger et al., and Milne et al. Although each SER 
had a similar objective—to determine which tools were best for 
administration during primary care visits—different comparison 
criteria to select the tools were applied (see  Table 1 in the original 
guideline document). Two other studies were also considered relevant 
to the developm ent of the workgroup recommendations: Ismail et al. 
conducted a literature review designed to identify widely used and 
m ost promising newer brief cognitive tools being used in primary care 
and geriatrics, and an SER by Kansagara and Freeman of six brief 
cognitive a ssessm en t tools that could serve as possible alternatives 
to the Mini-Mental State Examination (MMSE) for use by the U.S. 
Department of Veterans Affairs (VA). Neither study was designed to 
determine which brief tool is the "best," but both provided evidence  
related to primary care use and performance characteristics of brief 
assessm en ts  of cognition (see  Table 1 in the original guideline 
document).
Number of Source Documents
The workgroup focused on system atic evidence review (SER) studies  
published since 2000 , resulting in four studies. Two other studies 
were also considered relevant to the developm ent of the workgroup 
recommendations.
Methods Used to Assess the Quality and 
Strength of the Evidence
Not Stated




Methods Used to Analyze the Evidence
System atic Review
Description of the Methods Used to Analyze 
the Evidence
Systematic Review
The workgroup's research included comparing five system atic  
evidence reviews (SERs) of brief dementia screening tools published 
since 2000  and a 2010  literature review of newer brief a ssessm en ts  
of cognition. The workgroup's research focused on determining if 
there was a consensus among the published SERs as to which tool is 
m ost suited for primary care and if there were any common results 
across the publications.
Methods Used to Formulate the 
Recommendations
Expert Consensus
Description of Methods Used to Formulate the 
Recommendations
Not Stated




A formal cost analysis was not performed and published cost analyses  
were not reviewed.
Method of Guideline Validation
Not stated
Description of Method of Guideline Validation
Not applicable
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Evidence Supporting the  
Recommendations
Type of Evidence Supporting the 
Recommendations
The recommendations are supported by system atic evidence reviews
and a literature review.
Benefits/Harms of Implementing  
the Guideline Recommendations
Potential Benefits
• Detection of cognitive impairment during the Medicare Annual 
Wellness Visit
• Establishment of a baseline for longitudinal a ssessm en ts  for those  





• There are limitations to these  recommendations. They are based on 
assessm en t of recommendations from review articles and on expert 
opinion, not on a new, comprehensive review of original research to 
define the optimal approach to detection of cognitive impairment or 
review of emerging technologies that could assist in testing (e .g . ,  use  
of online or electronic tablet applications). Further complicating 
systematic evidence reviews (SERs) of brief cognitive assessm en t  
tools is that sensitivity and specificity will vary depending on the  
dementia prevalence of the study population, the tool(s) used, and 
the cut score selected for each tool. Brodaty et al. recognized that 
published research concerning cognitive impairment screening tools
is uneven in quantity and quality. The literature also is lacking in 
comparative validity of brief cognitive a ssessm en t tools in low- 
education or illiterate populations.
97
• The Alzheimer's Association Medicare Annual Wellness Visit Algorithm 
for A ssessm ent of Cognition is based on current validated tools and 
commonly used rule-out assessm ents. The use of biomarkers (e .g .,  
cerebrospinal fluid [CSF] tau and beta amyloid proteins, amyloid 
tracer positron emission tomography scans) was not considered as 
these  m easures are not currently approved or widely available for 
clinical use.
Implementation of the Guideline
Description of Implementation Strategy






For information about availability, see  the Availability o f  Companion  
D ocum ents  and Patient R esources  fields below.
Institute of Medicine (lOM) 







Identifying Information and 
Availability
Bibliographic Source(s)_______________________
I  Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, 
j Thies W, Fried LB, Medicare Detection of Cognitive Impairment
98
Workgroup. Alzheimer's Association recommendations for 
operationalizing the detection of cognitive impairment during the  
Medicare Annual Wellness Visit in a primary care setting. Alzheimers 
Dement. 2013 Mar;9(2): 141-50. [61 references] PubMed
Adaptation








Medicare Detection of Cognitive Impairment Workgroup
Composition of Group That Authored the 
Guideline
Workgroup Members'. Cyndy B. Cordell, Alzheimer's Association, 
Chicago, IL, USA; Soo Borson, Department of Psychiatry and 
Behavioral Sciences, University of Washington School of Medicine, 
Seattle, WA, USA, Memory Disorders Clinic and Dementia Health 
Services, University of Washington School of Medicine, Seattle, WA, 
USA; Maiaz Boustani, Indiana University Center for Aging Research, 
Indianapolis, IN, USA, Regenstrief Institute, Inc., Indianapolis, IN, 
USA, Department of Medicine, Indiana University School of Medicine, 
Indianapolis, IN, USA; Joshua Chodosh, Veterans Administration 
Greater Los Angeles Healthcare System , Los Angeles, CA, USA, 
Division of Geriatrics, David Geffen School of Medicine, University of 
California Los Angeles, Los Angeles, CA, USA; David Reuben, Division 
of Geriatrics, David Geffen School of Medicine, University of California 
Los Angeles, Los Angeles, CA, USA; Joe Verghese, Department of 
Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 
William Thies, Alzheimer's Association, Chicago, IL, USA; Leslie B.
99
Fried, American Bar Association, Washington, DC, USA, Alzheimer's 
Association Medicare Advocacy Project, Washington, DC, USA
Financial Disclosures/Conflicts of Interest
Soo Borson is the developer of the Mini-Cog and is the owner of its 
copyrights.
Over the past 5 years, MaIaz Boustani has received research support 
for investigator-initiated projects from Forest Pharmaceutical and 
Novartis; honoraria from Novartis and Pfizer, Inc.; and research  
support for investigator-initiated projects from the National Institutes 
of Health (NIH) and the Agency for Healthcare Research and Quality 
(AHRQ). Dr Boustani was a member of the US Preventive Services  
Task Force that published the system atic evidence review Dementia 
Screening for the AHRQ in 2003.
Guideline Status
This is the current release of the guideline.
Guideline Availability
Electronic copies: Available from the Alzheimer's &
Journal of the Alzheimer's Association Web site
Dementia, the
Print copies: Available from the Alzheimer's Association, National 
Office, 225 N. Michigan Ave., FI. 17, Chicago, IL 6 0 6 0 1 -7 6 3 3 , Phone: 
1-800 -2 7 2 -3 9 0 0 .
Availability of Companion Documents
A variety of resources, including the Medicare Annual Wellness Visit 
fact sheet, recommended cognitive a sse ssm en t tools, and 
instructional v ideos, are available from the Alzheimer's Association
Web site
Patient Resources
A variety of resources for patients concerned with cognitive decline 
and their families and caregivers are available from the Alzheimer's
Association Web site
Please note: This patient information is intended to provide health professionals with 
information to share with their patients to help them better understand their health and their 
diagnosed disorders. By providing access to this patient information, it is not the intention of 
NGC to provide specific medical advice for particular patients. Rather we urge patients and 
their representatives to review this material and then to consult with a licensed health
100
professional for evaluation of treatment options suitable for them as well as for diagnosis and 
answers to their personal medical questions. This patient information has been derived and 
prepared from a guideline for health care professionals included on NGC by the authors or 
publishers of that original guideline. The patient information is not reviewed by NGC to 
establish whether or not it accurately reflects the original guideline's content.
NGC Status
This NGC summary was completed by ECRI Institute on Septem ber  
27, 2013. The Information was verified by the guideline developer on 
October 22, 2013.
Copyright Statement
This NGC summary is based on the original guideline, which is subject 
to the guideline developer's copyright restrictions.
Disclaimer
NGC Disclaimer
The National Guideline Clearinghouseâ„(t (NGC) does not develop, 
produce, approve, or endorse the guidelines represented on this site. 
All guidelines summarized by NGC and hosted on our site are 
produced under the auspices of medical specialty societies, relevant 
professional associations, public or private organizations, other 
government agencies, health care organizations or plans, and similar 
entities.
Guidelines represented on the NGC Web site are submitted by 
guideline developers, and are screened solely to determine that they  
m eet the NGC Inclusion Criteria.
NGC, AHRQ, and its contractor ECRI Institute make no warranties 
concerning the content or clinical efficacy or effectiveness of the  
clinical practice guidelines and related materials represented on this 
site. Moreover, the views and opinions of developers or authors of 
guidelines represented on this site do not necessarily state or reflect 
those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or 
hosting of guidelines in NGC may not be used for advertising or 
commercial endorsem ent purposes.
Readers with questions regarding guideline content are directed to 
contact the guideline developer.
101
APPENDIX D 
The ABC’s of the Medicare Annual Wellness Visit
K N O W L E D G E  « R E S O U R C E S  '  T R A I N I N G
THE ABCs OF THE ANNUAL WELLNESS VISIT (AWV)
T arge t A u d ie n c e : M edicare Fee-For-SenÂ ce Program T he Hyperlink Table, a t  the  end  of this docum ent,
{also known a s  Original M edicare) provides th e  com plete URL for ea c h  hyperlink.
CRT codes, descriptions and other data only are o^yrighf 2016 American Medical Association. Ail Rights Reserved. Applicable FARS/HHSAR apply. CRT is a 
registered trademark of the American Medical Association. Applicable FARS.'HHSAR Restrictions Apply to Government Use. Fee schedules, relative value units, 
conversion factors and/or related components are not assigned by the AMA, are not part of CRT, and the AMAis not recommending their use. The AMA does not 
direcdty or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
P a g e  1 of 17 ICN 905706 April 2017 'CMS -W",medicare Leaminc Me W ork
102
•::: c' i^T he ABCs of the Annual W ellness Visit (AWV)
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INITIAL AWV COMPONENTS: APPLIES THE FIRST TIME A BENEFICIARY RECEIVES AN AWV
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medical/family history
D Past medical and surgical history, including experiences with illnesses, hospital stays, 
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Begin A s s e s s m e n t
□  A ssess
D Height, weight, body m ass index (or waist circumference, if appropriate), and 
blood p ressure
0 Other routine m easurem ents a s  deem ed appropriate based on medical and family history
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friends, caretakers, or others
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□  Establish a  written screenMg
a checklist for the next 5 to 10 years, 
as  appropriate
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D
preventive ièrv ices covered by M edic&e
□  Establish a  list of risk factors and 
conditions for which the primary, 
secondary, or tertiary interventions 
are recomm ended or underway for
0 Mental health conditions
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□  Furnish personalized health advice
referrals to health education or 
preventive counseling services 
or programs
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0  Fall prevention 
0 Nutrition 
0 Physical activity 
0 Tobacco-use cessation 
0 Weight loss
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planning services
Q Future care d écrion s that may need to be made
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D Explanation of advance directives, which may involve the completion of standard forms
Page 6 of 17 ICN 905706 April 2017
QNlie K» Mtnuc I. MCDIOUD MflNXB
107
SUBSEQUENT AWV COMPONENTS: APPLIES FOR ALL SUBSEQUENT AWVs AFTER A 
BENEFICIARY’S FIRST AWV
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idiL>0i>»O€Dii)B
0 Demographic data 
0 Self-assessment of health status 
0 Psychosocial risks 
0
□  Update the list of current providers 
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0 Past medical and surgical history, including experiences with illnesses, hospital stays, 
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D Use of, or exposure to, medications and supplements, including calcium and vitamins
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friends, caretakers, or others
Counsel Beneficary
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preventive services covered by Medicare
□  Update the list of risk factors and ^  
conditions for which primary, 
secondary, or tertiary interventions 
are recommebiüed or underway for 
«JL flip tiJE E
* p a i 4 c m . £ »
0 Mental health conditions
Q OXcfegBJO C IT ip » 3 4 »  iepW tL  
□ î O p D n p c c »
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C ounsel B eneficdy  (oont.
□  Furnish personiflized health advice
appropriate, to health education or 
preventive counseling services 
or programs
« p a i L o p p »  € i i ^ > « p E r a » î i i i p # i i p v ) ^ n L æ ^  m o iD isE )*  g o t i ^ g e
0 Community-based lifestyle interventions to reduce health risks and promote self- 
0 3 # l p i i # 2 m a .  iDwi! ♦
0  Fall prevention
0 Nutrition
0  Physical activity
0  Tobacco-use cessation
0  Weight loss
□  Furnish, a t th e  d iscre tion  of the 
b e n e fic a ry , advance care 
planning services
D Future care d écrion s  that may need to be made
D ^ i p i n i T O i j i L
0 Explanation of advance directives, which may involve the completion of standard forms





AWV CODING, DIAGNOSIS, AND BILLING 
Coding
AWV HCPCS C odes and Descriptors
G0438
G0439 Annual wellness visit, includes a  personalized prevention plan of service (PPS), 
subsequent visit
Diagnosis
You must report a  diagnosis code when submitting a  claim for theifWV. Since you are not required to document a specific  diagnosis 
PîILOTîll̂  t  DLOEBOilD X ip tffr IPS)^
Billing
«'îippiL?̂ €3̂  p rp   ̂iOCEEDÎiP(pE 
D Physiciaê(a doctor of medicine or osteopathy)
0 Medical professional (including a health educator, registered dietitian, nutrition professional, or other licensed practitioner), or a team 
of medical professionals w hfiàre directly supervised ly  a physician (doctor of medicine or osteopathy)
é-fippiL0$mm»tss3e» ïpiçiOTiiHtsûi»
CPT only copyright 2016 American Medical Association. All rights reserved.
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ADVANCE CARE PLANNING (ACP) AS AN OPTIONAL ELEMENT OF AN AWV
ACP is theiface-to-face conversation between a physician (or other qualifie health care prd essi anal ) aid a henef id ly t odisoiss t he 
benefica y s w ishes and preferences for medical treatm ent if he or she were unable to speak  or make decisions in the future. You can 
provide the ACP at the time of the AWV, at the benefica y s  discretion.
Coding
Use the following CPT codes to fii d a m  for ACP as  an optional element of an AWV.
ACP CPT C odes and Descriptors
ACP CPT C odes < Billing C ode D escriptors
99497 Advance care planning including the explanation and discussion of advance directives such 
a s  standard forms (with completion of such forms, when performed), by the physician or 
other qualifie health care proâessional; firt 30 minutes, face-to-face with the patient, family 
mem ber(s), and/or surrogate
99498 Advance care planning including the explanation and discussion of advance directives 
such a s  standard fcrms (with completion of such forms, when performed), by the physician 
or other qualifie heal th care pr d es  si anal ; s c h  aldit'anal 30 rhnjtes (lid  s e p a r d ë y in  
addition to code for primary procedure)
Diagnosis
You m ust report a  diagnosis code when submitting a  claim for ACP as  an optional elem ent of an AWV. Since you are not required to 
document a  spec ific  diagnosis code for ACP as  an optional elem ent of an AWV, you may choose any diagnosis code consistent with a 
benefica y s  exam.
CPT only copyright 2016 American Medical Association. All rights reserved.






é̂ nppiL» m . c p ^ n p i 4QMKsmi#L*'WiL(^  ̂ ^  )»)(a
D Provided on the sam e day as the covered AWV 
0 Furnished by the sS n e  provider as the covered AWV
0 eigWMiiaimie)
D 9  # # i "
The deductible and coinsurance for ACP are waived only once per year, when it is billed with the AWV. If the AWV billed with ACP is 
denied for exceeding the once per year limit, the deductible and coinsurance will be applied to the ACP.
NOTE: The deductible and coinsurance apply when ACP is provided outside the covered AWV.
FREQUENTLY ASKED QUESTIONS (FAQs)
What are the other Medicare Part B preventive services?
D Alcohol Misuse Screening and Counseling 
D rnpdpip
D Cardiovascular D isease Screening Test 
D Colorectal Cancer Screening 
D Counseling to Prevent Tobacco Use 
D Depression Screening 
D Diabetes Screening
D Diabetes Self-Management Training (DSMT)
CPT only copyright 2016 American Medical Association. All rights reserved.
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;ï
D Glaucoma Screening
Q Hepatitis C Virus (HCV) ScreenMg
0 f ###()=
D iwem#iiyKi]i(pi#mi mpm ̂  æ * #
D
D IPPE (also called the "Welcome to Medicare Preventive Visit”)
D Medical Nutrition Therapy (MNT)
Q Prostate C ancer Screening
0 Screening for Cervical C ancer with Human Papillomavirus (HPV) Tests 
0 Screening for Lung C ancer with Low Dose Computed Tomography (LDCT)
D itpm % tH#
D Screening Mammography 
D Screening Pap  Tests
D Screening Pelvic Examination (includes a  clinical breast examination)
D Ultrasound Screening for Abdominal Aortic Aneurysm (AAA)
ft Preventive Services Educational Tool for additional resources on Medicare preventive services.
Who is eligible for the AWV?
rippiiiipp a a  n- m ocm
coverage period, and who have not had either an IPPE or an AWV within the past 12 months. M edicare pays for only one first AWV 
per benefica-y p r  liË im  md m e subsequent AWV per y ear thereafter.
Page 13 of 17 ICN 905706 April 2017
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The ABCs of the Annual Wellness Visit (AWV)
Is the AWV the same as a benefica*y s yearly physical?
PREPARING ELIGIBLE MEDICARE 
BENEFICIARIES FOR THE AWV
ip WEZQ
for their AWV by encouraging them to come prepared with the
D Medical records, including immunization records
Q Family health history, in as much detail as possible
0 A full list of medications and supplements, including calcium 
and vitamins -  how often and how much of each is taken
Ü A full list of current providers and suppliers involved in 
providing care
No. The AWV is not a routine physical checkup that some seniors may 
practitioner. Medicare does not cover routine physical examinations.
Are clinical laboratory tests part of the AWV?
No. The AWV does not include any clinical laboratory tests, but you 
may make referrals for such tests as part of the AWV, if appropriate.
Do deductible or coinsurance/copayment 
apply for the AWV?
No. Medicare waives both the coinsurance or copayment and the
Can I bill an electrocardiogram (EKG) and the 
AWV on the same date of service?
Generally, you may provide other medically necessary services on the sam e date of service as  an AWV. The deductible and 
coinsurance/copayment apply ior these other medically nec lssa ry  services.
How do I know if a benefica-y d ready g>t H d 1er firs AWV from another provider and 
know whether to bill for a subsequent AWV even though this is the firt AWV I provided i 
to this benefica*^
You have different options for accessing AWV eligibility information depending on where you practice. You may access the information 
through the Health Insurance Portability and Accountability Act (HIPAA) Eligibility Transaction System (HETS) or through the provider 
call center Interactive Voice Responses (IVRs). CMS suggests providers checKwith their Medicare Administrative Contractor (MAC) 
€ •  rtpi* î S O K ï *  MAC for more information.
Page 14 of 17 ICN 905706 April 2017
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RESOURCES
The Medicare Preventive Services w ebpage lists educational products for Medicare Fee-For-Service providers and their staff about 
preventive services, coverage, coding, billing, payment, and claim filig frm edures.
AWV R esources
42 Code of Federal Regulations 410.15 
(policy governing AWV service)
GPO.gov/fdsys/pkg/CFR-2016-title42-vol2/pdf/CFR-2016-title42-vol2-part410-subpartB.pdf
CMS Provider Minute; Preventive 
Services
(pointers to help you submit correct 
documentation and avoid claim denials)
Youtube.com/watch?v=-tuMWM4KeZg&feature=youtu,be&list=PLaV7m2-
zFKpigbl UvmChI Q2cBKi1 SGk-V
Medicare B enefits  1 icy M nual Chapter 15
CM S.gov/Regulations-and-Guidance/Guidance/M anuals/Downloads/bp102c15.pdf
Medicare Claims Processing Manual Chapter 12, Section 30.6.1.1
CMS.gov/Regulations-and-Guidance/Guidance/M anuals/Downloads/clm104c12.pdf
Chapter 18, Section 140
CM S.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm1G4c18.pdf
MLN Guided Pathways: Provider 
SpecificMdi care R souroes
CMS.gov/Outreach-and-Education/Medicare-Leaming-Network-MLN/MLNEdWebGuide/
Downloads/Guided_Pathways_Provider_SpecificBookl é  .pdf
MLN Matters® Article MM7079,
Annual W ellness Visit (AWV),









-The ABCs of the Annual Wellness Visit (AWV) :  MLN Educational Tool -
AWV R esources (cont.)
MLN Matters Article MM9271, Advance 
Care Planning (AGP) as an Optional 
Element of an Annual \Afellness Visit (AWV)
CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/MM9271.pdf
MLN Matters Article MM10000, Billing for 
Advance Care Planning (AGP) Claims
CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/MM 10000.pdf
MLN Matters Article SE1338, Improve 
Your Patients’ Health with the Initial 
Preventive Physical Examination (IPPE) 
and Annual Wellness Visit (AWV)
CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/
Downloads/SE1338.pdf




Preventive Services Educational Tool CMS.gov/Outreach-and-Educatlon/Medicare-Learning-Network-MLN/MLNProducts/MLN-
Publications-ltems/CMSI 243319.html
R esources for Medicare 
B enefica is R ib listio i
CMS.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/MLN-
Publications-ltems/ICN905183.html
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Hyperlink Table








Framework for Patient-Centered Health 
Risk A ssessm ents Publication
https://www.cdc.gov/policy/hst/HRA/FramewcrkForHRA.pdf
Medicare Preventive Services W ebpage https://www.cms.gov/Medicare/Prevention/PrevntlonGenlnfo
Preventive Services Educational Tool https://www.cms.gov/Medicare/Prevention/PrevntionGenlnfo/medicare-preventive-services/
MPS-QuickReferenceChart-1 .html




Your MAC https://www.cms.gov/Research-Statistlcs-Data-and-Systems/M onitoring-Programs/
Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-lnteractive-M ap
Medicare Learning Network® Product Disclaimer
The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).
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OVERVIEW
The A lzheim er's A sso c ia tio n  -  d e d ic a te d  to  fu e ling  th e  a d v a n c e m e n t of ea rly  d e te c tio n  an d  d iag n o sis  of 
d e m e n tia  -  h a s  d eve lo ped  an  easy -to -im p le m e n t p ro c e ss  to  a s s e s s  cogn ition  during  th e  M ed ica re  A nnual 
W e lln e s s  Visit. D eveloped  by a  g roup of clinical d e m e n tia  ex p e rts , th e  reco m m en d ed  p ro c e s s  o u tlined  on 
p a g e  4 a llow s you to  efficiently  iden tify  p a tie n ts  w ith  p rob ab le  co gn itive  im p airm en t w h ile  giving you th e  
flexibility  to  c h o o se  a  cogn itive  a s s e s s m e n t  tool th a t  w orks b e s t  fo r you an d  your p a tie n ts .
This C ognitive A s s e s s m e n t Toolkit co n ta in s:
•  The M ed icare  A nnual W e lln e ss  V isit A lgorithm  fo r A s s e s s m e n t of C ognition, inco rporating  p a tie n t 
history, clinician  o b se rv a tio n s, an d  c o n ce rn s  e x p re sse d  by th e  p a tie n t, fam ily  or c a reg iv e r
•  T h ree  v a lid a ted  p a tie n t a s s e s s m e n t  too ls: th e  G eneral P rac titio ner A s s e s s m e n t of C ognition  (GPCOG), 
th e  M em ory Im pairm ent S creen  (MIS) an d  th e  Mini-Cog™. All too ls :
> Can be a d m in is te red  in 5 m in u tes  o r le ss
> A re eq ua l to  or sup e rio r to  th e  M in i-M en tal S ta te  Exam (M M SE) fo r d e te c tin g  d e m e n tia
> A re eas ily  a d m in is te red  by m edical s ta ff  m em b ers  w h o  a re  n o t phy sic ian s
> A re re la tively  fre e  from  ed u c a tio n a l, la n g u a g e  a n d /o r  cu ltu ra l b ias
•  T h ree  v a lid a ted  inform an t a s s e s s m e n t  of p a tie n t too ls : th e  S ho rt Form of th e  In fo rm ant Q u estio nn a ire  
on C ognitive D ecline in th e  Elderly (S hort IQCODE), th e  E ight-item  In fo rm an t In terv iew  to  D iffe ren tia te  
Aging and  D em en tia  (AD8) and  th e  GPCOG
•  The "A lzheim er's A ssoc ia tion  R ecom m en datio ns fo r O perationalizing  th e  D etec tion  of Cognitive 
Im pairm ent During th e  M edical A nnual W e lln e s s  Visit in a Prim ary C are S e tt in g ," a s  pub lish ed  in th e  
jou rnal A lzheim er's an d  D em entia .
For m ore inform ation  on th e  d e te c tio n , d ia g n o s is  an d  tre a tm e n t  o f A lzheim er's  d is e a s e , a s  w ell a s  d ire c t 
a c c e s s  to  p a tie n t an d  careg iv e r re so u rc e s , p le a se  v is it our (Health C are P ro fess io n a ls  an d  A lzheim er's  c e n te r  
a t  alz.org/hcps.
800.272.39001 alz.org alzheimer’s association*
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Medicare Annual Wellness Visit Algorithm for Assessment of Cognitfon^^'
A. R eview  HRA, c lin ician  o bse rv a tio n , se lf-re p o rte d  co n ce rn s , re s p o n se s  to  q u e rie s
S ig n s /sy m p to m s  p re se n t
In fo rm ant a v a ilab le  to  confirm
B.* C onduct b rie f s tru c tu re d  a s s e s s m e n t
•  P a tie n t A sse ssm e n t: M ini-Cog or GPCOG o r M IS
•  In fo rm ant a s s e s s m e n t  o f p a tie n t; S ho rt IQCODE, AD8 or GPCOG
Follow -up during  su b s e q u e n t AWV
Brief assessment(s) triggers concerns: P atien t: M ini-Cog 
<3 o r GPCOG <5 (5-8 sco re  is in d e te rm in a te  w ith o u t inform ant) 
o r M IS<4 or Inform ant: S ho rt IQCODE > 3 .38  or AD8 > 2 or 
GPCOG in form an t sco re  <3 w ith  p a tie n t sco re  <8
C. R efer OR C onduct full D em en tia  E valuation
No one too l is recogn ized  a s  th e  b e s t  brief a s s e s s m e n t  to  d e te rm in e  if a full d e m e n tia  ev a lu a tio n  is 
n e e d e d . S om e prov iders re p e a t  p a tie n t a s s e s s m e n t  w ith  an  a lte rn a te  tool (e.g., SLUM S, or MoCA) 
to  confirm  initial find ings b e fo re  referra l or initia tion  of full d e m e n tia  ev a lua tion .
AD8 = E ight-item  Info rm ant In terv iew  to  D iffe ren tia te  A ging and  D em entia ; AWV = A nnual W elln ess  
Visit; GPCOG = G eneral P rac titio n e r A ss e ss m e n t of Cognition; HRA =  H ealth  Risk A sse ssm e n t; MIS 
= M em ory Im pairm ent S creen ; MMSE = Mini M en ta l S ta tu s  Exam; MoCA = M o n trea l Cognitive 
A sse ssm e n t; SLUMS =  St. Louis U niversity  M en ta l S ta tu s  Exam; Short IQCODE = S ho rt Inform ant 
Q u estio nn a ire  on C ognitive D ecline in th e  Elderly
Cordell CB, Borson S, B oustan i M , C hodosh  J ,  R euben  D, V erg hese  J ,  e t  al. A lzheim er's  A ssoc ia tion  
reco m m en d a tio n s  for opera tio na liz in g  th e  d e te c tio n  of cogn itive  im p airm en t during  th e  M ed icare  
A nnual W e lln e s s  Visit in a p rim ary  ca re  se ttin g . Alzheimers Dement. 2013;9(2):141-150. A vailable a t  
h ttp ://d o w n lo a d .jo u rn a ls .e lse v ie rh e a lth .e o m /p d fs /jo u rn a ls /1 5 5 2 -5 2 6 0 /P IIS l5 5 2 5 2 6 0 1 2 0 2 5 0 1 0 .p d f.
800.272.3900 I aiz.org^ alzheimeT's Qj) association'
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Patient name: Date:
GPCOG Screen ing  T es t
Step 1: Patient Examination
Unless specified, each question should only be asked once 
Name and Address for subsequent recall test
1. 7 am going to give you a name and address. After I have said it, I want you to repeat
it. Remember this name and address because I am going to ask you to tell it to me 
again in a few minutes: John Brown, 42 West Street, Kensington." (Allow a maximum 
of 4 attempts).
Time Orientation
2. ]Miat is the date? (exact only)
Correct Incorrect
□ □
Clock Drawing -  use blank page
3. Please mark in all the numbers to indicate 
the hours of a clock (correct spacing required)




5. Can you tell me something that happened in the news recently? ,----- , ,— ,
(Recently = in the last week, if a general answer is given, I_ _ I I I
eg “war”, “lot of rain”, ask for details. Only specific answer scores).
Recall






(To get a total score, add the number of items answered correctly 
Total correct (score out of 9) /9
If patient scores 9, no significant cognitive Impairment and further testing not necessary 
If patient scores 5-8, more information required. Proceed with Step 2, informant section.
If patient scores 0-4, cognitive impairment is indicated. Conduct standard investigations.
© University of New South W ales a s  represented by the Dem entia Collaborative Re search  Centre -  A ssessm ent and Better Ca re; 





Informant’s  relationship to patient, i.e. informant is the patient’s:
These six questions ask how the patient is compared to when s/he 
was well, say 5 -  10 years ago
Compared to a few years ago:
Don’t
Yes No Know N/A
■ Does the patient have more trouble remembering things
that have happened recently than s/he used to? [ | | | ] [
■ Does he or she have more trouble recalling conversations
a few days later? [ | | | | [
■ When speaking, does the patient have more difficulty in ___ ___ ___
finding the right word or tend to use the wrong words
more often? ----- -----
Is the patient less able to manage money and financial I I I I I I I I
affairs (e.g. paying bills, budgeting)?--------------------------------- I----- ' I-----> I---- 1--'---- 1
Is the patient less able to manage his or her medication-------i----- 1 i-----1 i---- 1--i---- 1
independently?--------------------------------------------------------------I----- 1 I- ---- 1 I---- 1-- I---- 1
Does the patient need more assistance with transport 
(either private or public)?
(if the patient has difficulties due only to physical problems, e g bad leg, tick no')
□ □ □ □
(To get a total score, add the number of items answered ‘no’, ‘don’t know’ or ‘N/A’)___
Total score (out of 6 ) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ I_ _ I
If patient scores 0-3, cognitive impairment is indicated. Conduct standard investigations.
©  U niversity  of N ew  S o u th  W a le s  a s  r e p re s e n te d  by  th e  D em en tia  C o llaborative R e se a rc h  C e n tre  — A s s e s sm e n t a n d  B e tte r  C are ; 
B rodaty  e t  ai, J A G S  2002 ; 5 0 :5 3 0 -5 3 4
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MEMORY IMPAIRMENT SCREEN (MIS)
Instructions for Administration
1. Show patient a sheet of paper with the 4 items to be recalled in 24-point or greater uppercase 
letters (on other side), and ask patient to read the items aloud.
2. Tell patient that each item belongs to a different category. Give a category cue and ask patient to 
indicate which of the words belongs in the stated category (eg, "Which one is the game?"). Allow 
up to 5 attempts. Failure to complete this task indicates possible cognitive impairment.
3. When patient identifies all 4 words, remove the sheet of paper. Tell patient that he or she will be 
asked to remember the words in a few minutes.
4. Engage patient in distractor activity for 2 to 3 minutes, such as counting to 20 and back, counting 
back from 100 by 7, spelling WORLD backwards.
5. FREE RECALL —  2 points per word: Ask patient to state as many of the 4 words he or she can 
recall. Allow at least 5 seconds per item for free recall. Continue to step 6 if no more words have 
been recalled for 10 seconds.
6 . CUED RECALL—  1 point per word: Read the appropriate category cue for each word not recalled 
during free recall (eg, "What was the game?").





The maximum score  for the MIS is 8.
• 5-8 No cognitive impairment
•  < 4 Possible cognitive impairment
Copyright <S> 1999Albert Einstein College of Medicine. AH rights reserved
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M ini-Cog' Instructions for Adm inistration & Scoring
ID:. D a te :.
Step 1: Three W ord R eg is tra tion
Look d irectly  a t person  an d  say, “P lease  listen carefully. I am  going to  say  th re e  w ords th a t  I w ant you to  re p ea t back 
to  m e now and  try  to  rem em ber. The w ords are [se lec t a list of w ords from  th e  v e rsions below]. P lease  say  th e m  for 
m e now.” If th e  p erson  is u n ab le  to  rep ea t th e  w ords a fte r th re e  a tte m p ts , m ove on to  S tep  2 (clock draw ing).
The following and  o th e r word lists have been  u sed  in one or m ore clinical s tu d ie s .’'  ̂For rep ea ted  a d m in istra tio n s, 
u se  of an  a lte rna tive  word list is recom m ended .
Version 1
B anana



















D au g h ter
H eaven
M ountain
Step 2: C lock D raw ing
Say: “Next, I w an t you to  draw  a clock for me. First, p u t in all of th e  n u m b ers  w here they  go.” W hen th a t  is co m ple ted , 
say: “Now, se t th e  h a n d s  to  10 p a s t 11.”
Use p rep rin ted  circle (see  next p age) for th is  exercise. R epeat in s tru c tio n s  as n eed ed  as th is  is no t a m em ory  te s t. 
Move to  S tep  3 if th e  clock is no t co m ple te  within th ree  m inu tes.
Step 3: Three W ord Recall
Ask th e  p erson  to  recall th e  th ree  w ords you s ta te d  in S tep  l. Say: “W hat w ere th e  th ree  w ords I a sked  you to  
rem em b er?” Record th e  word list version n u m b er and  th e  p e rso n ’s an sw ers below.
Word List Version: P e rso n ’s Answers:
Scoring
Word Recall: fO-"i points) 1 point for each word spontaneously recalled without cueing.
Clock Draw; fo or 2 points)
Normal clock = 2 points. A normal clock has all numbers placed in the correct 
sequence and approximately correct position (e.g., 12, 3, 6 and 9 are in anchor 
positions) with no missing or duplicate numbers. Hands are pointing to the 11 
and 2(11:10). Hand length is not scored.
Inability or refusal to draw a clock (abnormal) = 0 points.
Total Score; fO-S points)
Total score = Word Recall score + Clock Draw score.
A cut point of <3 on the Mini-Cog™ has been validated for dementia screening, 
but many individuals with clinically meaningful cognitive impairment will score 
higher. When greater sensitivity is desired, a cut point of <4 is recommended as 
it may indicate a need for further evaluation of cognitive status.
M ini-Cog™  © S. B o rso n . All r ig h ts  re s e rv e d . R e p r in te d  w ith  p e rm is s io n  of t h e  a u th o r  so le ly  fo r  c lin ica l a n d  e d u c a t io n a l  p u rp o s e s .  




Clock Drawing ID: Date:
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Short Form of the Informant Questionnaire on Cognitive 
Decline in the Elderly (Short IQCODE)^
by A. F. Jorm
Centre for Mental Health Research 
The Australian National University 
Canberra, Australia
There is no copyright on the Short IQCODE. However, the author appreciates being 
kept informed of research projects which make use of it.
Note: As used in published studies, the IQCODE was preceded by questions to the 
informant on the subject's sociodemographic characteristics and physical health.
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Now we want you to remember what your friend or relative was like 10 years ago and
to compare it with what he/she is like now. 10 years ago was in 20__.* Below are
situations where this person has to use his/her memory or intelligence and we want 
you to indicate whether this has improved, stayed the same or got worse in that 
situation over the past 10 years. Note the importance of comparing his/her present 
performance with 10 years ago. So if  10 years ago this person always forgot where 
he/she had left things, and he/she still does, then this would be considered "Hasn't 
changed much". Please indicate the changes you have observed by circling the 
appropriate answer.
Compared with 10 years ago how is this person at:
12
1 2 3 4 5
1. Remembering things about 





































4. Remembering his/her 



































7. Remembering where to find 
things which have been put in 











8. Knowing how to work 














9. Learning to use a new 




























































14. Handling financial matters 












15. Handling other everyday 
arithmetic problems e.g. 
knowing how much food to 
buy, knowing how long 












16. Using his/her intelligence 











and to reason things through
*The original tool was published in 1994.
The Alzheimer's Association updated the year 19__ as published in the original tool to 20 .
Tool Reference: Jonn AF. A  short form o f the Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE): development and cross-validation. Psychol M ed 1994; 24: 145-153.
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14
ADS Dementia Screening interview Patient ID#:
CS ID#:___
Date:
Remember, “Yes, a change” indicates that 
there has been a change in the last several 








1. Problems with judgment (e.g., 
problems making decisions, bad 
financial decisions, problems with 
thinking)
2. Less interest in hobbies/activities
3. Repeats the same things over and 
over (questions, stories, or 
statements)
4. Trouble learning how to use a tool, 
appliance, or gadget (e.g., VCR, 
computer, microwave, remote control)
5. Forgets correct month or year
6. Trouble handling complicated financial 
affairs (e.g., balancing checkbook, 
income taxes, paying bills)
7. Trouble remembering appointments
8. Daily problems with thinking and/or 
memory
1 TOTAL AD8 SCORE
Adapted from Galvin JE et al, The AD8, a brief informant interview to detect dementia. Neurology 2005:65:559-564 
Copyright 2005. The AD8 Is a copyrighted Instrument of the Alzheimer's Disease Research Center, Washington University, St. Louis, Missouri. 
All Rights Reserved.
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The AD8 Administration and Scoring Guidelines
A spontaneous self-correction is allowed for all responses without counting as an error.
The questions are given to the respondent on a clipboard for self—administration or can be read 
aloud to the respondent either in person or over the phone. It is preferable to administer the AD8 
to an informant, if available. If an informant is not available, the AD8 may be administered to the 
patient.
When administered to an informant, specifically ask the respondent to rate change in the 
patient.
When administered to the patient, specifically ask the patient to rate changes in his/her ability 
for each of the items, w ithout attributing causality.
If read aloud to the respondent, it is important for the clinician to carefully read the phrase as 
worded and give emphasis to note changes due to cognitive problems (not physical problems). 
There should be a one second delay between individual items.
No timeframe for change is required.
The final score is a sum of the number items marked “Yes, A change”.
Interpretation of the AD8 (Adapted from Galvin JE et al. The AD8, a  brief informant interview to detect dementia, 
Neurology 2005:65:559-564)
A screening test in itself is insufficient to diagnose a dementing disorder. The AD8 is, however, 
quite sensitive to detecting early cognitive changes associated many common dementing illness 
including Alzheimer disease, vascular dementia, Lewy body dementia and frontotemporal 
dementia.
Scores in the impaired range (see below) indicate a need for further assessment. Scores in the 
“normal" range suggest that a dementing disorder is unlikely, but a very early disease process 
cannot be ruled out. More advanced assessment may be warranted in cases where other 
objective evidence of impairment exists.
Based on clinical research findings from 995 individuals included in the development and 
validation samples, the following cut points are provided;
□ 0 - 1 ;  Normal cognition
□ 2 or greater; Cognitive impairment is likely to 
be present R#ck»ver O p e ra to r C h ara cter is ties  (ROC) c u rv e  to r  A 0 8
Administered to either the informant (preferable) or the 
patient, the AD8 has the following properties;
□ Sensitivity > 84%
□ Specificity > 80%
□ Positive Predictive Value > 85%
□ Negative Predictive Value > 70%




Copyright 2005. The Eight-item informant Interview to Differentiate Aging and Dementia is a 
copyrighted instrument of W ashington University, St. Louis, Missouri. All Rights Reserved.
Permission Statement
W ashington University grants permission to use  and reproduce the Eight-item Informant Interview to 
Differentiate Aging and Dementia exactly a s  it appears in the PDF available here without 
modification or editing of any kind solely for end user u se  in investigating dementia in clinical care or 
research in clinical care or research  (the “Purpose”). For the avoidance of doubt, the Purpose does 
not include the (i) sale, distribution or transfer of the Eight-item informant Interview to Differentiate 
Aging and Dementia or copies thereof for any consideration or commercial value; (ii) the creation of 
any derivative works, including translations; and/or (ill) u se of the Eight-item Informant Interview to 
Differentiate Aging and Dementia a s  a marketing tool for the sale of any drug. All copies of the AD8 
shall include the following notice: “Reprinted with permission. Copyright 2005. The Eight-item 
Informant Interview to Differentiate Aging and Dementia is a  copyrighted instrument of Washington 
University, St. Louis, Missouri. Ail Rights Reserved.” P lease contact morrisi@ abraxas.wustl.edu for 
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Abstract The Patient Protection and Affordable Care Act added a new Medicare benefit, the Annual
Wellness Visit (AWV), effective January 1, 2011. The AWV requires an assessment to detect cog­
nitive impairment The Centers for Medicare and Medicaid Services (CMS) elected not to recom­
mend a specific assessment tool because there is no single, universally accepted screen that 
satisfies all needs in the detection of cognitive impairment. To provide primary care physicians 
with guidance on cognitive assessment during the AWV, and when referral or further testing is 
needed, the Alzheimer’s Association convened a group of experts to develop recommendations.
The resulting Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for Assessment 
of Cognition includes review of patient Health Risk Assessment (HRA) information, patient ob­
servation, unstructured queries during the AWV, and use of structured cognitive assessment tools 
for both patients and informants. Widespread implementation of this algorithm could be the first 
step in reducing the prevalence of missed or delayed dementia diagnosis, thus allowing for better 
healthcare management and more favorable outcomes for affected patients and their families and 
caregivers.
© 2013 The Alzheimer’s Association. All rights reserved.
Keywords: Annual Wellness Visit; AWV; Cognitive impairment; Assessment; Screen; Dementia; Alzheimer’s disease;
Medicare; Agorithm; Patient Protection and Affordable Care Act
1. Introduction
The Patient Protection and Affordable Care Act o f 2010 
added a new M edicare benefit, the Annual Wellness Visit
•Corresponding author. Tel.: 312-335-5867. Fax; 866-699-1246. 
E-mail address: cyndy.cordeII@alz.org
(AWV), effective January 1, 2011. The AWV includes 
routine meastnements such as height, weight, and blood 
pressure; a review of medical and family history; an assess­
ment to detect cognitive impairment; and establishment of 
a list o f current medical providers, medications, and sched­
ule for future preventive services. In addition, during the first 
AWV only, beneficiaries are to be screened for depression (if
1552-5260/$ - see front matter © 2013 The Alzheimer’s Association. A l  rights reserved. 
http://dx.doi.org/10.1016/j.jalz.2012.09.011
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not completed under a separate Medicare benefit) and for 
functional difficulties using nationally recognized appropri­
ate screening questions or standardized questionnaires. Al­
though the U.S. Preventive Services Task Force (USPSTF) 
in 2003 concluded that there was insufficient published evi­
dence o f better clinical outcomes as a  result of routine 
screening for cognitive impairment in older adults, the 
Task Force recognized that the use o f cognitive assessment 
tools can increase the detection of cognitive impairment 
[1]. As per the Centers for Medicare and Medicaid Services 
(CMS) regulation, the AWV requires detection o f cognitive 
impairment by “ ... assessment o f an individual’s cognitive 
function by direct observation, with due consideration o f in­
formation obtained by way of patient report, concerns raised 
by family members, friends, caretakers, or others” [2]. Dur­
ing the public comment period, several organizations, in­
cluding the Alzheimer’s Association, noted that the use of 
a standardized tool for assessment of cognitive function 
should be part of the AWV.
These comments are supported by a number of studies 
showing that cognitive impairment is unrecognized in 
27% -81%  of affected patients in primary care [3-7]. The 
use o f a brief, structured cognitive assessment tool 
correctly classifies patients with dementia or mild 
cognitive impairment (MCI) more often than spontaneous 
detection by the patients’ own primary care physicians 
(83% vs 59%, respectively) [8].
In response to concerns submitted during public comment, 
CMS elected not to recommend a specific tool for the final 
AWV benefit because “There is no nationally recognized 
screening tool for the detection of cognitive impairments at 
the present tim e...” [9]. However, CMS recognizes that with­
out clarification, the full intended benefits o f the AWV cogni­
tive assessment may not be realized [10]. CMS is working 
with other governmental agencies (e.g.. National Institutes 
on Aging) on recommendations for use of specific tools.
Understanding that, under the present regulation, each 
healthcare provider who conducts an AWV would have to 
determine how best to “detect cognitive impairment,” the 
Alzheimer’s Association convened the Medicare Detection 
o f Cognitive Impairment Workgroup to develop recommen­
dations for operationalizing the cognitive assessment com­
ponent in primary care settings. This workgroup was 
comprised o f geographically dispersed USA experts with 
published works in the field of detecting cognitive im pair­
ment during primary care visits. The focus on primary care 
was deliberate, as most Medicare beneficiaries will receive 
their AWV in this setting.
2. Guiding principles for recommendations
2.1. Consensus on general principles
Based on their expertise, the workgroup agreed on the fol­
lowing general principles to guide the development o f rec­
ommendations for cognitive assessment:
•  Detection o f cognitive impairment is a stepwise, itera­
tive process.
•  Informal observation alone by a physician is not suffi­
cient (i.e., observation without a specific cognitive 
evaluation).
•  Detection of cognitive impairment can be enhanced by 
specifically asking about changes in memory, lan­
guage, and the ability to complete routine tasks.
•  Although no single tool is recognized as the “gold stan­
dard” for detection o f cognitive impairment, an initial 
structured assessment should provide either a baseline 
for cognitive surveillance or a trigger for further eval­
uation.
•  Clinical staff can offer valuable observations o f cogni­
tive and functional changes in patients who are seen 
over time.
•  Counseling before and after cognitive assessment is an 
essential component o f any cognitive evaluation.
•  Informants (family member, caregiver, etc.) can pro­
vide valuable information about the presence of 
a change in cognition.
2.2. Principles specific to the AWV
•  The AWV requires the completion o f a  Health Risk As­
sessment (HRA) by the patient either before or during 
the visit. The HRA should be reviewed for any reported 
signs and symptoms indicative o f possible dementia.
•  The AWV will likely occur in a primary care setting. 
Tools for initial cognitive assessments should be brief 
(< 5  min), appropriately validated, easily administered 
by non-physician clinical staff, and available free of 
charge for use in a clinical setting.
•  If  further evaluation is indicated based on the results of 
the AWV, a more detailed evaluation of cognition 
should be scheduled for a follow-up visit in primary 
care or through referral to a specialist.
3. Review of available brief tools for use during the AWV
3.1. Workgroup review process
Although there is no single cognition assessment tool that 
is considered to be the gold standard, there is a plethora of 
tools in the literature. A M EDLINE (PubMed) search con­
ducted in October 2011, using the key words “screening or 
detection of dementia or cognitive impairment,” yielded 
over 500 publications. To narrow the search to tools more 
applicable to the AWV, the workgroup sought to determine 
whether the literature offered a consensus regarding brief 
cognitive assessment during time-limited primary care visits.
The workgroup focused on systematic evidence review 
(SER) studies published since 2000 resulting in four studies 
by Lorentz et al, Brodaty et al, Holsinger et al, and Milne et al 
[11—14]. Although each SER had a similar objective— to 
determine which tools were best for administration during
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primary care visits— different comparison criteria to select 
the tools were applied (Table 1). Two other studies were 
also considered relevant to the development o f the work­
group recommendations: Ismail et al [15] conducted a litera­
ture review designed to identify widely used and most 
promising newer brief cognitive tools being used in primary 
care and geriatrics, and an SER by Kansagara and Freeman 
[16] o f six brief cognitive assessment tools that could serve 
as possible alternatives to the Mini-Mental State Examina­
tion (MMSE) for use by the U.S. Department o f Veterans 
Affairs (VA). Neither study was designed to determine which 
brief tool is the “best,” but both provided evidence related to 
primary care use and performance characteristics of brief 
assessments o f cognition (Table 1).
3.2. Workgroup review results
O f the five publications that focused specifically on 
identifying b rief cognitive assessments m ost suitable or 
most used in primary care settings [11-15], all selected 
the M emory Im pairm ent Screen (MIS), and four o f these 
publications [11,12,14,15] also selected the General 
Practitioner Assessment o f Cognition (GPCOG) and the 
M ini-Cog (Table 2).
The following attributes o f the GPCOG, Mini-Cog, and 
the MIS contributed to their selection as most suited for rou­
tine use in primary care:
•  Requires 5 minutes or less to administer.
•  Is validated in a primary care or community setting.
•  Is easily administered by medical staff members who 
are not physicians.
•  Has good to excellent psychometric properties.
•  Is relatively firee from educational, language, and/or 
culture bias.
•  Can be used by clinicians in a clinical setting without 
payment for copyrights.
Charging a fee for clinical use o f brief cognitive assess­
ment tool has become an issue because o f increased enforce­
ment o f the MM SE copyright. First published in 1975 [17], 
the MMSE copyright is now held by Psychological Assess­
ment Resources, Inc., which charges a fee for each use (for 
exact fees see www.parinc.com). The comparative SER 
within the VA [16] evaluated alternatives to the proprietary 
MMSE, including the GPCOG and the Mini-Cog, along 
with four other brief tools (Table 2). The Mini-Cog and 
MIS are copyrighted, but the owners, Soo Borson, MD, 
and Albert Einstein CoUege o f Medicine, respectively, allow 
free use by clinicians as clinical tools with distribution re­
strictions for other entities (e.g., commercial companies). 
The GPCOG has similar use rules.
3.3. Patient structured cognitive assessment tools 
recommended fo r  AWV
In alignm ent with the w orkgroup’s guiding principles 
and supported by data in the six selected SERs/reviews,
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Table 2
Brief cognitive assessment tools evaluated in multiple review articles
Assessment Tool
Lorentz et al, 
2002 [11]
Brodaty et al, 
2006 [12]
Holsinger et al, 
2007 [13]
Milne et al, 
2008 [14]




7-Minule Screener X X X X
AMT X X X X
CAMCOG X Suited^
CDT X X Suited^ X X
GPCOG Most suited Most suited X Most suited Most suited X
Mi ni-Cog Most suited Most suited X Most suited Most suited X
MIS Most suited Most suited Suited* Most suited Most suited
MMSE X X Suited* X X
MoCA Suited* X X
RUDAS X X
SAS-SI X X X
SBT (BOMC, 6-CIT) X X X X X
SPMSQ X X
STMS X X X X
T&C X X
Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; AMT, Abbreviated Mental Test; BOMC, 6-item Blessed Orientation-Memory-Concentration Test; 
CAMCOG, Cambridge Cognitive Examination; CDT, Clock Drawing Test; GPCOG, General Practitioner Assessment of Cognition; MIS, Memory Impairment 
Screen; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; RUDAS, Rowland Universal Dementia Assessment; SAS-SI, Short 
and Sweet Screening Instrument; SBT, Short Blessed Test; SLUMS, St Louis Mental Status; SPMSQ, Short Portable Mental Status Questionnaire; STMS, Short 
Test of Mental Status; T&C, Time and Change Test
X =  assessment reviewed, but not identified as most suited for general use in primary care.
Suited — tool appropriate for the following clinical issue: f  available time is not limited; f available time is limited; and § cognitive impairment is at least 
moderate. Most suited — tool identified as most suited for routine use in primary care.
•Kansagara and Freeman evaluated six tools, including the SLUMS, which was not evaluated in any other review.
the GPCOG, Mini-Cog, and MIS are b rief structured 
tools that are suitable for assessment o f cognitive func­
tion during the AWV. Each tool has unique benefits. 
The GPCOG has patient and inform ant components 
that can be used alone or together to increase specificity 
and sensitivity [18]. The M ini-Cog has been validated in 
population-based studies and in com munity-dwelling 
older adults heterogeneous with respect to language, cul­
ture, and education [19-22]. The MIS is a verbally 
administered word-recall task that tests encoding as 
well as retrieval [23], and is an option for patients who 
have m otor impairments that prevent use of paper and 
pencil.
3.4. Structured cognitive assessment tools fo r  use with 
informants
Cognitive assessm ent com bined with inform ant- 
reported data improves the accuracy o f assessm ent 
[24-27]. I f  an inform ant is present during the AWV, 
use o f a structured inform ant tool is recom m ended. 
S im ilar to cognitive assessm ent tools for use with 
patients, there is no single “gold standard” inform ant 
tool; however, relatively few b rief inform ant tools 
have been validated in com m unity and/or prim ary care 
settings. B rief tools appropriately validated include the 
Short IQCODE [25], the ADS [28], which can be ad­
m inistered in-person or by telephone, and the aforem en­
tioned GPCOG [18], which has both patient and 
inform ant components.
4. Recom m ended algorithm  fo r detection of cognitive 
im pairm en t d u ring  the  AWV
4.1. Incorporating assessment o f cognition during the 
AWV
The A lzheim er’s Association Medicare Annual Wellness 
Visit Algorithm for Assessment o f Cognition for consistency 
(Figure 1) illustrates a stepwise process. The process is in­
tended to detect patients with a high likelihood of having de­
mentia. The AWV algorithm includes both structured 
assessments discussed previously and other less structured 
patient- and informant-based evaluations. By assessing and 
documenting cognitive status on an annual basis during the 
AWV, clinicians can more easily determine gradual cogni­
tive decline over time in an individual patient— a key crite­
rion for diagnosing dementia due to Alzheimer’s disease and 
other progressive conditions affecting cognition.
For patients with a previous diagnosis o f MCI or demen­
tia, this should be documented and included in their AWV 
list o f health risk factors. Annual unstructured and structured 
cognitive assessments could be used to monitor significant 
changes in cognition and potentially lead to a new diagnosis 
o f dementia for those with MCI or new care recommenda­
tions for those with dementia.
4.2. Detection o f cognitive impairment during the AWV— 
initial HRA review, conversations, and observations
The first step in detection of cognitive impairment during 
the A W V  (Fig. 1, Step A), involves a conversation between
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Medicare Annual Wellness Visit (HCPCS codes G0438 or G0439)
Review HRA (especially reports of functional deficits), clinician observations, and self- 




Conduct brief structured assessment
Patieiu Assessment: GPCOG ot Mini-Cog or MIS
Informant assessment of patient: AD8 or GPCOG or Short IQCODE
No
Yes
Refer for full dementia evaluation or 
Conduct fun dementia evaluation
If informant is available during AWV can follow up same day as AWV and bUl for E/M service with 
CPT codes 99201-99215. If not, schedule new visit for evaluation and request presence of 





Signs/symptoms of cognitive 
impairment present
Brief assessment(s) triggers concerns:
Patient: GPCOG <5 (5-8 score is indeterminate without 
informant) or Mini-Cog s3 or MISs4 
Informant: AD8 &2 or GPCOG informant score s3 with 
patient score <8 or Short KJCODE s3.38
* No one tool is recognized as the best brief assessment to determine if a full dementia evaluation is 
needed. Alternate tools (eg. MMSE. SLUMS, or MoCA) can be used at the discretion of the clinician. 
Some providers use multiple brief tools prior to referral or initiation of a full dementia evaluation.
A W V  =  Annua] W ellness V isit; G PC O G  =  G eneral P ractitioner A ssessm ent o f C ognition; H RA  »  H ealth  R isk A ssessm ent;
MTS a  M em ory Im pairm ent Screen; M M SE =  M ini M ental S tatus Exam ; M oC A  =  M ontreal C ognitive  A ssessm ent; SLU M S =
St. L ouis U niversity M ental S tatus Exam ; Short IQ C O D E  =  short Inform ant Q uestionnaire on  C ognitive D ecline  in the E lderly
Fig. 1. Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for Assessment of Cognition.
a clinician and the patient and, if present, any family member 
or other person who can provide collateral information. This 
introduces the purpose and content of the AWV, which in­
cludes: a review of the HRA; observations by clinicians 
(medical and associated staff); acknowledgment of any self- 
reported or informant-reported concerns; and conversational 
queries about cognition directed toward the patient and others 
present. If any concerns are noted, or if an informant is not 
present to provide confirmatory information, further evalua­
tion of cognition with a structured tool should be performed.
Patient completion of an HRA is a required element of the 
AWV and can be accomplished with the help of a family mem­
ber or other knowledgeable informants, including a profes­
sional caregiver. Published CMS guidance offers healthcare 
professionals flexibility as to the specific format, questions, 
and delivery methods that can be used for an AWV HRA 
[29], The following questions may be suitable for the AWV 
HRA and have been tested and evaluated in the general popu­
lation through the Behavioral Risk Factor Surveillance System 
or presented as HRA example questions:
1. During the past 12 months, have you experienced con­
fusion or memory loss that is happening more often or 
is getting worse [30]?
2. During the past 7 days, did you need help with others 
to perform everyday activities such as eating, getting 
dressed, grooming, bathing, walking, or using the toi­
let [29]?
3. During the past 7 days, did you need help from others 
to take care of things such as laundry and housekeep­
ing, banking, shopping, using the telephone, food 
preparation, transportation, or taking your own medi­
cations [29]?
A noted deficit in activities of daily living (ADLs) (e.g., 
eating and dressing) or instrumental activities o f daily living 
(lADLs) (e.g., shopping and cooking) that caimot be
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attributed to physical limitations should prompt concern, as 
there is a strong correlation between decline in function and 
decline in cognitive status across the full spectrum o f demen­
tia [31]. In addition to clinically observed concerns, any pa­
tient- or informant-reported concerns should trigger further 
evaluation [13]. Positive responses to conversational 
queries, such as “Have you noticed any change in your mem­
ory or ability to complete routine tasks, such as paying bills 
or preparing a meal?” should be followed up with a struc­
tured assessment o f cognition.
Upon realizing the time constraints o f a typical primary 
care visit, if  no cognitive concerns surface during the initial 
evaluation and this information is corroborated by an infor­
mant, the clinician may elect not to perform a structured cog­
nitive assessment and assume that the patient is not currently 
demented. This approach is supported by studies in popula­
tions with low rates of dementia that suggest the absence of 
memory difficulties reported by informants and patients re­
duces the likelihood that dementia is present [32,33].
4.3. Structured cognitive assessment tools fo r use with 
patients and informants during the AWV
The second step in detection o f cognitive impairment dur­
ing the AWV (Figure 1, Step B) requires cognitive assess­
ment using a structured tool. Based on synthesis o f data 
from the six review articles previously discussed, patient 
tools suitable for the initial structured assessment are the 
GPCOG, Mini-Cog, and MIS.
Recognizing that there is no single optimal tool to detect 
cognitive impairment for all patient populations and set­
tings, clinicians may select other brief tools to use in their 
clinical practice, such as those listed in Table 3. The 15 brief 
tools listed were evaluated in multiple review articles 
(passed through at least two review search criteria for tools 
possibly suited for primary care) or are used in the VA. Tools 
listed in Table 3 are subject to the inclusion/exclusion crite­
ria of each review and do not represent the entire listing of 
the > 1 0 0  brief cognitive assessment tools that may be suit­
able for primary care practices.
If an informant is present, defined as someone who can 
attest to a  patient’s change in memory, language, or function 
over time, it is suitable to use the AD8, the informant com­
ponent o f the GPCOG, or the Short IQCODE, during the 
AWV.
4.4. Primary care workflow considerations
According to the algorithm, any patient who does not 
have an informant present should be assessed with a struc­
tured tool. For such patients (and for practices that imple­
ment structured assessments during all AWVs), completion 
o f this structured assessment can be administered by trained 
medical staff as the first step for cognitive impairment detec­
tion. This could improve office efficiency. To increase ac­
ceptance of a structured assessment, the reason provided to
the patient can be normalized with a statement such as, 
“This is something I do for all o f my older patients as part 
of their annual visit.” When the initial assessment prompts 
further evaluation, explanation of results should be deferred 
until a more comprehensive evaluation has been completed. 
“There are many reasons for not getting every answer cor­
rect. More evaluation will help us determine that,” is an ex­
ample statement that may encourage patients to pursue 
further testing.
5. Full dementia evaluation
Patients with assessments that indicate cognitive im­
pairment during the AWV should be further evaluated to 
determine appropriate diagnosis (e.g., MCI, Alzheimer’s 
disease) or to identify other causes. As reflected in the algo­
rithm (Figure 1, Step C), initiation of a full dementia evalu­
ation is outside the scope o f the AWV, but can occur in 
a separate visit either on the same day, during a newly sched­
uled visit, or through referral to a specialist. Specialists who 
have expertise in diagnosing dementia include geriatricians, 
geriatric psychiatrists, neurologists, and neuropsychologists. 
The two-visit approach has been cited as a time-effective 
process to evaluate suspected dementia in primary care
[34] and is consistent with the two-step approach widely 
used in epidemiologic research on dementia. Regardless of 
the timing and setting, clinicians are encouraged to counsel 
patients to include an informant in the diagnostic process.
Components o f a full dementia evaluation can vary de­
pending on the presentation and include tests to rule in or 
out the various causes o f cognitive impairment and establish 
its severity. Diagnostic evaluations include a complete m ed­
ical history; assessment of multiple cognitive domains, in­
cluding episodic memory, executive function, attention, 
language, and visuospatial skills; neurologic exam (gait, mo­
tor function, reflexes); ADL and lADL functioning; assess­
ment for depression; and review for medications that may 
adversely affect cognition. Standard laboratory tests include 
thyroid-stimulating hormone (TSH), complete blood count 
(CBC), serum B 1 2 , folate, complete metabolic panel, and, 
if  the patient is at risk, testing for sexually transmitted dis­
eases (human immunodeficiency virus, syphilis). Structural 
brain imaging, including magnetic resonance imaging 
(MRI) or computed tomography (CT), is a supplemental 
aid in the differential diagnosis o f dementia, especially if 
neurologic physical exam findings are noted. An MRI or 
CT can be especially informative in the following cases: de­
mentia that is o f recent onset and is rapidly progressing; 
younger onset dementia (< 6 5  years o f age); history of 
head trauma; or neurologic symptoms suggesting focal 
disease.
6. Discussion
Unfortunately, up to 81 % of patients who meet the crite­
ria for dementia have never received a documented diagnosis
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Table 3
Key advantages and limitations of brief cognitive assessment tools evaluated in multiple reviews and/or for use in the VA
Assessment* Time ( — min) Advantages Limitations
7-Minute Screener [48] 7-12 •  Little or no education bias
•  Validated in primary care
•  Difficult to administer
•  Complex logarithmic scoring
AMT [49] 5-7 •  Easy to administer
•  Verbal memory test (no writing/drawing)
•  Education/language/culture bias
•  Limited use in US (mostly used in Europe)
•  Does not test executive function or visuospatial 
skills
CAMCOG [50] 20 •  Tests many separate domains (7) •  Difficult to administer
•  Long administration time
CDT [51] <1 •  Very brief administration time
•  Minimal education bias
•  Lacks standards for administration and scoring
GPCOG^ [18]
Patient 2-5 •  Developed for and validated in primary care •  Patient component scoring has an indeterminate
Informant 1-3 •  Informant component useful when initial 
complaint is informant-based
•  Little or no education bias
•  Multiple languages accessible at www.gpcog. 
com.au
range that requires an informant score to assess as 
pass or fail
•  Informant component alone has low specificity
•  Lacks data on any language/culture biases
Mini-Cogt [8, 19] 2-4 •  Developed for and validated in primary care 
and multiple languages/cultures
•  Little or no education/language/race bias
•  Short administration time
• Use of different word lists may affect failure rates
•  Some study results based on longer tests with the 
Mini-Cog elements reviewed independently
MIS [23.52] 4 •  Verbal memory test (no writing/drawing)
•  Little or no education bias
« Does not test executive function or visuospatial 
skills
MMSE [17] 7-10 •  Most widely used and studied worldwide
•  Often used as reference for comparative eval­
uations of other assessments
•  Required for some drug insurance reimbtuse-
•  Education/age/language/culture bias
•  Ceiling effect (highly educated impaired subjects 
pass)
•  Proprietary—unless used from memory, test needs 
to be purchased at www.parinc.com
• Best performance for at least moderate cognitive 
impairment
MoCAt [53] 10-15 •  Designed to test for mild cognitive impairment
•  Multiple languages accessible at www. 
mocatestorg
•  Tests many separate domains (7)
•  Lacks studies in general practice settings
•  Education bias (<12 years)
■ Limited use and evidence due to published data 
relatively new (2005) 
a  Admin time >10 min
RUDAS [54] 10 •  Designed for multicultural populations
•  Little or no education/language bias
a  Validated in Australian community 
a  Limited use and evidence due to published data 
relatively new (2004)
SAS-SI [55] 10 •  Detected dementia better than netirupsycho- 
logic testing in a coinmunity population
a  Does not test memory 
a  Lacks data on any education/language/culture
SBT (BOMC^ and 4-6 •  Verbal test (no writing/drawing) a  Education/language/cultural/race bias
6-CIT) [56.57] a  Scoring can be cumbersome 
a  Does not test executive function
SLUMSt [58] 7 » No education bias
•  Tests many separate domains (7)
•  Available at; http://aging.slu.edu/pdfsurveys/ 
mentalstatus.pdf
a  Limited use and evidence due to published data 
relatively new (2006) 
a  Studied in VA geriatric clinic (predominantly white
SPMSQ [59] 3 -4 •  Verbal test (no writing/drawing) a  Scoring can be cumbersome 
a Does not test short-term memory
STMS^ [60] 5 •  Validated in primary care
•  Tests many separate domains (7)
a Education/language/race bias 
a Studied in relatively educated subjects, may not be 
applicable to general population
T&C [61] < 1 •  Very brief administration time
• Little or no education bias
a  Strong language/cultural bias
Abbreviations: 6-CIT, 6-Item Cognitive Impairment Test; AMT, Abbreviated Mental Test; BOMC, 6-item Blessed Orientation-Memcny-Concentration Test; 
CAMCOG, Cambridge Cognitive Examination; CDT. Clock Drawing Test; GPCOG, General Practitioner Assessment of Cognition; MIS, Memory Impairment 
Screen; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; RUDAS, Rowland Universal Dementia Assessment; SAS-SI, Short 
and Sweet Screening Instrument; SBT, Short Blessed Test; SLUMS, St Louis University Mental Status; SPMSQ, Short Portable Mental Status Questioimaire; 
STMS, Short Test of Mental Status; T&C, Time and Change Test.
♦References provide descriptions of assessments.
% rief tools used in the VA healthcare system reviewed by Kansagara and Freeman.
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[35]. Delayed or missed diagnosis deprives affected individ­
uals of available treatments, care plans, and services that can 
improve their symptoms and help maintain independence. 
Studies show that interventions tailored to patients with de­
mentia can improve quality o f care, reduce unfavorable 
dementia-related behaviors, increase access to community 
services for both the patient and their caregivers, and result 
in less caregiver stress and depression [36-42], Early 
diagnosis o f dementia also provides families and patients 
an opportunity to plan for the future while the affected 
individual is still able to participate in the decision-making 
processes.
Early detection and medical record documentation may 
improve medical care. The medical record could inform 
all clinicians, including those who may be managing comor­
bidities on a sporadic basis, that treatment and care should be 
adjusted to accommodate cognitive impairment. According 
to a  2004 Medicare beneficiary survey, among patients 
with dementia, 26% had coronary heart disease, 23% had di­
abetes, and 13% had cancer [43].
It is important to note that the unstructured and structured 
cognitive assessments being recommended for the AWV are 
only the first steps in diagnosing dementia, and cognitive as­
sessment is best as an iterative process. For example, clini­
cians concerned with HRA information about decline in 
function may proceed directly to a structured assessment 
or continue to query the patient for additional information; 
a self-reported memory concern coupled with a failed struc­
tured cognitive assessment should always result in a full de­
mentia evaluation.
Not all who are referred for further assessm ent will u l­
tim ately receive a dem entia diagnosis. In a USA primary 
care population aged >65 years (N = 3340), 13% failed 
a b rief screen for cognitive im pairm ent and approxi­
m ately half (n =  227) agreed to be further evaluated 
for dem entia [7]. Among the 107 patients ultimately d i­
agnosed with dementia, 81% were newly diagnosed 
based on the absence o f any medical record o f dementia, 
thus facilitating appropriate m edical and psychosocial in­
terventions [7].
Despite the many advantages o f early dementia diagno­
sis, several barriers to diagnosis still exist. These include 
physician concerns of the time burden resulting from testing 
and counseling [35] and stigma concerns among physicians, 
patients, and caregivers [35,44,45]. Despite these barriers, 
successful widespread implementation of a brief cognitive 
assessment has been reported. McCarten et al [22] evaluated 
the Mini-Cog for routine cognitive assessment o f veterans 
presenting for primary care. Of the 8342 veterans ap­
proached, >96%  agreed to be assessed and those that failed 
the brief assessment exhibited no serious reactions upon dis­
closure o f test results.
The AWV provides an unprecedented opportunity to 
overcome current barriers and initiate discussions about cog­
nitive function among the growing population most at risk
for A lzheimer’s disease. Detection o f cognitive impairment 
during the AWV is further supported by previously pub­
lished quality indicators that state all vulnerable elders (de­
fined as persons >65 years who are at risk for death or 
functional decline) should be evaluated annually for cogni­
tive and functional status [46].
There are limitations to these recommendations. They 
are based on assessment o f recommendations from review 
articles and on expert opinion, not on a new, comprehensive 
review of original research to define the optimal approach 
to detection o f cognitive impairment or review of emerging 
technologies that could assist in testing (e.g., use of online 
or electronic tablet applications). Further complicating 
SERs of brief cognitive assessment tools is that sensitivity 
and specificity will vary depending on the dementia preva­
lence o f the study population, the tool(s) used, and the cut 
score selected for each tool. Brodaty et al [12] recognized 
that published research concerning cognitive impairment 
screening tools is uneven in quantity and quality. The liter­
ature also is lacking in comparative validity o f  brief cogni­
tive assessment tools in low-education or illiterate 
populations.
The Alzheim er’s Association Medicare Annual Wellness 
Visit Algorithm for Assessment o f Cognition is based 
on current validated tools and commonly used rule-out 
assessments. The use o f biomarkers (e.g., CSF tau and 
beta amyloid proteins, amyloid tracer positron emission 
tomography scans) was not considered as these measures 
are not currently approved or widely available for clinical 
use.
In 2011, greater than two million Medicare beneficiaries 
received their AWV preventive service [47]. There are no 
data available as to what methods were used to detect cogni­
tive impairment or how many beneficiaries were assessed 
as having cognitive impairment. For future AWVs, the 
Alzheimer’s Association Medicare Annual Wellness Visit 
Algorithm for Assessment of Cognition provides guidance 
to primary care practices on a process to operationalize 
this required AWV element. With widespread implementa­
tion o f the algorithm, the AWV could be the first step in re­
ducing the prevalence o f missed or delayed dementia 
diagnoses, thus allowing for better healthcare management 
and more favorable outcomes for affected patients and their 
families and caregivers.
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( R ESEA R CH  IN CO N TEX T
1. Systematic review: Our research included comparing 
five systematic evidence reviews (SER) of brief de­
mentia screening tools published since 2000 and 
a 2010 literature review of newer brief assessments 
of cognition. Our research focused on determining 
if there was a consensus among the published SERs 
as to which tool is most suited for primary care and 
if  there were any common results across the publica­
tions.
2. Interpretation: Our research concluded there is a con­
sensus in the literature concerning suitable tools for 
screening for dementia in primary care. We also reaf­
firmed that many validated tools are available, and 
that screening for dementia should not be solely 
based on a tool, but should be a stepwise process to 
include other assessments.
3. Future directions: Further validation of existing and 
emerging screening tools (e.g., iPad applications, 
gait monitoring) may result in newer tools being rec­
ognized more suitable and practical for primary care 
settings.
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APPENDIX F 
Mild Cognitive Impairment Screening Survey
If you agree to take this survey, your answers serve as your consent. If you would like 
to receive the results and implications from this study, please provide your email 
address below. (Answers will not be associated with email addresses when statistics are 
analyzed; survey responses will remain completely anonymous.)
Questions:
1. In what state do you primarily practice?




3. What is your primary area of practice?
a. Family Practice
b. Internal Medicine
c. Geriatrics/Long Term Care
d. Urgent Care
e. Emergency Room





5. Which response best describes your screening practices for Mild Cognitive 
Impairment in patients aged 65 and older?
a. I do not screen patients for Mild Cognitive Impairment.
b. I screen patients if  they or their family mention a concern over memory 
problems or a decline in ability to perform ADL’s.
c. I screen every patient aged 65 and older every year at their wellness visit.
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6. If a patient over 65 years of age comes into your clinic without any obvious 
signs of cognitive impairment, how likely are you to screen this patient for Mild 
Cognitive Impairment?
a. I will not screen
b. I am not likely to screen
c. I am somewhat likely to screen
d. I will very likely screen
7. Which factor/factors make you more likely to screen patients over 65 years of 
age for Mild Cognitive Impairment? * Choose all relevant answers.
a. Patient has not been screened in at least 12 months
b. Patient’s family mentions deterioration or changes in patient’s behavior
c. Patient appears somewhat “lost” in the conversation
d. Patient admits to forgetfulness or memory loss issues
e. Guidelines that dictate how often the patient should be screened
f. O ther_____________
8. Which factor/factors make you less likely to screen patients over 65 years of age 
for Mild Cognitive Impairment? * Choose all relevant answers.
a. Concerns over unnecessary testing.
b. Lack o f clear guidelines as to when and how to screen
c. Lack o f guidelines as to which screening tool to use
d. Lack of adequate time with each patient
e. O ther_____________
9. When/If you do screen patients for Mild Cognitive Impairment, what screening 
tool do you use?
a. Mini Mental State Examination
b. Short Portable Mental Status Questionnaire (SPMSQ)
c. Mini-Cog
d. Clock Test
e. 3 Word Recall Test
f. Health Risk Assessment
g. Another screening tool
h. I do not use any screening tools
10. Does your current clinic/place of employment have set guidelines in place for 
screening for Mild Cognitive Impairment?
a. Yes
b. No
